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One in three Australians are at increased risk for kidney disease. Involvement of the 
kidney can occur as a primary event, with a process that starts in the kidneys, or arise as 
a complication of other systemic illnesses, most notably systemic hypertension and 
diabetes mellitus (both of which are common afflictions, seen in about 6 million and 1.7 
million Australians respectively). Patients who develop kidney involvement run the 
risk of progression of the illness to terminal, end-stage kidney failure. Once organ 
failure has set in, patients will require close monitoring and intensive treatment; such 
patients are often offered dialysis treatment or kidney transplantation, depending on 
circumstances. Currently, about 13,000 adults in Australia are being treated with 
dialysis therapy for end-stage kidney failure.  
Dialysis was initially conceived as  life-sustaining therapy, used until the kidney 
function recovered. Over the years, indications have expanded, and treatment is now 
continued even when there is no hope of recovery of renal function, in a pathway 
referred to as maintenance dialysis. Many countries now provide dialysis free of cost to 
patients; this is obviously not possible in resource-poor environments. 
Dialysis typically consists of the removal of excess fluid and metabolic waste by 
exchanging these substances across a semipermeable membrane. There are two 
common types of dialysis: haemodialysis, where an artificial semipermeable membrane 
is used to remove waste from the bloodstream, and peritoneal dialysis, where fluid is 
instilled into the abdomen and the patient’s own peritoneal membrane is used as the 




latter requires that patients be trained to perform dialysis by themselves and therefore 
is not suitable for everyone. 
Dialysis treatment is not without problems. Patients undergoing this treatment have a 
high mortality rate, mainly contributed by accelerated cardiovascular disease. Dialysis 
is an intrusive treatment, requiring patients to undertake sweeping changes in lifestyle 
and to commit large periods of time to therapy. While continuing on dialysis, several 
patients, especially the elderly, suffer progressive functional and cognitive impairment, 
with a low quality of life. In some older patients with multiple other coexisting illnesses, 
starting dialysis may not significantly prolong life either, calling into question the 
benefit from undertaking this complex treatment. Such patients may actually be better 
managed with conservative, non-dialysis pathways of care. These considerations are 
relevant since across the world, the number of older individuals on dialysis treatment is 
increasing. For instance, those aged 65 and over are the fastest growing demographic 
group among patients new to dialysis in Australia.  
When contemplating treatment options, the length of survival with or without dialysis 
is the outcome most commonly considered by patients, clinicians and researchers. 
However, patients and families have other concerns too, such as quality of life and 
independence. Clinicians are faced with a relative paucity of data regarding these other 
outcomes that matter to patients. Doctors may even avoid discussions about 
unfavourable consequences, particularly if they find such conversations uncomfortable. 
The actual, day-to-day experience of dialysis, and the significant changes required to 
patients’ lifestyles are not discussed very often. With inadequate information, patients 
may tend to simplify the choice between dialysis treatment or conservative 




selection of therapy could lead to consequences such as deteriorating quality of life, 
worsening frailty, increasing morbidity or unexpected short survival.  
Significant numbers of patients regret the decision to start dialysis or withdraw from 
therapy after starting. In Australia in 2017, withdrawal from dialysis was the most 
common cause of death among patients on dialysis; 82% of these withdrawals occurred 
in those 65 and over, and a third of all withdrawals occurred for psychosocial rather 
than medical reasons (source: ANZDATA annual reports for 2018). Against this 
backdrop, we were interested in studying the experience and outcomes of treatment 
among elderly individuals and investigating whether they could be predicted or 
modified so that poor outcomes and needless suffering could be avoided. 
We used various analytic approaches. Through means of an extensive scoping review, 
we collected information available in the literature that was likely to be useful in 
discussing outcomes of treatment of end-stage kidney disease with patients and their 
families. We also analysed quality of life through the lens of symptom burden, with the 
understanding that physical symptoms have significant effects on health-related quality 
of life. We explored important clinical outcomes for patients through qualitative 
research, by conducting semi-structured interviews that elicited patient perspectives. 
The scoping review format was used for the literature review in order to gather all the 
available information from a wide variety of sources, both published and ‘grey’ 
literature. The main questions addressed in the review were as follows: markers of 
survival, factors influencing quality of life, available information about the lived 
experience of dialysis in older patients, and finally, the described information needs of 
older patients and their carers. We published the protocol for the scoping review 
beforehand in a reputed open-access journal. In the review, 248 articles were included 




was highlighted; details of prognostic indices for older people were collected and 
comparisons provided between conservative management and dialysis. Relatively few 
articles addressed quality of life. We classified the factors affecting quality of life into 
modifiable (e.g., symptom burden, physical status/functional ability, frailty, nutrition, 
depression) and non-modifiable (e.g., age, number of comorbidities) groups. With data 
from the lived experience of older adults with end-stage kidney disease (ESKD) and 
descriptions of their information needs, we provided a summary of areas to be covered 
in discussions with older patients regarding treatment options.  
We surveyed our dialysis population and demonstrated a significant symptom burden. 
This burden was similar in older (age greater than 70 years) and younger patients. The 
symptom burden was correlated with quality of life. We also showed that symptoms 
were poorly recognised by nurses and doctors caring for these patients. This could 
potentially be one of the reasons for a low quality of life in the dialysis population.  
In order to improve symptom recognition, the use of patient-completed symptom 
surveys is recommended; we validated the IPOS-Renal symptom survey – the most 
widely used survey in Australian dialysis patients today - in a separate study. This was 
the first published validation study of this commonly-used symptom survey. These 
findings generated two peer-reviewed publications and were also submitted at 
conferences as posters and oral presentations. 
Our qualitative study asked older people about their outcomes on dialysis and the 
factors influencing these outcomes. We identified themes of loss (of independence, of 
time, of activities undertaken prior to starting dialysis) and uncertainty (uncertain 
future, cyclical symptoms, unpredictable tiredness after dialysis sessions) as factors 




support of carers and healthcare professionals were the common themes among factors 
enabling better outcomes.  
Our recommendations for clinicians advising older patients with end-stage renal failure 
include the use of prognostic indices, documentation of symptoms using patient-
completed surveys, exploration of patient expectations, extensive discussions about the 
potential impact of treatment on lifestyle, the tailoring of information to suit learning 
styles of older individuals and the need for baseline assessments of nutritional status, 
physical and cognitive function. To ensure good outcomes in those that choose dialysis, 
we recommend ensuring appropriate skill-sets in staff assisting with dialysis treatment 
(particularly needling of AV fistulae), making efforts to ensure physical comfort in 
dialysis units, fostering relationships between patients and staff and focusing on the 
needs of carers.  
Prognostic uncertainty can never be completely resolved, and these difficult decisions 
about treatment will continue to be made based on individual circumstances. During 
this process, it is the duty of the clinician to provide relevant, patient-centred advice in 
an easily understandable format. Regardless of their choice of therapy, patients ought to 
be well informed, supported and regularly monitored. We have suggested practical 






   
The kidneys are small, fist-sized organs situated in the upper abdomen, below the rib 
cage, protected by layers of muscle posteriorly and the intra-abdominal organs and 
muscles anteriorly. They are not easily accessible to touch or auscultation. These silent 
workhorses receive 20% of cardiac output and continue to function throughout the 
lifetime, with no periods of rest. The kidneys are responsible for maintaining the milieu 
interior (1). They fulfil a central role as a “metabolic filter” and are the major excretory 
organ for soluble waste and water. Diseases of the kidney are usually insidious and 
slowly progressive, causing very few symptoms until advanced stages are reached. 
When patients with kidney failure become symptomatic, these symptoms are vague 
and often not attributed to kidney disease. 
On occasion, however, kidney failure can be acute and dramatic. The need to treat acute 
kidney failure developing in injured soldiers during conflict accelerated the 
advancement of dialysis therapy - a temporary treatment that helped remove metabolic 
waste and water with the use of filters and extracorporeal circulation (2). Over the 
years, the indications for dialysis have broadened. Today, patients with irreversible 
kidney failure are regularly supported with dialysis treatments. Such treatment 
continues indefinitely, unless either the kidney function recovers or the patient receives 
a kidney transplant. While initially a scarce resource, dialysis is now widely available. It 
is important to recognise that dialysis is one of the rare life-sustaining treatments that is 
paid for by providers such as governments or insurance agencies even though the 
treatment is not curative. 
Dialysis is an expensive therapy to provide (3). Patients on long-term dialysis often 





medical attention. Dialysis patients suffer an increased risk of sudden death and 
cardiovascular complications. Physical and cognitive decline is common (4–7). It is an 
intrusive treatment, placing huge demands on time and requiring significant changes in 
lifestyle. Thus, although dialysis prolongs life once the kidneys have failed, it does so at 
a significant cost. 
Across the world, as societies age, the average age of patients on dialysis is also 
increasing. The adverse effects of dialysis are perhaps most acutely felt by older 
individuals who require the treatment, with the benefits of treatment decreasing 
progressively as  age advances to beyond 65 to 70 years. Significant changes to lifestyle, 
functional deterioration and cognitive impairment are common complications in the 
elderly on dialysis. Recent research has suggested that in the elderly, particularly if they 
have multiple other illnesses, dialysis does not significantly prolong life. Where 
prognosis is poor and life prolongation is no longer guaranteed, the value of dialysis 
treatment becomes questionable. This situation has prompted the development of 
“maximal conservative therapy” or  “conservative management without dialysis” (8–
14). Patients undergoing this treatment pathway receive holistic, complete care for 
kidney failure, with a focus on symptom management, but does not include dialysis 
(15). In appropriate patients, such conservative management can have good results (16–
18). 
In conventional practice, patients are introduced to treatment options for their kidney 
failure as the estimated glomerular filtration rate (eGFR) drops from normal values of 
>90 ml/min (per 1.73 m2 body surface area) to values around or below 25 ml/min. 
Patient education at this stage comprises of information about treatment of end-stage 
kidney disease as well as about measures to slow the progression of kidney disease. 




receiving more and more detail regarding treatment as kidney function worsens. As the 
eGFR reaches around 15 ml/min, patients are expected to have decided on a treatment 
option. This is often difficult for patients, since at this level of eGFR, they often do not 
have overwhelming symptoms. In other words, they are choosing between life-altering 
treatment options for an abstract, potentially symptomatic stage in the future. The lack 
of symptoms at the time of decision-making is a problem, leading some patients to 
postpone the decision, or to turn to health professionals or other patients with similar 
illnesses for advice. If the benefit from dialysis is itself ambivalent, this adds further 
uncertainties to the decision-making process - and this is often the situation for older 
patients (19). 
For the older patient contemplating treatment options for ESKD, the unpredictable 
results from dialysis treatment raise a decisional dilemma. Such patients have to choose 
between undertaking dialysis treatment with its uncertain survival benefit or 
undertaking non-dialysis, conservative management which carries the real risk of a 
shortened life span.  Once more, these decisions are to be made at a time when there are 
very few severe or troubling symptoms. Understandably, they turn to their healthcare 
providers for advice. The renal specialist (nephrologist) often leads these discussions. 
These are difficult conversations. Research suggests that nephrologists are often not 
comfortable discussing poor prognosis (20,21). Although there are many reasons why 
nephrologists find these discussions difficult, a prominent concern is the uncertainty of 
outcomes, regardless of the treatment options chosen. Medical decision-making has 
moved from “paternalistic medicine” practices to patient-centred paradigms. In other 
words, whereas at one time doctors considered options, weighed the information and 
advised the patient on the decision to be taken, today the expectation is “shared 




information and arrive at decisions that are consistent with the patients’ values and 
expectations (19). 
Clinicians involved in discussions around dialysis treatment are expected to behave as 
experts, and to provide the information required in this setting. The patients’ 
expectations, anxieties, preferences and values are an important component of shared 
decision-making. The process of information exchange, including the setting, 
communication skills of the clinician and the learning styles of the patient are also 
relevant. The ultimate goal of the shared decision-making process is to arrive at a 
treatment recommendation that is most likely to provide the best outcomes for the 
patient. Optimally, the clinician should tailor discussions to the patients’ information 
needs and expected outcomes (22). 
Uncertainty about outcomes complicates these discussions. In everyday practice, 
nephrologists encounter some older patients who thrive on dialysis treatment despite 
its limitations whereas other older patients deteriorate and suffer with the treatment.  
Predicting outcomes in each individual patient is not easy. While prognostic indices 
offer some information about patient characteristics associated with poor survival, it is 
much more difficult to predict other, non-survival outcomes. This is paradoxical, since 
patients are often concerned equally about outcomes other than survival when they 
take on lifelong treatments such as dialysis. This inability to predict outcomes other 
than survival, the lack of clarity around these outcomes and the absence of sufficient 
information regarding patients’ perceptions of outcomes on dialysis are all significant 
gaps in the literature. This thesis is directed at exploring outcomes with treatment of 
ESKD in the elderly and seeks to address these gaps. 
Exploration of outcomes encompasses a vast area of study. Broadly, potential outcomes 




above) into survival outcomes and non-survival outcomes. The latter include outcomes 
such as quality of life. In fact, when patients consider treatment choices, they sometimes 
make the distinction between “quantity of life”, referring to the prolongation of life 
provided by dialysis in opposition to “quality of life”, a concept that is difficult to 
define, but is related to individual values and expectations. Quality of life has different 
meanings for different people. In medical literature, one speaks of an overall quality of 
life of which health-related quality of life is an important subset. Health-related quality 
of life has been well studied. In addition to several other factors, biophysical factors and 
symptom burden are important components of health-related quality of life (23). If one 
were to broaden the concept of “outcome”, then patient perceptions of outcome are 
important as well. Ultimately, it is the patients’ judgement of their outcome that speaks 
to the success or failure of the treatment chosen.  
The focus on patients’ values is spreading to other aspects of research in kidney 
diseases. For instance, there is a perception that the results commonly reported in 
research papers today  may not often be directly relevant or useful to clinicians working 
in the field or to patients themselves (24). This impacts on the practical value of research 
outputs and is potentially wasteful of resources. An approach to tackle this divide 
(between what is important to stakeholders versus what is actually studied by 
researchers) has been to establish what the outcomes valuable to stakeholders are, 
through a rigorous, validated process. Once these outcomes are identified and 
published, the research community knows where stakeholders’ interests lie. Subsequent 
research could focus on these valuable outcomes, or include the effects on these 
outcomes in the research reports. Potentially, this would reduce wasteful research, 
enable better translation of research into practice and enable comparisons between 
different interventions using common comparators. For instance, considering that 




intervention to treat anaemia might report not only the effect on improving laboratory 
tests of haemoglobin, but also the effects on improving fatigue (25). Such an approach to 
reporting results comes from the belief that current research ought to address the 
outcomes that have been rigorously studied and found to be important to patients, 
clinicians and policy-makers. These principles are the basis for the establishment of the 
Standardised Outcomes in Nephrology (SONG) initiative, launched in 2014 (26). The 
effort recommends the identification of core outcomes important to all stakeholders 
within each research area in Nephrology, using validated processes. The effort has 
recommended the inclusion and reporting of these core, standardised outcomes in trials 
involving patients undergoing various forms of dialysis, transplantation or in specific 
patient groups (27,28). These recommended outcomes have been endorsed by several 
renal and research organisations, paving the way for their widespread use and 
adaptation (26). 
In planning the research associated with the exploration of outcomes in this thesis, the 
areas I chose to work on reflected the considerations discussed here. A systematic 
review of literature summarised the factors to be considered (survival and other 
outcomes) in the elderly with advanced kidney disease. A separate line of research  
studied symptom burden, its effects and the recognition of these symptoms by 
clinicians, with the understanding that not only are symptoms important to patients, 
but they also contribute to health-related quality of life (23,29,30). As discussed above, 
symptoms are only one group among the many contributors to health-related quality of 
life. A detailed description of the models of quality of life and the influence of 
symptoms is resented in Chapter 3. Lastly, qualitative research was undertaken, in the 
form of analysis of semi-structured patient interviews, attempting to obtain the patient 




In the following paragraphs, the background to the thesis is presented, followed by 
further discussion of the research studies included here and finally, an overview of the 
thesis publication itself. 
 
1.1 Background: The Ageing population on dialysis, 
and their outcomes 
 
1.1.1 Incidence and prevalence of kidney failure and dialysis among 
older patients: Australian experience 
In 1998, there were 5536 patients on dialysis in Australia. Twenty years later, at the end 
of 2017, that number had more than doubled to 13,051. The prevalence of dialysis per 
million population rose from 298 to 531 during the same period. In 2017, people 
between 75 – 84 years had the highest prevalence of renal replacement therapy (which 
includes dialysis and transplantation), followed by those aged between 65 – 74 years, 
and then by those aged 55 – 64 (2926, 2693 and 2099 patients per million population 
[pmp] respectively) (31).  When considering the relative incidence (i.e., new patients 
starting treatment in 2017) among population groups, the highest incidence was in 
those aged 75 – 79 (459 pmp), followed by those 80 – 84 ( 433 pmp) and those 70 – 74 
(414 pmp) (32). Therefore, the Australian population with end-stage kidney disease has 
a high proportion of older individuals both in terms of existing patients (prevalence) 
and in terms of those new to treatment (incidence). Similarly high incidence rates in the 
elderly have been reported for the end-stage renal disease populations in the USA, UK 





1.1.2 Outcomes on dialysis for older persons: Mortality 
Dialysis in older adults continues to be associated with very high mortality rates.  The 
5-year survival rate in those aged 75 – 84 years was 33%, in those aged 65 – 74 years it 
was 50%. Median survival in the same age groups was 3.5 years and 4.7 years 
respectively (32). These survival rates are worse than several types of disseminated 
cancer (36).  
 
1.1.3 Outcomes on dialysis for older persons: Outcomes other than 
mortality 
There are several outcomes other than mortality that are significant for the older 
individual. Some of these include (8,20,37–44):  
• Preservation of functional capacity 
• Preservation of mobility 
• Avoiding fatigue and its effects 
• Preservation of cognitive function 
• Forced assumption of the ‘sick role’, as a result of 
o Restriction of activities away from dialysis 
o Changing social interactions 
o Progressive physical and cognitive deterioration 
o Post-dialysis fatigue and limitations imposed 
Discussions about outcomes on dialysis ought not to be restricted only to survival. 
Dialysis is a very intrusive treatment, and its effects are felt in all aspects of life. Older 
patients on dialysis have a lower quality of life, greater functional deterioration, 




compounded by significant regret regarding the decision to start dialysis and reports 
that the information provided before starting dialysis was inadequate (45–47). 
When quality of life is measured objectively using surveys, older patients on dialysis, 
like the younger counterparts, continue to have a lower overall score compared to their 
peers without renal disease. The biggest restrictions for dialysis patients are seen in 
physical attributes of quality of life (48). 
Patients with CKD already have worsening functional status as their disease progresses. 
Studies have shown worsening physical status as disease advances, and an already low 
functional status at dialysis initiation (49–51). Worryingly, this low physical activity 
status at dialysis initiation is also associated with subsequent mortality and with poorer 
quality of life (52,53). As can be expected, patients who maintained their physical 
activity status after the initiation of dialysis did better, both in terms of survival, and 
quality of life (54,55).  
The risk of physical deterioration appears to be most significant in the initial months 
after dialysis initiation. Jassal and colleagues showed in 2009 that 30%  of patients over 
the age of 80 who initiated dialysis suffered functional deterioration requiring support 
in the first 6 months after dialysis initiation (56). In a Dutch study of the trajectory of 
physical function after initiation of dialysis, only 15% were able to maintain functional 
ability at 2 years - the rest had either died or worsened in status (57). In the same study, 
increasing age was associated with worsening physical status. Just 3.6% of those ≥75 
years old maintained a good physical condition after 2 years. This progressive 
functional decline is especially worse among those who are already in nursing homes at 
the time of initiation. A study from Kurella-Tamura and colleagues found that up to 





Another constant for patients on dialysis is the symptom burden. Symptoms in dialysis 
are often quite severe, and the burden of symptoms are sometimes considered as bad as 
the burden in patients with advanced cancer (59). A typical example of a common 
symptom, not well relieved by dialysis is fatigue. Fatigue is a major concern for patients 
already established on dialysis (60). Associations with fatigue include older age, high 
ultrafiltration rates, anaemia, inflammation as evidenced by a raised CRP, pain and 
poor sleep, among other factors (61). Post-dialysis fatigue is especially common in the 
older patient and can have significant negative effects on quality of life. If post-dialysis 
fatigue forces patients to rest in bed for a while after dialysis, for instance, this means 
that even more time is taken from normal activities beyond the time already 
surrendered for undergoing dialysis. Thus, persistent fatigue is one of the outcomes of 
dialysis that can have potentially significant effects on quality of life and is a factor that 
older patients need to consider when making treatment choices. 
Frailty is a concept that is becoming increasingly relevant for the dialysis population. 
Frailty has been defined in many ways but most practically, can be evidenced by 
slowness, weakness, low physical activity, exhaustion and shrinkage (sarcopenia) (62). 
Life on dialysis is characterised by gradual physical deterioration in several older 
patients. Physical deficits in the elderly population are seen even in the earlier stages of 
CKD. A study by Kittiskulnam and colleagues reported that the elderly with CKD were 
three times more likely to be frail compared to their peers (63). Many are already frail 
prior to initiation of dialysis and suffer adverse consequences when on dialysis (64). 
These consequences include progressive cognitive impairment while on dialysis, 
especially in the older patient (5). Structural changes in the brain could accompany the 
cognitive decline, such as white matter damage, brain oedema, microbleeds or changes 




(65). Additionally, older patients on dialysis are likely to suffer increased 
hospitalisations and healthcare costs, intensive care unit admissions and interventions 
(66). They are also more likely to die in hospital, rather than at a place of their choice 
(16,67). 
Faced with worsening functional status, cognitive decline and the other components of 
frailty discussed above, many elderly patients adapt by compromise. They restrict their 
activities and social roles, giving up the things they do not consider vital anymore. This 
could be detrimental to them in the long run, as they are assuming the ‘sick’ role. 
Therefore, dialysis treatment for ESKD, instead of improving the patient’s physical 
status, potentially leads to increasing dependency and poorer outcomes. 
 
1.2 Value of predicting outcomes on dialysis for older 
persons 
 
1.2.1 Effects on the decision to start or continue dialysis 
In modern renal practice, patients with ESKD who receive regular nephrology follow-
up prior to needing dialysis will have a series of discussions with healthcare 
professionals regarding their choice of treatment pathway. Unfortunately, whether 
patients are informed about treatment options such as non-dialysis management 
depends on the unit that they present to (68). Several patients report that they viewed 
the decision to start dialysis as not a decision or choice - rather, dialysis was the only 
option, since they understood that the alternative was death. There remains very little 
understanding of the grim prognosis even with dialysis treatment in this age group. 




communicating prognosis when they discuss outcomes of dialysis with their patients 
(20). 
The modern healthcare professional is expected to present patients with all the 
information required for them to arrive at an optimal decision. Patients today expect 
greater involvement in their healthcare decisions. This was eloquently summarised by 
the patient statement “Nothing about me without me”, presented at the Salzburg 
seminar session in 1998, and subsequently expounded in the Salzburg statement on 
Shared Decision-Making articulated in December 2010 (69). Physicians have a 
responsibility to share important decisions with patients, encourage patients to ask 
questions and provide accurate information, tailored to patients’ needs. These 
principles have been espoused in guidelines released by various physician associations 
in renal disease (70–72).   
Research into the decision-making process has shown that patients, when compared to 
the clinicians advising them, may have different or additional considerations as they 
decide about undertaking treatments such as dialysis (42,73). When counselling older 
patients and their families regarding dialysis, it is important that the clinician conveys 
information not only about prognosis and the survival but also about all the other 
effects that dialysis could have on their lives. This is particularly relevant when 
considering that patients may regret the decision to start dialysis (45). In addition to the 
registry data quoted above, several analyses of patient populations have reported poor 
survival for the elderly, especially if they are already in nursing homes or have multiple 
illnesses in addition to kidney disease (74,75). There is evidence that older patients often 
suffer functional impairment in the first few months of starting dialysis (58,76). Many 




They tend to view the decision to have dialysis or not as an alternative between life and 
death, and are often more optimistic about their own prognosis (77). 
While there are several reasons as to why physicians struggle with conversations about 
prognosis in the shared decision-making process (42,78–80), the fact remains that many 
patients are not fully informed about all the possible outcomes as they consider 
treatment options. There is a lack of appropriate information to pass on to families and 
patients. Considering the relatively fewer benefits of dialysis in the older population, 
the poorer quality of life, the increased hospitalisation episodes and the associated  
healthcare costs, it is important that older patients make optimal choices about 
treatment. This will help them avoid the unnecessary suffering that could result from an 
ill-considered decision to start dialysis treatment.  
Additionally, it is quite difficult to predict which older adult will do well on dialysis 
and who will not. There are no uniform definitions of what ‘doing well’ means - it is 
conceivable that healthcare providers and patients have differing expectations. There is 
insufficient data on quality of life outcomes; we also do not know enough about factors 
which predict positive outcomes.  Anecdotal experience (see Section 1.4) suggests that 
there are unique personal factors that affect these outcomes, and this is exemplified by 
the fact that while some older patients deteriorate functionally and psychologically after 
starting treatment, others appear to thrive and continue in their life-roles. Therefore, a 
method to predict all these potential outcomes, in addition to mortality, will be useful 
for clinicians who provide information to a patient considering dialysis treatment for 





1.2.3 Predicting survival 
Within the literature, several prognostic instruments have been described which predict 
both the risk of developing ESKD as well as the risk of mortality once the older patient 
starts dialysis (81). Estimates exist for 3-, 6- and 12-month survival predictions. 
Predictive equations can use combinations of demographic variables, presence of 
comorbidities, biochemical tests, functional assessments or clinical input, such as the 
response to the surprise question (82,83). Similarly, other equations that predict the risk 
of renal deterioration to a stage that needs renal replacement therapy (84,85). The 
challenge is to be able to effectively use the information from these tools in discussions 
with patients. 
Clinical personnel could use prognostic scores to streamline management of patients in 
a CKD clinic - for instance, to select patients for more intensive follow-up if they run a 
higher risk of developing ESKD or consider input from palliative care (or other 
supportive services) if there is a high risk of mortality. 
It remains unclear how patients use or understand information gleaned from prognostic 
tools that predict survival. In general, patients tend to be overly optimistic about their 
survival probabilities. Patients receiving calculated estimates of survival will need help 
in understanding how the numbers apply to their individual situation.  
However, prognostic information cannot be used in isolation. More likely, prognostic 
information is one of the many factors that patients and the families consider as they 
make their decisions regarding treatment. In Chapter 2, the scoping review of literature 





1.2.4 Predicting outcomes other than survival 
Ideally, patients considering dialysis should have access to predictions of the outcomes 
other than survival as well. There are no easy means of predicting these outcomes in 
their entirety.  
Several studies have analysed the factors that could influence quality of life. Such 
factors include those likely to affect mental components of quality of life, such as 
depression, anxiety, spiritual well-being, age, gender, educational level, dialysis 
vintage, nutritional status, sleep quality, locus of control / illness perception and coping 
strategies (avoidance coping strategies were associated with lower QOL scores) (86–90). 
Physical symptoms have been suggested to directly impact quality of life - this 
association has been shown in dialysis patients (91). Symptoms are an important 
contributor to health-related QOL, as postulated in the Ferrans model (30). Therefore, 
the presence of severe unremitting symptoms could signal a poor quality of life 
outcome, especially if the symptoms are not relievable by dialysis (e.g., fatigue, 
depression). Table 4 in Chapter 2 summarises the modifiable and non-modifiable 
factors that could affect quality of life. 
There are few predictors of other outcomes. Fukuma and colleagues, using data from 
the Dialysis Outcomes and Practice Pattern Study in Japan, created and validated a 
score to predict functional decline in the elderly after starting dialysis (92). Similarly, 
other research has shown that being in a nursing home at the start of dialysis is also 
associated with a high incidence of functional decline (58). 
In summary, research that addresses factors affecting outcomes other than mortality is 






1.3 Clinical dilemmas in the selection of therapy for 
the older patient with end-stage kidney disease 
 
Patients with ESKD tend to approach the decision regarding dialysis treatment as a 
choice between life and death. However, recent experience has shown us that older 
patients who are managed with what has been called ‘maximal conservative 
management ‘ tend to do quite well, both in terms of survival and in terms of quality of 
life. Direct comparisons between patients managed conservatively  and those receiving 
dialysis have helped identify a subset of elderly patients, often with multiple 
comorbidities (such as ischemic heart disease or peripheral vascular disease) who 
derive no benefit from dialysis. These studies have been summarised in Table 2–3. 
Individual decision-making continues to remain problematic. The increasing evidence 
that dialysis treatment may not be beneficial in all patient groups has opened the eyes 
of clinicians to the need for a more balanced approach, and for decisions to be made 
with wider ranging discussions. Shared decision-making, with optimal discussions of 
prognosis are recommended. The focus has to be on arriving at a treatment decision 
(dialysis or conservative management) that is best suited for the patient. Currently, 
there are attempts to develop decision support tools for patients having to make this 
decision. A good example is the Patient Decision Aid developed by the Conservative 
Kidney Management Care Research Group at the University of Alberta (93). This tool 
attempts to elicit the preferences of patients with a series of questions and recommends 
the treatment pathway that is most likely to suit their preferences. 
The final decision, though, may be dependent on other, individual factors. Sometimes, 




may even modify treatment regimens to suit patient preferences (94). Anecdotal 
experience suggests that family members may have an important role - not surprisingly, 
patients that choose dialysis treatment from family compulsions often regret their 
decision. On other occasions, despite the belief that dialysis may not be in their best 
interests, older patients may choose to undertake the treatment in order to achieve other 
goals - for instance, staying alive to support an unwell spouse.  
Naturally, patients will turn to their clinicians for advice. It is difficult for the clinician 
to be completely neutral in this process - i.e., to be a dispassionate provider of 
information alone (94). Ideally, the clinician, armed with the knowledge of possible 
outcomes, should be able to elicit in great detail the patient’s preferences, and then help 
the patient to arrive at a decision that is most likely to result in the outcomes that the 
patient desires.  
It is important for the clinician to have adequate knowledge of the outcomes with 
treatment (mortality as well as other , non-mortality outcomes) in order to have an 
optimal discussion with her patient. To that end, the purpose of my research was to 
explore the literature, study the experiences of elderly patients on dialysis and finally 
arrive at the knowledge of important outcomes and factors that affect these outcomes. 
 
1.4  Researcher’s background and context 
 
1.4.1  A nephrologist’s role and perspective 
In 2011, while working as a consultant nephrologist at a regional Australian hospital, I 
was struck by the number of older patients who chose not to have dialysis and were 
subsequently referred back to general practitioners, away from the nephrology 




advanced kidney disease choose to have non-dialysis, supportive care, otherwise called 
conservative management (CM) (13). My enquiries into the treatment options for 
patients that choose not to have dialysis led to the establishment of the renal supportive 
care service with my hospital. As part of the service, we ran a multidisciplinary clinic 
that looked after the management of patients that chose CM, including the management 
of symptoms, psychological support and provision of social or palliative care 
interventions as required. Anecdotally, several older patients appeared to be satisfied 
with their choice of CM, with preserved, excellent quality of life until the end-of-life 
period. This contrasted with many older patients on dialysis. While some of these 
patients appeared to maintain a satisfactory quality of life, the majority appeared to 
undergo a spiral of progressive physical deterioration (personal observation). These 
contrasts awakened my interest into outcomes in the older patient with ESKD, and into 
whether these outcomes could be predicted.  
Further discussions with peers and dialysis nurses, and a brief analysis of the literature 
revealed that while there were significant amounts of research into survival of patients 
on dialysis, very little was known about non-survival outcomes such as quality of life. 
These considerations seemed important to patients and families, especially as they 
considered whether to undertake dialysis treatment or not. The need to address these 
gaps in our knowledge was the primary driver for the start of this research project. 
 
1.4.2 The context: treatment pathways for patients with end-stage 
kidney disease 
Tasmania, where this research project was undertaken, is an island-state in Australia 
which has the distinction of having the oldest population in the country (95,96).  Within 




community are referred to specialist nephrologists by their general practitioners. 
Specialists see these patients either in the public hospital system or in private clinics. 
Once patients have a progressive drop in eGFR, particularly to levels below 20 - 25 
ml/min, they are referred to the chronic kidney diseases educator, who is usually an 
experienced nurse. This educator talks to patients and their families about renal 
replacement therapy options. Armed with this information, patients return to their 
nephrologist and discuss their choices before making a decision.  
At the time this research project was initiated, there was no systematic approach to 
documenting their experiences of life on dialysis; there was no structured method to 
elicit their views about the future, advance care directives or wishes for the end of life. 
For new elderly patients with ESKD being counselled about renal replacement options, 
there was no structured method to communicate prognosis (survival and non-survival 
outcomes). Patients that choose to have dialysis will continue regular follow-up until 
they start dialysis; they are then seen by the nephrologist once every 6 - 8 weeks. In 
routine practice, there are few opportunities to elicit information about lived 
experiences on dialysis. 
 
1.5 Aims of research and anticipated outcomes 
 
Given these circumstances, we were in need of more information about the 
characteristics that predicted a satisfactory outcome on dialysis, so that patients and 
families could make informed choices about treatment, thus avoiding needless 
suffering. A desire to help patients make the best choices and to help them avoid 





• What are the factors influencing survival and other outcomes in older 
patients with ESKD, whether managed with dialysis or on non-dialysis 
care - conservative management? (through literature review; Chapter 2) 
• What can we learn of the experience of end-stage kidney disease, by 
studying the physical symptoms and impairment of quality of life? 
(descriptive, survey-based research studies, Chapter 3) 
• In the lived experience of dialysis, what are patients’ perceptions of 
outcomes and factors influencing these perceptions? (qualitative research 
project, Chapter 4) 
 
The anticipated outcomes from the project were: 
• To conduct a scoping review of the literature on the considerations 
relevant to the discussions about choosing between dialysis and 
conservative management in the older adult, including: 
⁃ survival and mortality outcomes, 
⁃ quality of life outcomes,  
⁃ learnings to be had from understanding the lived experience of 
dialysis and  
⁃ other reported information needs of older patients and carers when 
considering dialysis.  
• To describe physical symptoms in the ESKD population and how well 
they are recognised by treating clinicians (since recognising symptoms is 
the first step to treating and relieving them) 




• To identify factors associated with satisfactory outcomes for the elderly 
patient with advanced renal disease, from the patients’ perspectives, and  
• To create a checklist of factors to be considered during the decision-






1.5 Thesis Organisation 
 
Chapter 1: Introduction  
This section introduces the background to the research, the gaps in knowledge that exist 
and the questions that the research seeks to answer. It also provides background to the 
research and researcher. Subsequent chapters are arranged according to the objectives 
of the thesis. 
Chapter 2: Scoping review of the literature 
In the second chapter, I present a review of the literature on information that could be 
used in the discussions regarding treatment in older patients. I used the scoping review 
format, which seeks to explore the breadth of the research available, rather than grade 
research quality, so as to produce a comprehensive review. The chapter includes the 
published protocol for the review, as well as the review itself, in the format that it has 
been submitted for publication. 
While this review summarises what is available in the literature, the subsequent 
chapters report on research studies done with patients, initially focusing on the 
experience of dialysis (through the study of symptoms) and subsequently eliciting 
patient perspectives through qualitative research. 
Chapter 3: Quantitative, survey-based research - Symptoms and quality of life 
As discussed earlier, symptoms  influence the experiences of patients with end-stage 
kidney disease and affect health-related quality of life and. This chapter reports on the 
research studies that addressed the symptom burden of patients on dialysis. Studies 
reported here include descriptions of symptoms and their interaction with quality of 




my subsequent research investigated the validity of using a patient survey to improve 
symptom recognition. 
Chapter 4: Improving symptom recognition 
Following the results in the previous chapter that symptoms were poorly recognised by 
clinicians, there was a need for a validated method to identify symptoms accurately. 
This chapter describes a research study where I validated a commonly used symptom 
survey for patients with end-stage kidney disease, thus paving the way for its 
widespread adoption and use. 
Chapter 5: Qualitative research: living on dialysis 
Survey-based research described in earlier chapters allows quantification of pre-selected 
outcomes such as symptoms. I anticipated that qualitative analysis of conversations 
with those already on dialysis would yield insights into the outcomes considered 
important by older patients. This chapter presents the methodology and results of a 
qualitative study into the experience of dialysis by older individuals. I summarise the 
patient perspectives on what ‘doing well on dialysis’ means to them.  
Chapter 6: Discussion and Conclusion 
In this final chapter, I summarise the findings in the thesis and consider how they relate 
to the initial objectives. I draw on the lessons learnt from the literature review and our 
research studies to propose checklists of important factors and possible initiatives for 
the clinical team to consider as they try to improve outcomes for older patients with 
ESKD. Next, the possible contributions from this thesis to the existing literature are 
summarised, followed by a consideration of the implications for routine practice. Areas 












               
            
          
         
               
            
          
         
           
             
          
            
          
        
 
    
!"# $%&'&(&) *&% '"# )+'#%,'-%# %#.+#/ ",0 1##2 $-1)+0"#3 +2 '"# 456 7$#2 8&-%2,) 9,23 
,$$#23#3 1#)&/:; <&))&/+2= '"+0 '"# (&>$)#'#3 0(&$+2= %#.+#/ +0 ,'',("#3; !"+0 %#.+#/ 
",0 1##2 0-1>+''#3 *&% $-1)+(,'+&2; ?-$$)#>#2',%@ >,'#%+,) +0 ,.,+),1)# &2)+2# 90##
?#('+&2 A;B;B: ,23 +2 '"# ,$$#23+C 9',1)#0 DEB '& DEF:;
!"# $%&'()#*+,(%& %- %.,$%/#' (' $*.$(+0 ,% ,"# )('$.''(%& 1#,2##& $0(&($(+&' +&)
3+,(#&,'4 5%2#6#*7 ,"#*# (' + )#+*," %- 3.10('"#) (&-%*/+,(%& +1%., %.,$%/#' (& ,"# 
0(,#*+,.*#7 3+*,($.0+*08 -%* %0)#* +).0,'7 +&) 3+*,($.0+*08 -%* %.,$%/#' %,"#* ,"+&
/%*,+0(,84 98 .,(0('(&: + '$%3(&: *#6(#2 -%*/+, 7,"# $%00#$,(%& +&) '8&,"#'(' %-
(&-%*/+,(%& -*%/ 6+*(#) '%.*$#' (' 3%''(10#4 !"(' (&-%*/+,(%& (' '.1'#;.#&,08
'.//+*('#) +&) 3*#'#&,#) (& ,"# -%00%2(&: ,+10#' +&) :*+3"'4
Chapter 2 :




2.1 Older patient considering treatment for 
advanced renal disease: protocol for a scoping 
review of the information available for shared 
decision-making  
 
This protocol has been published as: 
Raj R, Ahuja K, Frandsen M, Murtagh FEM, Jose M. Older patient considering treatment 
for advanced renal disease: Protocol for a scoping review of the information available 
for shared decision-making. BMJ Open 2016; 6:e013755. doi:10.1136/bmjopen-2016-
013755. 
This is an Open Access article distributed in accordance with the Creative Commons 
Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to 
distribute, remix, adapt, build upon this work non-commercially, and license their 
derivative works on different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ 
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Introduction: Older adults constitute the largest
group of patients on dialysis in most parts of the
world. Management of advanced renal disease in
the older adult is complex; treatment outcomes and
prognosis can be markedly different from younger
patients. Clinical teams caring for such patients are
often called on to provide information regarding
prognosis and outcomes with treatment—
particularly, the comparison between having dialysis
treatment versus not having dialysis. These
discussions can be difficult for clinicians because
they have to contend with incomplete or nascent
data regarding prognosis and outcomes in this age
group. We aim to summarise the currently available
information regarding the prognosis and outcomes
of advanced renal disease in the older adult by
means of a scoping review of the literature. This
article discusses our protocol.
Methods: This scoping review will be undertaken
in accordance with the Joanna Briggs Institute’s
methodology for scoping reviews. A directed search
will look for relevant articles in English (within
electronic databases and the grey literature), written
between 2000 and 2016, which have studied older
patients with advanced renal disease (estimated
glomerular filtration rate <30 mL/min/1.73 m2). After
screening by two independent reviewers, selected
articles will be analysed using a data charting tool.
Reporting will include descriptions, analysis of
themes using qualitative software and display of
information using charts.
Ethics and dissemination: This scoping review
will analyse previously collected data, and so does
not require ethical approval. Results will be
disseminated through academic journals,
conferences and seminars. We anticipate that our
summary of the currently available knowledge
regarding the older adult with advanced renal
disease will be a repository of information for
clinicians in the field. We expect to identify areas of
study that are suited to systematic reviews. Our
findings can also be expected to influence
guidelines and clinical practice recommendations in
the future.
Strengths and limitations of this study
▪ Previous reviews have not attempted to systemat-
ically collect, describe and synthesise all the con-
siderations in making treatment decisions for the
older adult with advanced renal disease. This
review will collect information across quantitative
and qualitative spectra of research, drawing on
both published and grey literature. It will also
describe data that highlights patient and carer
perspectives, both of which are relevant to this
life-intrusive illness and its treatment. This
widens the sources of information beyond
those traditionally used for systematic reviews
in the area - this will be a strength of the pro-
posed study.
▪ Such a wide-ranging review can serve as a
useful repository of information for clinicians
and others working (or conducting research) in
this area; it can suggest areas for further system-
atic reviews and contribute to generating
guidelines.
▪ The scoping review conducted according to this
protocol will address the information available
for the shared decision-making process in the
older adult. So as to preserve focus, it does not
include other aspects of dialysis decision-
making, including how this information is pre-
sented/received, types of decision-making
models, decision science, the impact of health
literacy, socioeconomic factors, mental capacity
and cognition, cultural/language barriers or
resource limitations.
▪ Studies included will not undergo a formal
quality assessment—this is part of the design,
as a scoping review attempts to describe all the
information available, rather than only select the
highest quality of evidence.
▪ This protocol is for a scoping review that only
considers material written in English. Potentially,
large populations of the non-English-speaking
world may not be represented. Our conclusions
may not apply to the different cultural and social
environments in these regions.
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BACKGROUND
Approximately half of all patients on dialysis in Australia
at the end of 2014 were aged 65 and above. Patients
aged 65–85 years have the highest incidence (patients
per million) of renal replacement therapies.1 These
numbers will conceivably rise in subsequent years as the
population on dialysis ages, and as incident patients are
added. However, several researchers have suggested that
the older patient may not do well on dialysis in terms of
quality of life, preservation of independence or survival.
Studies suggest that in the presence of severe comorbid-
ities such as frailty or heart disease, there is no survival
advantage to being on dialysis.2 On the contrary, some
older patients who choose not to have dialysis enjoy a
good quality of life, and may not have a significantly
shortened survival in comparison.2–6
Several renal units now also offer a distinct, non-
dialysis pathway of care for patients opting not to have
dialysis treatment for end-stage renal disease—thus pro-
viding another valid and available treatment choice for
these patients.7 This pathway may be called the ‘conser-
vative’, ‘supportive’ or ‘renal palliative’ care pathway.
Principles of holistic care in the management of the
older patient are widely applicable—including detailed
symptom management, advance care planning, func-
tional assessment and appropriate support, and targeted
measures to improve quality of life. However, uncertainty
exists regarding the benefits of dialysis therapy in the
older adult. Predicting which older patient will do well
on dialysis is quite difficult.
Nephrologists and other members of the renal team
are often central to the discussions around treatment
choices for advanced renal impairment. National organi-
sations, such as the Australia New Zealand Society of
Nephrology or the Renal Physicians Association in the
USA, suggest a process of shared decision-making for
patients considering dialysis.8 9 Shared decision-making
is defined as ‘a process by which a healthcare choice is
made by the patient (or significant others, or both)
together with one or more healthcare professionals’.9
Clinical practice recommendations in this area suggest
that ‘nephrologists do not shy away from these discus-
sions’—rather, they suggest, treating teams ought to have
‘realistic discussions’ with patients about survival and
quality of life with and without dialysis treatment.8 9
The provision of information is an important compo-
nent of shared decision-making, as exemplified in
several popular models of the process. For instance, in
the Interprofessional Shared Decision-Making Model,10
‘information exchange’ is an integral part of the
process. Similarly, in the model suggested by Elwyn and
colleagues,11 which consists of a 3-step shared decision-
making model for clinical practice—‘choice talk, option
talk and decision talk’, provision of information is an
integral part of discussions about options and choice.
Accurate information is central to shared decision-
making, as it ‘rests upon knowing and understanding
the best available evidence on the risks and benefits
across all available options, while ensuring that the
patient’s values are taken into account’.10 However, pro-
viding or accessing such information often proves diffi-
cult for the clinician, as sufficient, comprehensive
information is not readily available.
Comprehensive conservative treatment for renal
impairment that does not include dialysis is an actively
evolving paradigm of care, with few practices backed by
high-quality evidence, making standardisation difficult.
Additionally, most such care is provided in heteroge-
neous settings, by different professionals (eg, multidis-
ciplinary clinics). Such factors make head-to-head
comparisons of the two modalities (dialysis vs non-
dialysis) cumbersome, limiting the information available
for a discussion comparing the two pathways.
There are other practical difficulties. Studies have
shown significant variability in how different doctors
make decisions about recommending dialysis.12 13
Estimates of prognosis made by doctors are likely to be
inaccurate. Age and non-renal factors may not always
receive consideration. Factors such as comorbidities,
frailty, mental status, dependency for transfers and resi-
dence in a nursing home can all impact on the progno-
sis on dialysis, but it is difficult to consider these
variables systematically in making decisions. Efforts to
construct prognostic indices for the older adult consider-
ing dialysis have met with limited acceptance. Often,
these indices document prognosis for patients already
on dialysis, or they do not consider non-renal factors.
Not surprisingly, patients may consider non-medical
factors important to their decision—such as the number
of hospital visits required, or the restrictions on
travel.14 15 Clinicians may not be aware of such research
into patient and caregiver preferences for treatment or
end-of-life choices.
In summary, there are uncertainties and gaps in
knowledge when renal teams are called on to provide
appropriate comparisons between treatment with or
without dialysis in the older patient with advanced
renal disease. The life-sustaining nature of dialysis pre-
sents difficulties in the design of a randomised trial
comparing dialysis treatment with treatment without
dialysis in this population. Given this scenario, the
scoping review methodology, extending across quantita-
tive and qualitative research domains, appears well
suited as a first step in detailing the breadth of informa-
tion available in this particular area at present. From
the information gathered, we anticipate that the need
for future systematic reviews in particular areas will be
identified.
METHODS AND ANALYSIS
(Please see figure 1 for a flow chart detailing the major
steps in the scoping review.)
This scoping review will be undertaken in accordance
with the Joanna Briggs Institute’s methodology for
scoping reviews.16
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From readings of published literature and clinical
guidelines/recommendations, we anticipated, empiric-
ally, that five broad categories of information are likely
to be relevant to the discussions around treatment
options for the older adult, as follows:
▸ information about prognosis/survival in older
patients with advanced renal disease managed either
with or without dialysis treatment;
▸ information about quality of life in older patients
with advanced renal disease managed either with or
without dialysis treatment;
▸ information describing the lived experiences of the
older adult with advanced renal disease;
▸ information on the factors important to older
patients and their careers as they make treatment
choices around advanced renal disease;
▸ other factors, not included above.
A preliminary search of the literature in The Cochrane
Library, JBI Database of Systematic Reviews and
Implementation Reports, TRIP database and Prospero
failed to identify a scoping review that summarises the
entire range of considerations discussed above.
Operational definitions
Older adult
Different chronological ages have been used in the lit-
erature to define the term ‘older adult’ or ‘elderly’.17 In
order to include all relevant data, we will include studies
where the population studied has been described by
primary researchers as ‘elderly’, ‘geriatric’ or ‘older
adult’ without specifying beforehand an age cut-off to
define the older adult. In the summaries created, we will
mention the ages of patients included under this term
in relevant studies.
Patients with advanced renal disease
This is defined as patient populations in any of the fol-
lowing categories:
▸ having established (>3 months) renal impairment
with an estimated glomerular filtration rate (eGFR)
of <30 mL/min/1.73 m2;
▸ described as having ‘advanced renal disease’ by the
primary researchers;
▸ receiving education regarding renal replacement
therapies;
Figure 1 Flow chart of proposed scoping review.
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▸ on dialysis;
▸ on non-dialysis, supportive or conservative care.
Carers
Includes all individuals involved in directly caring for
the patient, whether associated through family, friend-
ship or marriage.
Clinicians
Clinicians include doctors, nurses and allied healthcare
staff directly involved in the medical care of, and the
shared decision-making process with, patients and
carers.
Dialysis treatment
Dialysis treatment involves renal dialysis, including all
forms of haemodialysis and peritoneal dialysis, including
in-centre, home-based, assisted or self-care approaches.
Conservative care
Conservative care includes care given to patients with
advanced renal disease who have decided not to
undergo dialysis treatment, described as ‘non-dialysis’,
‘supportive’, ‘conservative’ or ‘palliative’ renal care.
Objectives
The objective of this review is to identify and summarise
the nature and scope of information available for consid-
eration when discussing treatment options for advanced
renal disease with an older patient.
The study aims to synthesise information from quanti-
tative and qualitative literature, so as to
▸ provide a coherent summary for clinicians;
▸ explore the need for future comprehensive systematic
reviews on the subject.
Review questions
The questions for this scoping review are as follows
(summarised in box 1):
▸ What information is available to be used in the
shared decision-making process for the older adult
considering treatment options for advanced renal
disease? Specifically, the details examined are:
▸ markers of prognosis (survival) in the older patient
with advanced renal disease;
▸ factors influencing quality of life in the older
patient with advanced renal disease;
▸ reports of lived experiences of older adults under-
going treatment (with or without dialysis) for
advanced renal disease.
▸ What do we know about the information needs of
older adults and their carers as they consider treat-
ment options for advanced renal disease?
Inclusion criteria
Study selection
This scoping review will consider, for all questions, arti-
cles that address the older adult with advanced renal
disease, their carers or the clinicians involved in their
care, regardless of sex, region, diagnoses or comorbid-
ities (see figure 1). Articles from peer-reviewed scientific
literature as well as those from grey literature will be con-
sidered (details below).
Concept
The core concept of this scoping review is to provide a
summary of the breadth of information relevant to dis-
cussions and decision-making in the older adult with
advanced renal disease who is considering treatment
options. The primary focus is on the information that is
likely to be of value in choosing whether to have dialysis
(any type of dialysis) or not. With regard to the specific
questions articulated above,
▸ For question 1, studies that report on prognosis, prog-
nostic indices, survival and mortality in the popula-
tion described will be considered for inclusion.
▸ For question 2 (A), studies that describe quality of
life data in this population, either in isolation or in
relationship to other variables, including descriptive/
observational and interventional studies will be
included.
▸ For question 2 (B), studies that describe the lived
experience of these patients and their carers will be
considered.
▸ For question 3, studies that have described the infor-
mation needs of older adults and their carers around
the decision-making process in advanced renal
disease will be considered.
Context
This scoping review will consider articles pertaining to
the older adult in inpatient, outpatient, home or resi-
dential care facility settings.
Sources: study types
(Please see online supplementary table S1 for a draft
version of the initial appraisal tool.)
This scoping review will consider quantitative and
qualitative study designs, including:
Box 1 Review questions
1. What are the factors affecting prognosis and survival in the
older patient with advanced renal disease either choosing to have
dialysis treatment, or choosing to have conservative care without
dialysis?
2. (A) What factors influence the quality of life in the older patient
being treated for advanced renal disease?
(B) What information is available regarding the lived experiences
of older adults treated for advanced renal disease?
3. What is known about the information needs of older adults and
their carers considering treatment options for advanced renal
disease?
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▸ Experimental and quasi-experimental studies (rando-
mised and non-randomised controlled trials), before
and after studies and interrupted time-series studies.
▸ Analytical and descriptive observational studies
including prospective and retrospective cohort
studies, case–control and cross-sectional studies, case
series and case reports.
▸ Qualitative studies will also be considered that focus
on qualitative data including, but not limited to,
designs such as phenomenology, grounded theory,
ethnography, qualitative description and action
research.
▸ We will also include searches of the grey literature
(see description of databases below).
▸ Textbook chapters and opinion papers will also be
considered for inclusion.
▸ We will also include recommendations made by
national bodies involved in setting standards and pro-
viding guidelines for renal care.
Studies published from January 2000 to October 2016
will be included so as to reflect the increasing number
of older patients on dialysis, the changing attitudes to
the treatment of older adults in recent years and the
establishment of conservative care without dialysis as a
valid treatment option. Only studies with abstracts pub-
lished in English will be included in the initial screening
process.
Exclusion criteria
▸ research that does not address older adults (see oper-
ational definition above) as a main or subpopulation
of interest;
▸ research that exclusively addresses patients with an
eGFR >30 mL/min/1.73 m2;
▸ studies in languages other than English.
Search strategy
An initial limited search of MEDLINE, Scopus, Embase,
PsycINFO, CINAHL and Cochrane Library databases has
been undertaken to identify articles on this topic.
Analysis of the words contained in the titles, abstracts
and index terms used to describe these articles was used
to develop an initial list of search terms and keywords, as
follows:
▸ humans; aged; geriatric; elderly; older;
▸ chronic kidney disease; chronic kidney failure;
chronic renal insufficiency; renal replacement
therapy; renal dialysis;
▸ conservative care; palliative care; supportive care;
withholding treatment;
▸ risk assessment; risk factors; logistic models;
▸ time factors; life expectancy; Kaplan-Meier estimate;
▸ treatment outcome; prognosis; prognostic score;
quality of life; lived experience; adaptation,
psychological;
▸ patient selection; decision-making; information
needs; patient preference; patient education;
physician advice; doctor–patient communication;
surveys and questionnaires.
The keywords/search terms will be appropriately used
for each database. As studies are being considered, their
reference lists will be screened for additional studies.
Databases searched
The following databases will be searched: PubMed
PsycINFO, CINAHL, Embase, Scopus, Mednar, Turning
research into practice, NTIS, ProQuest Dissertations and
Theses, Google Scholar and Current Contents.
The search for articles in the grey literature will
include electronic sources including OpenSIGLE,
Healthcare Management Information Consortium
(HMIC) Database, National Technical Information
Service (NTIS), PsycEXTRA, BIOSIS Databases, Open
Grey, Trove, EThOS, OATD.org and OpenThesis.
The search for guidelines will include searches at the
National Guideline Clearinghouse, http://www.cari.org,
http://www.kdigo.org, the National Kidney Foundation
(NKF-DOQI), Kidney Health Australia, the Renal
Physicians Association, ERA-EDTA and national specialty
organisations (USA, UK, Australia, European).
Data extraction
Data will be extracted from papers included in the
scoping review using the draft data extraction tools listed
in online supplementary tables S2–5 by two independent
reviewers, and entered into spreadsheets. The data
extracted will include specific details about the popula-
tions, concept, context, and study methods of signifi-
cance to the scoping review question and specific
objectives. Any disagreements that arise between the
reviewers will be resolved through discussion, or with
opinion from a third reviewer. When required, authors
of papers will be contacted if possible to request missing
or additional data. The draft data extraction tool will be
modified and revised as necessary during the process of
extracting data from each included study. Modifications
will be detailed in the full scoping review report.
Data mapping/analysis/synthesis and presentation of the
results
The extracted data will be presented in diagrammatic or
tabular form that is relevant to the objectives and scope
of this scoping review. We will summarise the informa-
tion separately for each question that forms the basis of
this scoping review.
For questions 1 and 2 (A), we will present in tabular
form the various factors reported to influence progno-
sis/survival and quality of life, respectively, detailing the
number of studies for each such factor, the number of
patients studied, the settings, and provide comment
about the generalisability of the findings.
For information addressing question 2 (B)—‘the lived
experience of dialysis’; and question 3—‘information
needs for the shared decision-making process’, the find-
ings will be displayed in tabular and diagrammatic form,
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and in addition, we will use N-Vivo qualitative research
software (QSR International, Australia) to synthesise the
various themes identified.
A narrative summary will accompany the tabulated
and/or charted results and will describe how the results
relate to the primary questions around shared decision-
making in the older patient with advanced renal disease.
We anticipate that the identification of information
needs will also guide the organisation of the information
collected.
Ethics and dissemination
Ethical approval for the conduct of this study will not be
required as this research only includes analysis of previ-
ously collected data. Results will be disseminated
through academic journals, conferences and seminars.
We will attempt to publish our findings in international
open-access, peer-reviewed medical journals so that they
are freely available.
CONCLUSION
The older patient with renal disease is different from
younger counterparts on several counts—comorbidity
burden, disease progression, survival, outcomes with
therapy and considerations that influence quality of life.
A ‘one-size-fits-all’ approach to counselling and prescrib-
ing renal replacement therapy cannot be recommended.
The scoping review proposed will attempt to synthesise
the disparate pieces of information available, and to be
a resource for clinicians advising such older patients.
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2.1.1 Scoping review protocol: Supplementary material. 
Drafts of the initial appraisal tool and the data extraction tool for articles addressing 
each of the questions in the scoping review have been published as supplementary 







2.2. Shared decision-making in older adults with 
advanced renal disease: a scoping review of the 
information available 
 
The following is the final proof of the article submitted for publication as: 
Raj R, Thiruvengadam S, Ahuja K, Frandsen M, Jose M. Shared decision-making in 




Older adults may not receive the same benefits from dialysis as their younger 
counterparts. Clinicians often have to provide information regarding prognosis and 
outcomes with or without dialysis treatment. We performed a scoping review to 
summarise the information available for shared decision-making with older patients 
considering dialysis and to identify areas for further study. 
Methods 
A directed search was undertaken for articles in English (within electronic databases 
and the grey literature), published between 2000 and August 2018, studying older 
adults with advanced renal disease (eGFR ≤30 ml/min/1.73 m2). Articles were grouped 
by topic into those describing prognosis, factors influencing quality of life, lived 
experience of dialysis or information needs of patients. Research comparing dialysis 







 Two independent reviewers screened 15,445 initial results and selected 248 for 
final analysis. Original research focused primarily on prognosis or described lived 
experience; comparatively fewer addressed factors affecting quality of life or patients’ 
information needs. We summarised prognostic instruments and factors affecting quality 
of life; reported comparisons of conservative care to dialysis, and suggested 
improvements to provision of patient-centred information. We propose areas for future 
research. 
Conclusion 
Increasing age and comorbidities reduce survival and other health benefits from 
dialysis for the elderly when compared to conservative management. Although existing 
tools can predict survival, patients desire more information and greater involvement in 
decision-making. Research needs to address the provision of knowledge more relevant 






Physicians are uncomfortable about communicating prognosis to seriously ill patients 
(97,98). This is also true for nephrologists looking after patients with advanced renal 
disease (20,43,80,99,100).  There is evidence to suggest that patients receive insufficient 
information, or are unrealistically optimistic about their prognosis (68,77). Patients often 
wish they had received more information prior to commencing dialysis. For instance, 
they expect their doctors to provide them information about prognosis even without 
being prompted to do so (101,102). These descriptions, on both sides of the physician-
patient relationship, become even more important when considering shared decision-
making in elderly patients with advanced renal failure (103). 
In older patients who develop advanced kidney disease, the rate of progression of 
kidney disease may not be as rapid as their younger counterparts (104). Additionally, in 
older patients who do progress to end-stage renal failure, treatment with dialysis, 
which is the default option, may not always lead to better outcomes or improve quality 
of life (12,17) . With this in mind, several nephrology centres across the world and in 
Australia now recommend or offer a dedicated program of renal conservative 
management (that is, holistic patient management that does not include dialysis or 
transplantation) (11,13,14,105–108). The current dilemma, for patients and physicians 
alike, is in deciding which among these two options – dialysis or conservative 
management – is ideal for an individual patient (109). 
Professional nephrology associations call upon the community to ensure that decisions 
regarding dialysis, especially in the older, sicker adults, be made according to the 
principles of patient-focused, shared decision-making (71,72). Open, transparent and 
complete sharing of information, particularly with regards to prognosis and quality of 




physicians may be handicapped by the lack of appropriate information regarding 
outcomes of the various forms of treatment in the older population (110). Different 
prognostic instruments that predict renal worsening or survival exist, but while some 
are rigorously developed and validated, others may not be accurate or ideally 
developed; similarly, instruments validated in one population may not be automatically 
transferable to another population. (84,111–113) . There is a perceived paucity of 
information on outcomes other than survival – such as functional status or quality of 
life – that are important to patients.  
The numbers of older patients on dialysis are increasing (80). The information required 
to provide appropriate advice is spread across multiple domains, and not easily 
available in a consolidated form. These characteristics are well addressed by the scoping 
review format, which reports on the breadth of information available in the area, 
intending to describe the field and uncover gaps in the literature, if any. We therefore 
undertook a scoping review of the information available to the clinician for use in the 
process of shared decision-making with the older patient considering the choice 
between dialysis or conservative management. The objectives, inclusion criteria and 
methods for this scoping review were specified in a previously published protocol 
(114). In brief, this scoping review sought to address the following questions in the 
older patient with advanced renal disease:      
• What are the factors affecting prognosis and survival (with dialysis 
treatment, or with conservative management not including dialysis)? 
• Which factors influence the quality of life? 
• What information is available regarding the lived experiences with the 




• What is known about the information needs of this population as they 
consider treatment options? 
2.2.3 Methods 
The scoping review adhered to the PRISMA-ScR checklist for scoping review conduct 
and reporting, as detailed in the table provided in supplementary material (115). 
Objectives and research questions 
The objective of this review was to identify and summarise the nature and scope of 
information available for consideration when discussing treatment options for 
advanced renal disease with an older patient. 
The study aimed to synthesise information from quantitative and qualitative literature, 
with reference to the research questions listed above, so as to: 
• Provide a coherent summary for clinicians, and 
• Explore areas for future research. 
 
Inclusion criteria 
The scoping review included articles that addressed older adults with advanced renal 
disease, and focused specifically on survival/mortality, factors affecting prognosis or 
quality-of-life, descriptions of the lived experience of treatment (on dialysis or 
conservative management) or descriptions of the information needs of older adults. 
These four areas were developed by consensus between the authors after considering 
the areas of relevance to the dialysis decision.  
In order to capture all relevant data, we included all studies where the population 
studied was described by primary researchers using terms such as ‘elderly’, ‘aged’, 




Advanced renal disease was defined as an estimated glomerular filtration rate (eGFR) ≤ 
30 ml/min/1.73m2.  
 We included articles from the time period of January 2000 to August 2018. This time 
period was chosen so as to reflect the increasing number of older patients on dialysis, 
the changing attitudes to the treatment of older adults in recent years and the 
establishment of conservative care without dialysis as a valid treatment option. All 
forms of research, including quantitative and qualitative methods, and articles that 
were published in peer- reviewed literature as well as the “grey” literature were 
included. The focus was on information that was likely to be of value in choosing 
whether to have dialysis (any type of dialysis) or not. Only articles written in English 
were included (as we had limited translation resources). 
Exclusion criteria 
• research that did not address older adults (see operational definition 
above) as the main population or as a subpopulation of interest,  
• research that primarily focused on those with an eGFR > 30 
mL/min/1.73 m2), 
• research exclusively comparing variations of dialysis treatment 
modalities or transplantation with each other,  
• research describing the effects of interventions other than dialysis, or   
• research with reports in languages other than English. 
 
Search methodology 
Databases searched included: PubMed, Embase, PsycINFO, CINAHL, EbscoHost, 
Mednar, Cochrane, TRIP databases, and Web of Science for peer-reviewed research, and 




Websites of national specialty societies and clinical guideline collections were also 
searched.  Searched terms included those relevant for elderly patients, chronic kidney 
disease, dialysis, conservative management, prognosis, survival, quality of life, lived 
experiences and information needs. These terms were adapted to suit searches in 
individual databases; examples of search terms are provided in the appendix as 
supplementary material. 
Initial screening of articles was undertaken by 2 researchers (RR and ST) working 
independently, using the web-based Rayyan QCRI software (Qatar Computer Research 
Institute and Qatar Foundation, Qatar) (116). Charting of included studies and the 
extraction of relevant information was done using FileMakerPro16© (FileMaker Inc., 
California, USA) and Microsoft Excel© software (Microsoft Corporation, Washington, 
USA). Separate data extraction forms and charting sheets were used for the four 
different research questions, as shown in the published protocol (114). For included 
articles, the following data was extracted: primary author, year of publication, type of 
research, modality of treatment studied, population, focus of research, and main 












Figure 1 shows the flowchart summarising the selection of studies to be included in this 
scoping review, and the reasons for exclusion. All 15,445 articles identified in databases 
were imported into the reference management software as detailed. Subsequent 
screening of titles and removal of duplicates provided 4776 articles for review with 
abstracts. These articles were divided into groups depending on the questions of the 
survey; and 971 articles for used for full text review. Cohen’s  kappa for inter-rater 
agreement between the two reviewers screening the articles for inclusion was 0.54, 
suggesting "moderate" agreement (117). All conflicts were discussed with remaining 
authors and resolved. Finally, after perusal of full text, 228 articles were included, along 
with 20 articles found by hand-searching reference lists of included articles, making up 
248 articles selected for analysis. This included three theses obtained from screening of 
the grey literature.  
The majority of included articles have primary authors resident in the English-speaking 
countries - USA, UK, Canada and Australia. Japan, France, Taiwan and Holland were 
the other significant contributors (Figure 2-2). A greater proportion of research 
literature was written in the previous five years (2012-2017); the number of articles on 
older patients with renal failure showed an increasing trend in recent years. 
Overall, half the included articles refer to patients on haemodialysis (HD) exclusively; 
18% were studies on patients not on dialysis and 5% included all elderly patients with 
end-stage kidney disease (ESKD), regardless of treatment choice. Peritoneal dialysis 
(PD) patients alone contributed to 8% of studies while 17% included patients 










Figure 2-3: Modality of treatment in included studies 


























For purposes of analysis, the included studies were analysed in groups, according to the 
research questions for the review detailed above (prognosis, quality of life, lived 
experiences and information needs respectively). The following Section on results is 
also presented according to these questions. 
Characteristics of studies describing prognosis 
A hundred and twelve articles that specifically focused on the prognosis of the elderly 
patient with advanced renal failure were included in the review. Thirty-four were 
single centre studies; 28 involved patients in multiple centres, while 24 studies, often 
with participant numbers in excess of 1000, were conducted as registry-based research. 
Sixty-six studies (61.8%) were retrospective studies (including 20 out of the 24 registry-
based studies). Studies that only included patients on haemodialysis predominated (39 
studies). 
Content and scope of studies describing prognosis 
Mortality/survival was the commonest prognostic outcome of interest. Other outcomes 
were also studied, usually in addition to mortality included quality-of-life outcomes, 
time to renal replacement therapy/end-stage renal failure, hospitalisation, functional or 
nutritional status (see supplementary material for details).  
Researchers considered several different variables for inclusion as prognostic markers 
(Table 2-1). The stated aim in several papers was to use easily available, clinical 
indicators to predict prognosis. Most commonly, researchers used a combination of 
variables - clinical, laboratory, demographic or instrument-based data to derive 
prognosis. These variables could be grouped into sociodemographic variables 
(including age, nursing home residence), comorbidities, functional status, nutritional 
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 A common method was to use a combination of variables in order to predict prognosis. 
While some studies investigated particular combinations of variables in single cohorts, 
others reported inception and validation cohorts, presenting the combination of 
variables as an index or prognostic score. Some of these scores were developed 
specifically in patients with renal failure, while others were adaptations of prognostic 
tools used in the general population.  Table 2-2 and 2-3 describe such indices that were 
developed exclusively in the elderly or use age as a variable in the index to derive 
prognosis (therefore making them suitable for use in the elderly population). 
Table 2-2: Prognostic Indices developed in the Pre-dialysis Renal Population  
Author& 
Year 
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We identified 12 studies that compared dialysis treatments to conservative management 
without dialysis. Table 2-4 lists these studies, in chronological order, where the elderly 
have been the focus of comparisons between dialysis or conservative management. 
 
Table 2-4: Studies Comparing conservative management (CM) and renal replacement 
therapy (RRT, all forms of dialysis) 
Author/ 
year 
Aim/objectives Population of interest Main findings* Conclusions / 
Comments 




CM and RRT in 
octogenarians; 








formula), not yet on 
dialysis; seen in a 
single French unit in 
1989-2000 
 
n= 146 (CM: 37; RRT: 
107) 
Age: CM: 84.1±2.9; 
RRT: 83.2±2.9 
Later referral, poor 
functional status and 
diabetes were more 
common in CM 
cohort; number of 
comorbidities similar 
between both cohorts 
Survival: less with 





 1-year mortality: 
poor nutritional 




the first year: 
peripheral 
vascular disease 
In those > 80, best 
1-year survival is 
seen in those with 
early referral, 



















CM and RRT, in a 
group of pre-
All pre-dialysis 
patients presenting for 
assessment/counsellin
g regarding RRT 
Survival: 
Recommended 
CM: 6.3 vs 8.3 









Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
dialysis patients in 
a single UK 
hospital, analysing 
outcomes 







options in a renal 
clinic, classified into 
two groups based on 
recommended 
therapy-CM or RRT; 
followed for 3 to 57 
months; eventual 
treatment choice and 
outcomes studied 
 
n= 321 (recommended: 
CM – 63; RRT – 258) 
Age: 61.5±15.4 
(recommended: CM – 
71±12; RRT – 59±15) 
RRT: 186 started 
treatment; rest died or 
chose CM 
CM: 11 switched to 
RRT 
eGFR: by derivation, < 
10 in both groups 




Cox PH: no 
survival benefit of 
RRT in those 
recommended for 
CM, regardless of 
eventual choice 
 






likely to survive 
one year 
diabetes, who are 
recommended for 
CM, no survival 
benefit from RRT 
Murtagh et 
al, 2007 (74) 
Comparison of 
survival between 
CM and RRT in 
patients ≥ 75 from 
4 UK renal units; 
retrospective 
study 
All patients ≥ 75 
receiving renal care, 
with survival 
calculated from the 
date of first recorded 
eGFR ≤15 
 
n= 129 (CM 77, RRT 
52). 
Median age: CM 83; 
RRT 79.6 
Comorbidities: similar 
CM cohort: older; but 
otherwise similar 
After eGFR ≤ 15: 
Median survival 
time: less in CM 
(540 Vs. 588 days) 
1-year survival 
rate: lower in CM 
(68% vs 84%) 
2-year survival 
rate: lower in CM 
(47% vs 76%) 




difference CM vs 
RRT 






RRT over CM 
 






patients who had 
Patients older than 70 
who either started 
RRT or attended CM 
clinic from 1997 to 
2003 
 
CM cohort was 
older. Survival: 
less with CM  
[13.9 vs. 37.8 
months] 
In those > 70, RRT 
provided longer 
survival (by 2 
years) than CM, 
but there were 






Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
ESKD and chose 
either CM or RRT 
n= 202 (CM: 29; RRT: 
173) 
Age: CM: 81.6; RRT: 
76.4 
eGFR: Median value at 
start of RRT was 10.8. 
For CM group, 
survival calculated 
from the time they 
were estimated to 
reach eGFR 10.8. 
Comorbidity scores: 
similar in both groups 
 
Hospitalisation: 
less with CM 
during follow up; 
CM cohort more 
likely to die at 
home or hospice 
than hospital 
(odds ratio 4.15) 
hospital-free days 
in both RRT and 
CM 
Chandna et 
al, 2011 (136) 
Comparison of 
survival between 
CM and RRT in 
ESKD patients 
with high vs. low 
comorbidity in UK 
clinic from 1990-
2008 
All adults progressing 
to stage 5 CKD seen in 
clinic over 18 years; 
followed from the 
time of first recorded 
eGFR @10 to 15. 
n= 844 (CM 155, RRT 
689) 
Ages: CM 77.5±7.6; 
RRT 58.5±15. 
eGFR: 13.2±1.4 in both 
groups at study entry. 
Comorbidity scales 
scored for every 
participant 
 


























RRT over CM 
 
Hussain et 






CM and RRT 
cohorts of elderly 
patients in a single 
UK unit; studied 
retrospectively 
All patients aged >70 
and eGFR <20, 
receiving advice 
regarding CM vs RRT 
during pre-dialysis 
education. Survival 
was calculated from 
three time points: 
when the eGFR was 
<20, <15 and <12. 
Survival from all 
three time points: 
less with CM 
Survival from 
eGFR <20 2.4 years 




In those >80, no 
survival 
advantage for 
RRT over CM 
 










Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
 
n= 441 (CM 172, RRT 
269). 
Age: CM 82±5.6; RRT 




score worse in CM 
cohort; CM cohort 
more likely to be 
institutionalised 
CM & RRT is 
reduced in: 
- those > 80:  







risk:  more with 




review: more with 





RRT over CM 




related quality of 
life between CM 
and RRT in 
patients with 




eGFR 8 - 12, who were 
>75 or had CCI>8, seen 
in single Singapore 
hospital. 
Quality of life for 
assessed with 
KDQOL-SF v1.2, 




n=101 (CM 63, RRT 38) 
Age: CM: 78; RRT 71. 
eGFR: similar in both 
groups. 
eGFR decline: faster in 
RRT group 
PCS, MCS stable in 







scale, but worse 
scores on effective 
kidney disease and 
burden of kidney 
disease scale 
In those > 75 with 
severe 
comorbidity, RRT 






compared to CM 







, EOL care) for 
Chinese patients 
with CKD stage 5 
Adults ≥ 65; followed 
for at least 1.5 years 
from first dialysis 
assessment visit; 
retrospectively chosen 
from the period 2003- 
2010; 
 
CM cohort was 
older, less likely to 
have home help 
with PD. 
Survival: less with 
CM 
[2.35 vs 3.75 years] 
In those > 65, 
home-based PD 
provided greater 
survival than CM, 
with less 
hospitalisation 






Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
that chose either 
CM or PD 
n=199 (CM 42; PD 157) 
Age:  
CM 75.3±5.7; PD: 
73.4±5.3  




more with CM 
cohort than PD 
cohort even after 




: risks were 
similar. 
EOL care: CM 
cohort more likely 
to receive renal 












quality of life 
between CM and 
RRT in elderly 




All patients receiving 
care in pre-dialysis, 
renal supportive care 
or emergency dialysis 
start pathways. 
Symptoms, quality of 
life assessed using 
surveys. 
 
n= 467 (CM 122, RRT 
345). 
Age: CM 82±9; RRT 
67±14  
eGFR at study entry: 
16 in both groups 
 
Survival: less with 
CM  
(20 vs 33 months) 
Survival in those > 
75:  
less with CM (19 
vs 31 months) 
Mean survival 
from eGFR<15:  
less with CM (13 
vs 20 months) 
Mean survival, 
eGFR<15, age> 75: 





(IHD or CHF) ≥ 2: 
not statistically 
different 
Symptom control:  
similar in both CM 
and RRT 
Quality of life 
changes:  
In those >75, with 










Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
similar in both CM 
and RRT 
Verberne et 
al, 2016 (140) 
Comparison of 
survival between 
CM and RRT in 
patients ≥ 70; 
retrospective 
study single Dutch 
hospital 
All patients ≥ 70 
receiving renal care in 
one centre, eGFR <20. 
Survival calculated 
from time of decision 
regarding RRT/CM 
 
n= 311 (CM 107, RRT 
204). 
Age: CM 82.5±4.5; RRT 
75.9±4.4 
eGFR: CM 15.3, RRT 
13.1  
eGFR decline: similar 
in both groups 
Comorbidities: similar 
Survival: less with 
CM (0.5 vs 2.8 
years at eGFR<10; 
1.5 vs 3.1 years at 
eGFR<15) 
Survival in those 
over 80: no 
statistically 
significant 
advantage (1.4 Vs 
2.1 years, p 0.08) 
Survival in those 
with high 
comorbidity: 
benefit of RRT 
significantly 
reduced (1 vs 1.8 
years, CM vs RRT) 








al, 2016 (141) 
Comparison of 
survival between 
CM and RRT in 
elderly patients in 
a single Spanish 
unit; studied 
prospectively 
All patients aged >70 
receiving care in the 
advanced CKD clinic, 
with separate analyses 
in those with CKD 
stage 5 regarding CM 
vs RRT and survival 
 
Group with eGFR<15: 
n= 162 (CM 93, RRT 
69). 
Median Age: CM 78; 
RRT 76   
eGFR at study entry: 
14 in both groups 
Survival (overall 
study duration): 
less with CM (39 
vs 65 months) 
Survival from 
eGFR<15: less with 
CM (21 vs 46 
months) 
Survival in those > 
75: less with CM 
(p=0.003) 
Survival in those > 
80: no difference 
between CM vs 
RRT 
 
Survival in those 
with IHD - no 
difference between 
CM vs RRT 
Survival with high 
comorbidity CCI 
score: less with 
CM (p=0.009) 
In those >80, no 
survival 
advantages from 
RRT over CM 
 
In those > 70 with 
IHD, survival 








Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
Chandna et 
al. 2016 (142) 
Investigation of 
role of rate of 
kidney function 
decline on survival 
and treatment 
choices in older 
ESKD patients 
seen in UK clinic 
from 1995-2010 
Patients over 75 years 
old progressing to 
eGFR 10-15, seen in 
renal clinics between 
1995-2010; (second 
follow-up eGFR taken 
prior to dialysis start 
or prior to death (CM 
patients) to calculate 
the rate of decline of 
eGFR) 
 
n= 250 (CM: 158; RRT: 
92) 
Age: 80.9±4 (CM: 
82±4.1; RRT: 79.1±3.1) 
Index eGFR:  
13.3±1.4 in both 
groups. 
Follow-up eGFR:  
CM: 8.8±3.2; RRT: 
6±2.5 
Median rates of eGFR 
decline (ml/min/mth):  
CM: 0.21; RRT - 0.45; 
(p<0.001) 
CM cohort: similar 
age, more 
comorbidities, but 
slower rate of 
decline in eGFR 
 
Survival: less in 
CM  
(23.1 vs 38.2 
months) 
Survival with high 
comorbidity: less 
in CM  
(20.3 vs 28.4 
months; p<0.049) 
 
High rate of eGFR 
decline: worse 
survival in CM, 
minimal effect in 
RRT 
 
Predictors of RRT 
choice:  
Age > 75, gender, 
comorbidity, rate 
of decline of eGFR. 
 
In those > 75 with 
high comorbidity, 
only marginal 
advantage of RRT 
 
Rapid rates of 
eGFR decline 
worsens survival 




CM choice is more 
often taken in 
patients with low 
rates of decline 
Reindl-
Schwaighofe




CM and RRT in 
the same era, 
using Austrian 




All patients > 65 years 
starting haemodialysis 
between 2002 and 2009 
in the Austrian 
dialysis and transplant 
registry were 
compared to patients 
managed 
conservatively, after 
the GFR declined <10; 
in a single hospital 
(aged >65, in 2002 – 
2009); bootstrapping 
used for propensity 
scores 




Survival: less with 
CM (1.1 months vs 
26.9 months) 
Survival benefit: 
less with CM (HD 







In those >65, with 
comorbidities, 
survival benefit 
for RRT did not 
persist beyond 2.9 
months (females) 








Aim/objectives Population of interest Main findings* Conclusions / 
Comments 
n = CM – 174; RRT 
(only HD) – 8622 
Age: CM 81.22±7.23; 
RRT 74.06±5.78 
eGFR: CM <10; RRT - 
not specified 
 
*Confidence intervals, interquartile ranges and P values not included for all articles. 
 
Characteristics of studies describing effects on quality of life 
Eighty studies were selected as being representative of research that evaluated the 
factors that influence the quality of life in older adults on dialysis. Of these, 29 were 
clinical research papers, the rest being reviews of related topics or expert opinion.  
Among the 29 articles reporting on original clinical research, 24 used questionnaires or 
surveys to interrogate quality of life. The supplementary materials include a list of the 
commonly used instruments to measure quality of life in the elders on dialysis. 
Content and scope of articles discussing factors influencing quality of life 
Table 2-5 lists the factors affecting quality of life, identified from analyses of the 





Table 2-5: Factors affecting quality of life 






Unplanned dialysis starts 
Depression 
Cognitive impairment 









Socio-economic status (some aspects 
amenable to interventions) 
Comorbidities (some aspects amenable to 
interventions) 
Dialysis -related factors (dialysis vintage, 




Age had an impact on quality of life. While physical aspects of quality of life in the 
elders was low, especially once on dialysis, other aspects of quality of life such as life 
satisfaction, mental component scores or social well-being appeared to be more stable in 
older than younger patients (144,145).  
Researchers who compared the quality of life outcomes in older people between the 
conservatively managed pathway versus the renal replacement pathway reported either 
no major differences between the two, or worse quality of life with dialysis (52,139,146).  
Psychological factors were relevant to quality of life. Depression scores, spiritual and 
emotional well-being and even cognitive impairment have been reported to affect 
quality of life (147,148). Functional impairments and frailty, diminished exercise and 
impaired activities of daily living all worsened quality of life. Despite diminishing 
functional status, rates of hospitalisation were not significantly different between older 
and younger patients on dialysis (149). For patients already on dialysis, several dialysis 




in dialysis regimes or the duration of dialysis sessions. Finally, other comorbidities such 










Several studies used scores or indices to study life on dialysis; importance is also given 
to symptoms, functional and cognitive aspects (and, particularly in this age group, to 
falls). Discussions of decision-making, survival and ageing were also common. 
Elderly patients reported  difficulties in getting information, feeling disempowered and 
dominated by the healthcare team and not being part of decisions (150). Patients 
reporting disempowerment were more likely to regret the decision to go onto dialysis; 
this was more common if they started dialysis from family compulsions (151). Patients 
wanted greater involvement in deciding practical aspects of dialysis such as dry weight, 
the time of treatment, dietary restrictions or the access to use for dialysis (152).  
Coping and adaptation to treatment were important parts of the narrative. Successful 
coping was vital (153). Patients that coped successfully had “a transformed care 
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dynamic,  positive appraisal and active everyday engagement” (153). Useful coping 
strategies included letting go, overcoming, keeping a sense of humour, looking at the 
good side of things and thinking positively (154,155). 
The incurability of renal failure forces patients to reinvent themselves, make 
compromises or adopt beliefs or behaviours discordant with medical opinion (156–159). 
Despite these burdens, the majority of patients reported satisfaction with treatment and 
improvement of symptoms; another study found that the majority of patients reported 
no decision regret or ambivalence about starting dialysis (46,160). It should be noted, 
however, that patients’ decisions, goals and expectations are not static but change with 
time as different issues emerge (151,161). 
Patients constantly reflect on themselves in relation to others - being a burden, receiving 
help or having other relationships (157,162). Partnership was frequently mentioned, 
whether spousal or with professionals (153,163). Patients reported close and supportive 
relationships with healthcare professionals in some centres; dialysis nurses often 
encouraged patients to be independent and assisted with coping (160). Otherwise, 
elders reflected on the busy cultures of units, with infrequent opportunities to speak to 
doctors (164). 
Several included studies referred to the effects of dialysis on the functional status of 
older patients, particularly in the first six months where up to 30% face decline 
(56,165,166). This is even worse for patients living in nursing homes where 61% 
declined in functional status or died within the first three months; this figure was 87% 
at one year (58). Falls are common, particularly soon after dialysis (167). 
The symptom burden was high, and this was confirmed by qualitative studies which 
provided stories of suffering and burden inflicted by dialysis (168). Despite this, scores 




equal to or better than that for younger patients (144).  Other correlates of a good 
quality of life in these studies included living with family rather than alone or in a 
nursing home and having widespread social relationships. The social well-being of 
elderly dialysis patients did not decline significantly with time (169,170). Physical scores 
were uniformly lower (58,171,172). There were several interactions among these factors, 
such as those between cognition and depression, physical decline and risk of falling and  
insomnia and depression (173,174). Octogenarians were frequently hospitalised for 
infections; while those patients who had access to a conservative management pathway 
were less likely to be admitted to hospital, particularly at the end of life (16,149). 
Older patients are aware of impending mortality and frequently contemplate death 
(175). These topics are difficult to talk about (176). The haemodialysis machine is seen as 
a lifeline as it attempts to relieve suffering even though dialysis can be seen as a prison, 
or between life and death (150,156,162). Thoughts of stopping dialysis arise often - 
increasing age, female gender, dementia and prior cerebral vascular disease are risk 
factors for withdrawal (177,178).  
Characteristics of studies reporting on information needs of the elderly 
A total of 32 articles, mostly published in the last 10 years, were concerned with 
information needs of elderly patients with advanced renal failure. Seventeen articles 
were original research papers, eight were opinion pieces and six were reviews 
(predominantly narrative reviews). Most research was in the qualitative realm (12/17 






Figure 2-4 Information needs - themes elicited 
 
Content and scope of studies reporting on information needs in the elderly 
Articles discussed broad themes which are summarised in Figure 2-4 above. The most 
frequently recurring theme related to the need for complete information about 
treatment modalities, including non-dialysis pathways.  Such information is not 
uniformly provided to patients - discussion about conservative care options, for 
instance, was more likely to happen if the particular renal unit had an established 
conservative treatment pathway (68). 
Considering the perceived uncertainty regarding kidney disease and its treatment 
requirements, patients desire information about kidney disease, progression and the 




though survival was an important aspect of prognosis relevance to patients, they often 
report not receiving information regarding this. Clinicians are hesitant or unwilling to 
discuss prognosis for many reasons (because of uncertainty, not wanting to take away 
hope, et cetera) (20). Yet, this is vital information which could affect the choices they 
make about therapy. Fine and colleagues,  in two separate questionnaire-based studies 
on  pre-dialysis populations, showed that patients expect doctors to give them 
prognostic information even without being prompted (101,102). 
Mortality, and thoughts about dying, were very common, especially in those 
considering conservative treatment or discontinuation of dialysis. Some patients were 
reticent to engage with the topic of discontinuation and death because they found 
themselves overwhelmed, and continued dialysis even without making a deliberate 
choice to do so -  they did not want to think about other options since they knew that 
death was certain without dialysis (37). The frequent discussion of mortality and 
consideration of future care by elderly patients suggests that they will be amenable to 
advance care planning discussions. 
Information needs and dialysis decisions are a fluid process, subject to change for most 
patients (179). With limited choices, the alternative to dialysis is often interpreted as 
death (40). Patients welcomed the opportunity to participate in shared decision-making 
but regretted the "pressure" they felt from the clinical team for a decision (180). They 
sought information on the outcomes if they did not have dialysis or withdrew from 
treatment (37). In general, they requested information pertinent to the elderly and 
reflective of patient-centred values and considerations (73). Patients had their own 
estimates about the importance of quality of life for survival rather than the perceived 
benefits of treatment (42,73,181). As expected, patients had different preferred learning 




verbal. It was important that information be presented in small chunks, in simple rather 
than complex terms and without medical jargon (182). 
Several practical issues were important to patients. These included information on the 
need for lifestyle, diet or fluid intake changes, travel, hospital visits, anticipated support 
needs and availability of support services in the community (8).  
 
2.2.5 Discussion 
The aim of the scoping review was to collate the information available for decision-
making in older adults considering dialysis, so as to serve as a reference for physicians 
and others involved in shared decision-making. While several prognostic models and 
prediction instruments that estimate survival have been developed, decision-making for 
patients, carers and their healthcare professionals does not rely merely on survival 
statistics (183). Rather, a deliberate approach, which takes into consideration several 
other factors, including the needs of the patients themselves, should be considered. We 
gathered information on prognosis, the factors affecting quality of life, the lived 
experiences of older patients with advanced renal failure and the information needs of 
these patients.  
Addressing prognosis, the majority of studies focused on mortality as an outcome. 
Several variables have been reported as important prognostic factors among the 
included articles, with advancing age and increasing comorbidity exerting prominent 
influence. We also identified a variety of prognostic indices available for use in the 
older population; we anticipate that this will benefit clinicians who can choose tools 
relevant to their own patients. Use of these indices have been recommended as an 
important part of the shared decision-making process (71,72). We specifically 




since advancing age has its own prognostic import which needs to be considered 
separate from many of the other factors that operate in people of all ages (103). It is 
worthwhile remembering that the information obtained using prognostic indices can be 
used not only to inform patients of risk, but also to help plan treatment pathways. 
Given the lower risk of progression of renal disease in the elderly, a prognostic index 
predicting risk of progression to ESKD will be useful to identify a group of patients 
most likely to progress and therefore most in need of planning for therapy. The Kidney 
Failure Risk Equation developed by Tangri et al in a Canadian population (ages around 
70 in original and validation cohorts) has now been validated multi-nationally (mean 
age 74 in 31 cohorts in the Chronic Kidney Disease Prognosis Consortium) (84,184). 
Available in 4- and 8-variable formats, the equation is now part of popular handheld 
applications, and can be recommended for routine use – the development of baseline 
risk adjustments for non- north American populations increases its accuracy. For 
assessment of mortality risk, the Bansal index, which was derived in an elderly 
population, is useful because it predicts the risk of death before reaching ESKD (118). 
Potentially, this index can be used to select a group of elderly individuals at high risk 
for progression. However, it must be noted that the population used for the 
development of the Bansal score had a lower number of patients with CKD stages 4 and 
5; also, the score does not take into consideration other important mortality risks such 
as frailty that are predictive in this population (185,186). Currently, the Bansal score can 
be used to identify patients at high risk for mortality that are more suited to a 
conservative line of management. 
Several papers reported that there is a cohort of very elderly patients, above 80 years of 
age, with multiple comorbidities, who derive little survival benefit from being on 
dialysis (16,140,141). The data in table 2.4 summarises the differences in survival 




dialysis are not compared with each other, some generalisations can be made. First, 
most studies are single-centre efforts, and similar standards of conservative 
management may not be replicable across different centres. Additionally, differing 
definitions of comorbidity may have been used. Nevertheless, it appears that there is no 
survival advantage to rail replacement therapy in those aged over 80. For those aged 
over 75, the presence of comorbidities takes away any survival advantage of renal 
replacement therapy. In those 65 or 70 years of age and above, in general, renal 
replacement therapy has greater survival than conservative management except, once 
more, in the presence of severe comorbidities, where the difference is less significant. 
 When elders discuss treatments such as dialysis, there is often a consideration of 
quality of life, which is often rated as important as ‘quantity’, or longevity. There is a 
paucity of original research on the quality of life and the (potentially modifiable) factors 
that affect quality of life, as also evidenced by a 2017 systematic review (48). Included 
studies (29 detailing clinical research) suggests that age, gender, physical status, 
comorbidities, cognition and psychological variables such as depression affected 
quality-of-life outcomes in the elderly (63,183,187,188). There are apparently no 
significant differences in quality of life between dialysis and conservative management 
(17,52,137,139). Our review identified a few potentially modifiable factors that could 
improve quality of life in elders considering dialysis. As shown in Table 4, some of 
these factors, such as depression, sleep disturbances or poor nutrition may be amenable 
to intervention in the pre-dialysis stage itself. Brown (2012) suggests that engaging 
patients in discussion, emphasizing lifestyle effects of treatment, considering benefits of 
all interventions - even renal clinic visits - are additional measures to improve quality of 




Multiple social connections and close family relationships appear to improve the 
experience of dialysis. While some patients were able to cope successfully and “reinvent 
themselves” in their new lives, others described negative outcomes (58). The lived 
experience of these patients is dominated by disempowerment, lack of knowledge, 
cognitive impairment, depression, difficulties with strict regulations regarding diet, 
fluid and dialysis timings, and finally, functional decline, which called into question 
their relationships with family and made them feel a burden to others. These reports 
suggest that clinicians  should measure physical status, functional impairment and 
cognitive status frequently so that appropriate interventions can be planned early (189). 
There are dominant thoughts regarding death in this population, suggesting the role for 
discussions regarding end-of-life care or advance care directives. Healthcare 
professionals play important roles in these patients’ lives.  
Finally, we surveyed the literature on patients’ information needs. It is evident that 
there are several areas where information provision to patients could be improved. 
Patients are interested in their prognosis (survival, quality of life, eventual outcome) 
with and without dialysis treatment (73). Older patients already on dialysis tell us that 
they would have liked more practical knowledge about what is actually involved in 
having dialysis, as well as the effect of dialysis daily life. Matters relevant to the elderly, 
presented in a non-technical, jargon-free manner, involving patients, and giving them 
“more rather than less” information can be recommended. Frequent thoughts about 
death and dying in this age group mandate that healthcare professionals attempts to 
engage their patients with these topics and discuss matters such as advance care 






Domains to consider Areas for future research 
Survival (use prognostic indices 
developed in the older population). 
Indices that predict outcomes other than 
survival (e.g., quality of life, functional 
decline) 
Quality of life outcomes (explore 
patients’ expectations) 
Factors that affect quality of life in 
elders; modifying these factors; impact 
on outcomes 
Lessons from the experience of older 
people on treatment (lifestyle changes; 
functional and cognitive worsening; 
impact on daily life, relationships; 
symptom burden). 
Modifiable factors that might improve 
the experience of treatment (dialysis or 
conservative management) 
Involve family/friends (acknowledging 
their multiple, important roles, 
especially in frail, dependent elders). 
Provision of information, support and 
follow-up of carers of older adults with 
advanced CKD 
Tailor information to the older person 
(avoid medical jargon, purposively 
include prognosis information, consider 
cognitive impairment and depression). 
Improving communication of 
information; and monitoring delivery 
and understanding  
 
Strengths and limitations   
In our estimation, this is the first scoping review focused specifically on the older 
patient and the wide spectrum of knowledge relevant to the shared decision-making 
process for ESRD. We include a comprehensive survey of prognostic instruments 
developed in this population, as well as a summary of comparisons between 
conservative management and dialysis, both of which will be useful resources for 
clinicians.  
Studies were not graded on the basis of quality, since this was a scoping review. The 
preponderance of included work from Western, English-speaking nations ignores 




information from other parts of the world. Research done on non-professional carers 
has not been included because of the difficulty in specifically identifying research done 
on carers of older adults with advanced renal failure. We did not compare between 
dialysis modalities or transplantation – often, there are regional or local factors that 
dictate availability of these choices for older adults. However, despite these limitations, 
we believe our review not only summarises a diverse body of knowledge and identifies 
potential gaps, but also presents this information with practical interpretations that are 
likely to be useful for clinicians. 
 
2.2.6 Conclusion 
Length of survival is an important consideration when older patients compare dialysis 
treatment to conservative care. Physicians now have several validated indices to help 
with prognostication. However, as evident from this scoping review, longevity or 
survival are not the only factors patients and families take into account.  Therefore, 
discussions about outcome ought to also address other expectations of treatment, such 
as the anticipated quality of life or functional status. All information ought to be 
presented in a manner that the older patient can easily understand, retain and apply. 
When providing advice, a well-rounded, holistic approach that is informed by the 
experiences and expectations of older adults is likely to lead to optimal decisions and 






   
 






             
           
     
     
        
 
Health-related quality of life is therefore one part of the overall spectrum of quality of 
life.  Several models have been used to study the components of health-related quality 
of life (HRQOL), and in most models, the presence of symptoms directly affects the 
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Chapter 3 :
Symptom burden, recognition
and effects on quality of life
3.1 Patient-reported symptoms and quality of life
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HRQOL. For instance, in the Ferrans modification of the classic Wilson-Cleary model 
(30,191), symptoms, functional status and health perceptions interact on the biological 
substrate to contribute to overall HRQOL.  Since the presence of several persistent 
symptoms is a  characteristic feature of the experience of dialysis, it is possible that 
poorly treated symptoms contribute significantly to the low quality of life reported by 
dialysis patients. In fact, this relationship between symptoms and quality of life in 
patients with end-stage kidney disease has been extensively reported in the literature 
(91,139,192–198); we have also reported on this in our scoping review detailed in 
Chapter 2.  
 
3.1.1 Symptom burden in dialysis: Prevalence and recognition by 
clinicians 
Patients on dialysis have a significant symptom burden,  reported to be similar to 
patients with terminal cancer (59).  The excessive burden of symptoms in dialysis 
patients has been reported in research from all over the world – UK (199,200), Spain 
(201), Hong Kong (194), USA (202), Canada (203,204), Taiwan (205), Australia (91,139), 
and Sri Lanka (206). 
Researchers have attempted to explore why a severe symptom burden persists in 
dialysis patients (207,208). There are practical difficulties in managing the symptoms of 
patients with ESKD, which are often recalcitrant. Renal physicians may not consider 
symptom management as their responsibility; similarly, patients may not report their 
symptoms to renal clinicians because of the belief that the symptoms are not related to 
their kidney disease.  In addition to these difficulties with symptom management, 
attention has also focused on poor recognition of symptoms by providers. This could 




symptoms, proper symptom recognition is the first step.  Linking these observations 
together, one could postulate that the low quality of life of patients on dialysis is 
affected by their persistent, severe symptoms, and that these symptoms persist also 
because of poor recognition by their clinicians. In fact, a paper from the United States by 
Weisbord and colleagues, published in 2007,  suggested that clinicians do not recognise 
their patients’ symptoms very well (209).  In this article, they compared patient-
reported symptoms to symptoms identified by healthcare providers (predominantly 
dialysis nurses and technicians) and showed very poor sensitivity toward patients’ 
symptoms by the clinical team.  This was an important finding, and we were eager to 
see if such a finding would be replicated in our population. 
Compared to the population described by Weisbord and colleagues, the dialysis 
population in North and North-West Tasmania has subtle differences, and it was 
possible that clinician recognition of symptoms would be better (209). The dialysis 
populations are smaller, with a physician to dialysis patient ratio of approximately 1: 5, 
and a dialysis nurse to dialysis patient ratio of approximately 1: 4. Within the dialysis 
units, dialysis nurses are “allotted” particular patients, which means that each nurse is 
responsible for a few patients as “primary” patients (personal communications). All 
these factors suggested that there was greater contact between clinicians and patients in 
the local population and suggested that clinician recognition of patient symptoms could 
potentially be better than that reported in the literature. 
 
3.1.2  Objectives of the research project 
This research project was conceived to explore, in a local dialysis population, the 
relationships between symptoms, their recognition and quality of life. We designed a 




of life in the dialysis population. Our main research aim was to look for correlations 
between symptoms and quality of life, in order to understand whether severe 
symptoms were responsible for poor quality of life outcomes. Additional expected 
outcomes from the study were to document the recognition of symptoms by nurses and 
clinicians, and to compare this recognition with patient-reported symptoms so as to be 
able to gauge the degree of agreement with patient reports and the clinicians’ sensitivity  
to symptoms. We were also interested in comparing symptoms and quality of life in the 
older population (age >70) to that in the younger population. 
 
 
3.2 Symptoms and their recognition in adult 
haemodialysis patients: Interactions with quality of life 
 
The following research paper has been published as :  
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haemodialysis patients: Interactions with quality of life. Nephrology (Carlton). 22(3) 
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SUMMARY AT A GLANCE
This preliminary observational study investi-
gated the recognition of symptom burden in
haemodialysis patients by healthcare staff.
The results showed that nephrologists’
tended to under recognize patient symptom
burden, whereas nursing staff performed
better in this task.
ABSTRACT:
Aim: We investigated the symptom burden in adults on haemodialysis, the
recognition of symptoms by nurses and nephrologists, and the relationship
between symptoms and quality of life.
Methods: In this cross-sectional observational study, symptoms and quality of
life inhaemodialysis patientsweredeterminedusingvalidated surveys.Nurses
and nephrologists independently estimated their patients’ symptoms, and
these estimates were compared with patient responses (sensitivity; kappa
values for interrater agreement). Associations between symptoms and quality
of life were assessed using multi-level regression.
Results: Forty-three patients, 18 nurses and 3 nephrologists participated. The
commonest symptoms (95%CI) reported by patients were weakness, 69%
(53 to 82); poor mobility, 44% (29 to 60); and drowsiness, 44% (29 to 60).
Sensitivity less than 50%was seen towards 11 of 17 symptoms in nurse ratings
comparedwith 15 of 17 in nephrologist ratings. Agreementwith patient symp-
tom ratings was mostly ‘fair’ (0.21–0.4), with nurses’ scores showing greater
agreement than nephrologists’. Physical, mental and kidney disease compo-
nent summary scores of quality of life were negatively associated with total
symptom score and the number of ‘major’ symptoms (r2 values 0.3–0.36); while
with multivariate regression, 50% to 60% of the variance in these scores was
accounted for by parsimonious models containing symptoms such as pain
and poor mobility.
Conclusion: Symptom burden worsened quality of life scores in haemodialysis
patients. Clinician recognition of symptom burden was inaccurate, although
nurses were more accurate than nephrologists. Using patient-completed sur-
veys or including dialysis nurse feedback in routine outpatient settings may
help improve symptom recognition by nephrologists.
Adults onmaintenance dialysis experience a poor quality of life
(QOL) comparedwith their peers,1 similar to those experiencing
other chronic illnesses such as cancer.2,3 Several studies of
dialysis patients in the last three decades have demonstrated
poor QOL outcomes, suggesting that despite advancements
in renal replacement therapy, QOL has been difficult to
improve.4–8
Patients undergoing maintenance dialysis experience a
significant symptom burden, and this can directly influence
their perceived QOL.6,9–12 Heath-related quality of life
(HRQOL), part of the larger canvas of overall QOL, is a particu-
lar area of interest for clinicians. HRQOL is influenced by
illness, treatment and its perceptions, and has been described
as a composite of physical, psychological and social domains,
each of which is composed of several contributing factors.11 A
comprehensive theoretical model detailing how various factors
interact in affecting QOL was proposed by Ferrans and
colleagues.13,14 In this model, symptoms (physical, emotional
and cognitive) have effects on QOL and are also influenced by
other variables. Because several symptoms in dialysis patients
are amenable to treatment, it can be postulated that reduction
of the symptom burden could improve HRQOL. However, the
identification and treatment of symptoms in dialysis patients
are not straightforward. Suboptimal recognition of patients’
symptoms by their healthcare providers has been described in
the dialysis population.15
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We studied symptoms, their recognition and their interac-
tion with QOL in an Australian dialysis population using vali-
dated symptom and QOL questionnaires. The purpose of this
study was threefold: firstly, to obtain a cross-sectional snapshot
of the symptoms andQOL, secondly, to study the recognition of
symptoms by healthcare providers (nurses and nephrologists)
and finally, to document the interactions between symptoms,
their recognition and QOL.
METHODS
Study participants
A cross-sectional survey of maintenance haemodialysis
patients, dialysis nurses and nephrologists was conducted at
the satellite dialysis facility of a regional hospital in Tasmania,
Australia (Australian Standard Geographical Classification
RemotenessArea –RA2, Inner Regional).16 All adult (>18years
old) patients undergoing regular in-centre haemodialysis three
times a week (for at least 3months before enrolment) were
eligible for inclusion. We excluded patients that had been
hospitalized in the 1month prior to data collection, because
being in the hospital would mean greater interaction with the
healthcare providers than the usual norm. Consecutive
sampling was used, and all eligible patients were offered partic-
ipation. Because this was an exploratory study within a small
population (52 eligible patients in all), no sample size calculation
was made. Participating healthcare providers consisted of each
patient’s designated ‘primary dialysis nurse’ and treating
nephrologist.
Materials and procedures
The Palliative Outcome Score-Renal (POS-Renal) question-
naire, validated for use in patients with advanced kidney
disease and recommended by recent guidelines,was used to sur-
vey symptoms.17–20 The POS-Renal lists the same 17 symptoms
(e.g. pain, shortness of breath and itching) on both patient-
completed and staff-completed forms. Symptoms are rated on
a 5-point Likert scale (see later). Healthcare providers indepen-
dently rated the severity of each symptom in their patients,
without seeing the results of patient – completed surveys.
Self-reported QOL scores were collected from patients using
the Kidney Diseases Quality of Life-Short Form 1.3 (KDQOL-
SF 1.3).21 Responses to this 80-item questionnaire are used to
calculate scores for multiple subscales of QOL, as well as three
overall composite scores – the SF-12 Physical Composite
(PCS), SF-12Mental Composite (MCS) and the Kidney Disease
Component Score (KDCS).
Data collection
The study protocol was approved by the Tasmanian Health and
Medical Human Research Ethics Committee (H0013482). Data
collection from consenting patients (and their dialysis nurses)
occurred during the week prior to their scheduled outpatient
visit to their nephrologist. Patients completed the POS-Renal
and the KDQOL-SF 1.3 forms. Nephrologists completed the
symptom surveys within 48h of seeing the patient in the out-
patient clinic. Data were collected from December 2013 to
March 2014.
Demographic data collected from the dialysis and hospital
records included age, gender, years on dialysis and the presence
of comorbidities. Comorbidities and functional status were
ascribed as per the treating nephrologist. The Charlson’s
Comorbidity Index22,23 and the Karnofsky Functional Index24
were calculated for each patient. Biochemical parameters
reported within 1month of the data collection week were
collected – including haemoglobin, albumin, phosphate and
dialysis Kt/V (measured with Diascan© real-time monitoring
system, Gambro AB/Baxter International Inc., USA).
Data analysis
Symptom burden, sensitivity and interrater agreement
The total symptom score was used to reflect symptom burden.
Symptom scores were converted into categorical variables for
sensitivity analysis, with two categories possible; ‘minor’ or
‘major’. Scores of 0 (not at all) and 1 (slightly, but not bothered
to be rid of it) were categorized as ‘minor’, while scores of 2
(limits some activity or concentration), 3 (activities/concentra-
tionmarkedly affected) and 4 (unable to think of anything else)
were categorized as ‘major’. The number of symptoms reported
as major was calculated.
We calculated the sensitivity of symptom recognition using
the patients’ reports as the gold standard, shown in Table 1
(as previously described by Weisbord et al.).15 Sensitivity {(TP/
[TP+FN])×100%} of recognition – which was the probability
of identifying a symptom as ‘major’when the patient also iden-
tifies it as being ‘major’ – was calculated for all the symptoms
for both nurses and nephrologists.
A rating for a symptom by patient and by a healthcare
provider was considered to be in agreement if both scored it
either ‘minor’ or ‘major’. We used the Cohen’s kappa statistic
to determine interrater ‘agreement’. The kappa statistic is
standardized so that a value of zero is ‘exactly that expected
by mere chance’ while a value of 1 denotes ‘perfect
agreement’.24
Table 1 Symptom classification for estimating the sensitivity of recognition
Description Patient scored as Staff scored as
True positive (TP) 2, 3 or 4 [Major] 2, 3 or 4 [Major]
True negative (TN) 0 or 1 [Minor] 0 or 1 [Minor]
False positive (FP) 0 or 1 [Minor] 2, 3 or 4 [Major]
False negative (FN) 2, 3 or 4 [Major] 0 or 1 [Minor]
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Quality of life
The KDQOL-SF 1.3 was scored using theMicrosoft Excel-based
KDQOL-SF 1.3 Scoring Program (v2.0).26 This program gener-
ates scores for each patient for each of the subscales listed
earlier, as well as descriptive statistics and summary scores
across all patients.
Relationship between quality of life and symptom burden
Univariate regression was used to analyse relationships
between total symptom score and the number of symptoms
reported as ‘major’ with the summary scores of QOL – Kidney
Disease Component Summary (KDCS), Physical Component
Summary (PCS) and Mental Component Summary (MCS).
We also constructed mixed-effects linear regression models
for KDCS, PCS and MCS, using the five most common symp-
toms in our population. Observations that had missing data
for a particular component were excluded from the related
analysis. Data analysis was performed using Microsoft Excel
and Stata v 12.1 (Stata Corp, College Station, TX, USA).
RESULTS
Of 52 patients invited, 43 (82.6%) consented to participate in
the study (Table 2). All healthcare providers approached
consented to participate, including 3 nephrologists and 18
haemodialysis nurses. The study population was predomi-
nantly Caucasian (Caucasian 41, Torres Straits Islander 1,
Filipino 1).
Frequency of symptoms
Themean total symptomscore per patient (possible range: 0 to68)
was 16.8 (SD=11.3). On average, patients scored 5 symptoms
out of 17 as ‘major’ (range: 1 to 9 symptoms). Among symp-
toms reported as major by patients, the most common were
weakness or lack of energy (in 69%), followed by poor
mobility, drowsiness, difficulty sleeping and shortness of
breath (Table 3).
Nurse/nephrologist sensitivity and interrater
agreement
Themean (SD) total symptom score assigned by nurses to their
patients was 14 (8.93), and the average (SD) number of
symptoms that they recorded as ‘major’ for their patients was
4 (4). For nephrologists, the mean (SD) total score was only 5
(6) and the average (SD) number of symptoms per patient
reported as ‘major’ was 1.5 (2).
Sensitivity was less than 50% for nurses in 11 out of 17
symptoms. Among nephrologists, sensitivity was less than
50% in 15 out of 17 symptoms (Table 3). The symptoms that
were identified with the highest sensitivity scores were similar
for both nurses and nephrologists – poor mobility (reported as
major by 41% of patients), feeling depressed (seen in 15% of
patients), weakness/lack of energy (seen in 66% of patients)
and pain (seen in 27% of patients).
Table 3 lists the values of the kappa statistic of interrater
agreement. Agreement between nurses and patients was ‘fair’
for 10 symptoms, ‘moderate’ for two and ‘substantial’ for one
(poormobility). For comparisons between doctors and patients,
the statistic was reported as ‘fair’ agreement for four symptoms
and ‘moderate’ for two.
Symptoms and effect on quality of life
Of the 43 patients in the study, 27 also completed the KDQOL-
SF v1.3. There were no significant differences in the demo-
graphic characteristics and symptom scores between patients
that completed the QOL questionnaires and those that did
not. The common symptoms in the two groups were mostly
similar.
On univariate analysis, QOL summary scores were nega-
tively correlated with total number of symptoms as follows
(Coefficient; 95%CI): KDCS (!0.96; !1.5 to !0.4); PCS
(!0.57; !0.94 to !0.2) and MCS (!0.59; !0.98 to !0.2); all
p values< 0.005. Similar negative correlation was seen with
the number of ‘major’ symptoms as follows (Coefficient; 95%
CI): KDCS (!2.5; !4 to !0.98); PCS (!1.56; !2.54 to !0.58)
and MCS (!1.72; !2.74 to !0.7); all p values<0.003. Using
mixed-effects multi-linear regression, we created parsimonious
models for the summary scores of KDCS, PCS andMCS, initially
using the most common symptoms along with variables such as
age, gender, dialysis vintage, Charlson’s Comorbidity Score and
Karnofsky Performance Index (Table 4). We used a p value of
0.2 as initial cut-off. After stepwise regression, the model for
KDCS (adjusted r2 = 0.52) included the symptom of poor mo-
bility. For the PCS, themodel (adjusted r2 = 0.5) included poor
mobility and pain. Similarly, the model for MCS (adjusted
r2 = 0.6) also included poor mobility and pain.
Table 2 Characteristics of the study population
Characteristic Patient data (n = 43)
Mean age (SD) 63.9 (±15.7)
Male/female gender (%) 63/37
Mean years on dialysis (SD) 5.2 (±4.2)
Mean Charlson’s comorbidity score (SD) 6.5 (±3.2)
Mean Karnofsky score (SD) 70 (±10)
Diabetes (%) 40
Hypertension (%) 91
Ischaemic heart disease (%) 42
Peripheral vascular disease (%) 33
Mean Biochemical parameters (SD)
Haemoglobin g/L 113.3 (±13.5)
Albumin g/L 33 (±3.8)
Phosphate mmol/L 1.7 (±0.6)
Kt/V Urea 1.4 (±0.2)
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Symptom recognition and quality of life
Patients’ healthcare providers, as a whole, under-estimated
symptom burden (reflected in the total symptom score in the
POS-Renal) and severity (estimated as the number of
symptoms scored as major). Despite this, on univariate
analysis, higher total symptom scores and number of major
symptoms recorded by nurses and by nephrologists were
correlated with lower QOL summary scores (similar to
patient-reported scores). The absolute difference per patient
in the total symptom score or the number of major symptoms
recorded, compared with their healthcare providers, did not
influence QOL scores.
DISCUSSION
A significant burden of symptoms was observed in the
haemodialysis patients participating in the study. The most
common symptoms were weakness, poor mobility and drows-
iness, similar to findings from other studies.5,6,12,27 Healthcare
providers did not perform well in recognizing the presence or
the severity of symptoms, exhibiting low sensitivity rates and
poor agreement with patient estimates.
Similar findings were reported by Weisbord and col-
leagues,15who performed an observational study of 75 patients
on haemodialysis and 18 renal providers (nephrologists, nurse
practitioners and nurse managers), with the aim of studying
the recognition of symptoms and their severity, using the
30-item Dialysis Symptom Index.15 They estimated that
providers underreported the presence of 29 of 30 symptoms,
under-estimated severity in 19 of 30 symptoms and demon-
strated a sensitivity rate of<50% in 27 of 30 symptoms. Differ-
ences between nephrologists and other types of providers were
not reported. Although the study was conducted in a different
country and healthcare system compared with our study, the
similarities in the findings are clear.
Our study extended the findings of Weisbord and colleagues
by comparing nurses and nephrologists, and also by exploring
the impact of symptom burden on patients’ QOL. Within our
healthcare setting, nephrologists are primarily responsible for
symptom management, and we felt it was important to
compare their recognition of symptoms with that of nurses.
Additionally, we demonstrated an important consequence of
persistent symptoms by showing their impact on QOL scores.
Mean summary scores (for PCS, MCS and KDCS) in our
population were similar to the mean scores reported in other
studies within Australia and internationally.28,29 Higher values
for ‘total symptom score’ or ‘number of major symptoms’were
both associated with a lower self-reported QOL, whether
scoring was completed by patients, nurses or nephrologists.
This underscores the influence of perceived and recognized
symptoms on QOL in this population. Our findings are similar
Table 3 Frequency of symptoms reported as ‘major’, sensitivity of recognition and agreement with patient reports
Symptom (n = 43)












69 (53–82) 69 54 0.32* 0.23*
Poor mobility 44 (29–60) 68 58 0.62* 0.51*
Drowsiness 44 (29–60) 37 11 0.28* 0.11*
Difficulty sleeping 40 (24–55) 59 6 0.17 0.03
Shortness of breath 38 (22–52) 31 7 0.37* 0.07*
Pain 35 (20–49) 64 29 0.48* 0.21*
Poor appetite 30 (16–45) 38 36 0.14 0.23
Changes in skin 29 (14–42) 42 18 0.37* 0.22*
Nausea 28 (14–42) 38 0 0.37* 0.00
Itching 21 (8–34) 22 13 0.21 0.19*
Restless legs 21 (8–34) 44 0 0.29 0.00
Feeling anxious 19 (6–31) 63 14 0.32* 0.01
Diarrhoea 19 (6–31) 38 14 0.43* 0.22*
Vomiting 17 (5–28) 29 14 0.23* 0.22*
Feeling depressed 17 (5–28) 67 67 0.39* 0.55*
Mouth problems 12 (6–22) 20 0 0.13 -0.02
Constipation 10 (0–18) 0 0 -0.08 0.00
*p value< 0.05. †Interpretation of kappa statistic of agreement25:<0 – less than chance; 0.01–0.2 – slight; 0.21–0.4 – fair; 0.41–0.6 –moderate;0.61–0.8 – substantial;
0.81–0.99 – almost perfect.
Table 4 Regression models for quality of life summary scores using common
symptoms
Summary score Symptoms correlated† Coefficient (95%CI)
KDCS (r2 = 0.52) Poor mobility !21.68 (!31.2 to -12.2)
PCS (r2 = 0.50) Poor mobility !11.98 (!16.91 to -7.05)
Pain !7.71 (!12.67 to -2.77)
MCS (r2 = 0.60) Poor mobility !11.61 (!16.91 to -6.3)
Pain !8.98 (!14.2 to -3.8)
†Adjusted for age, gender, years on dialysis, Karnofsky’s score and Charlson’s
comorbidity index.
Symptoms and quality of life on dialysis
© 2016 Asian Pacific Society of Nephrology 231
to those of a recent study of 893 subjects, where the presence of
symptoms such as pain and poor mobility had detrimental
effects on health-related QOL.12
Nurses performed better than nephrologists in terms of
sensitivity to symptoms and interrater agreement with patient
estimates. This should be interpreted with caution, however,
because we did not adjust for potential confounders in the
patient interaction, such as the influence of gender, or the
differences in duration and setting of patient contact (regular,
4hour dialysis unit interactions for nurses vs the, 20minute
outpatient clinic visit with nephrologists, which occurs once
in 6 to 8weeks in our model of care). Future research could
consider further investigation of the suggestion that different
healthcare providers vary in their sensitivity to their patients’
symptom burden.
Additionally, we studied the associations between symptom
recognition and QOL scores. Within the limitations placed by
the small numbers of healthcare providers and patients, it is
worthwhile to note that nephrologists did not perform well in
recognizing the symptoms that were significantly associated
with summary scores of QOL (sensitivity for poor mobil-
ity =54%and for pain=29%).We could not showdirect corre-
lations between underestimation of symptoms by healthcare
providers (i.e. difference between patient and nephrologist
ratings) and QOL scores – this reflects the complexity of the
interaction. One can anticipate that symptom amelioration is
more likely to affect QOL than mere recognition.
Our study had limitations. The dialysis population studied
was almost entirely Caucasian, and results may be different in
other areas where linguistic or cultural barriers coexist.
Nephrologists’ responses could only be collected 24 to 72h after
a clinic visit. This could have contributed to underreporting of
symptoms (compared with nurses) because we relied on the
nephrologists’ recall of patient encounters. Nephrologists spent
much shorter periods of time with patients compared with
nurses. However, this is a realistic representation of current
models of care, mirroring how much (or little) time nephrolo-
gists have to elicit symptoms or understand QOL experiences.
An important factor limiting the generalizability of our find-
ings and the robustness of the regression is the small sample
size. These numbers are indicative of the size of our dialysis
facility – in fact, over 80% of the patients consented to partici-
pate, as did 100% of the nurses and nephrologists. Addition-
ally, only 65% of patients with recorded symptom burden
could comply with the request to return the completed 81-item
QOL surveys within 1week of the symptom survey, perhaps
suggesting that more time ought to have been allotted for
submitting QOL data.
Despite these limitations, our study reflects actual clinical
practice in a regional Australian dialysis centre, with its limited
numbers of patients and healthcare personnel. Therefore, our
study has important clinical implications for our currentmodels
of care, and we believe these findings need further exploration
in a larger sample of patients, clinicians and participating cen-
tres. It remains to be seen if similar findings will be obtained
in more urban or rural areas, which can differ widely from us
in terms of the proportions of nurses and doctors to patients
and the models of care employed.
The recognition of symptoms by the treating nephrologists is
the first step to providing symptom relief, and there is clearly
room for improvement here. We suggest that the clinical
review of dialysis patients should deliberately include input
from dialysis nurses. Additionally, we recommend the use of
a short patient-completed symptom survey, such as the
POS-Renal, during the routine outpatient review of dialysis
patients. This will enable the comprehensive documentation
of patients’ symptoms and direct the attention of healthcare
providers towards troubling symptoms more accurately.
It remains to be seen ifmore accurate symptomdocumentation
will then lead to appropriate treatment, a reduced symptom
burden and, subsequently, improvements in health-related
QOL. Along this pathway, there are barriers to symptom
recognition and to their management, and insufficient
evidence that patient-reported symptom documentation im-
proves management or reduces the symptoms themselves.30
More likely, considering that the symptom burden is but one
of the many contributors to health-related QOL, easing the
symptom burden may produce only modest benefits.
However, patients on dialysis already experience multiple
impediments to regaining a satisfactory QOL, and any amelio-
ration of this burden will be meaningful to the individual
patient.
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3.4 Comparison of the older ( ≥70 years) to the 
younger (<70 years) population 
 
Our sample included  43 participants, of whom 15  were over 70 years in age (Table 3-1). 
The Charlson comorbidity index was significantly higher (more co-morbidities) in the 
older group; they also had lower scores in the estimation of performance status. There 
was no difference in the total symptom score reported by these patients; similarly, there 
was no difference in the total symptom score assigned to these patients by doctors. 
Nurses appeared to assign more symptoms to the younger group of patients, but the 
relevance of this finding in our small-sized groups is not certain. There was no 
difference in the kidney disease, physical or mental component summaries of quality of 






 Aged ≥70 




Age (mean ± SD) 77.3 ± 5.2 52.3 ± 12.3 - 
Albumin (g/L) 33.9 ± 3.5 32.6 ± 4 .31 
Charlson’s Comorbidity Index Score 8.9 ± 2  5.3± 3 .0002 
Karnofsky Performance Score 65.3 ± 12.5 78.6 ± 10.4 .0006 
Total of Symptom Score – patient reported 13.2 ± 7.5 18.7 ± 12.6 .13 
Shortness of breath – patient reported (n) 2 14 .042 
Total of Symptom Score – nurse assigned 10.3 ± 7.2 16.2 ± 8.6 .03 
Total of Symptom Score – doctor assigned 5.1 ± 4.2 5.4 ± 5.5 .84 
KDQOL – KDCS score 62.1 ± 17.1 64.8 ± 17.2 .70 
KDQOL – PCS score 36.2 ± 10.2 35.6 ± 11.3 .89 
KDQOL – MCS score 43.7 ± 12.9 47 ± 10.8 .52 








3.5 Symptoms in a population of conservatively 
managed patients 
 In a brief analysis, we documented the prevalence of symptoms in 35 patients (mean 
age 79; mean eGFR 19 ml/min). A summary of these findings is presented in Section 
3.5.1, which showcases a poster presented at the annual meeting of The Australia New 
Zealand Society of Nephrology in 2016.  
 
3.5.1 Patients managed with conservative, non-dialysis care: 
Symptoms and comorbidities 
The following brief research report, appended in the form of the final manuscript, was 
presented as a poster at the Annual Conference of the Australasian Society of 
Nephrology, 2016; it has been referenced in conference proceedings as :  
Raj R, Brown B; Patients managed with conservative, non-dialysis care: symptoms and 








Patients with advanced renal failure experience significant symptoms. Since 2011, we 
have provided supportive, non-dialysis care for patients with chronic renal impairment 
in a dedicated, nephrologist-led clinic. Relatively little is known about the 
conservatively managed population.  
Aim 
To describe the burden of symptoms and comorbidities in patients with chronic renal 
impairment (CRI) managed without dialysis.  
Methods 
Retrospective, descriptive study, using demographic information and biochemical test 
results from hospital records (2012-15). Symptoms were documented using the Patient 
Outcome Score - Renal survey, which allows symptom severity to be rated along a 
Likert scale from 0 (least) to 4 (maximum).  
Standard summary scores were used to describe the data. Linear regression and 
student’s t-tests were used to look for associations between age, estimated glomerular 
filtration rate (eGFR), biochemical variables and symptoms. 
Results 
Data was available for 35 individual patients (mean values: age - 79 years, eGFR - 19 
ml/min). Common comorbidities (average two to three conditions per patient) included 
hypertension (69%), diabetes (46%), ischaemic heart disease (31%), and peripheral 





Figure 3-5: Distribution of eGFR (ml/min/1.73m2) among patients. 
 

















The mean total symptom score was 13. On average, each patient scored four symptoms 
as 2, 3 or 4. Weakness, poor mobility, drowsiness and dyspnoea were the most common 
among the 17 queried symptoms. Age, eGFR, number of comorbidities, haemoglobin or 
albumin did not correlate significantly with the presence of any symptom or the total 
symptom burden. 
 
Figure 3-7: Distribution of Symptoms 
 




























Our results match the expected profile of the conservatively managed patient – older, 
and with multiple comorbidities. Such patients also suffer a significant symptom 
burden, similar to those on dialysis. Their complex care needs and their multiple 
symptoms provide clinical justification for a dedicated, multidisciplinary renal 
supportive care service. 
 
3.6 Results in context 
 
 We documented a significant symptom burden in patients treated with dialysis or with 
conservative care.  There was significant association of persistent reported symptoms 
with dimensions of quality of life. Patients reported, on average, at least 4 to 5 
symptoms (over 17 symptoms queried) as affecting them with moderate, severe or 
overwhelming intensity. It must be noted here that the assignment of scores  of 2, 3 or 4 
as ‘significant’ was made arbitrarily; the survey itself has not been validated on the 
differences between these scores in individual patients. We intended to make sure that 
the presence of symptoms was captured comprehensively, but our approach carries the 
risk of ‘over-calling’ symptoms.  Our reports of symptom burden are not unique - 
considering scores of 3 and 4 on the same survey as significant, Brennan and colleagues 
reported a mean number of 8.1 (±3.99) symptoms in a conservatively managed 
population. Similar symptom burdens have been reported internationally as well 
(29,59,192,195,206). Within the limitations of our small patient sample, however, we 
were able to show symptom burden, correlation with quality of life, prevalence of 
symptoms in older patients and the differences in symptom recognition between 




Recognition of symptoms by nurses and doctors was uniformly poor when compared to 
self-reported symptoms as the reference. There was low sensitivity even for the 
common symptoms, suggesting that despite our initial belief that the local population 
of dialysis patients would have their symptoms adequately recognised by their 
clinicians, this was not the case. 
While our study suggested that our dialysis population had a significant symptom 
burden and that this symptom burden was negatively impacting components of quality 
of life, we also showed that these symptoms were poorly recognised by clinicians.  This 
has confirmed, in a local Australian regional hospital dialysis population, that the 
experience of dialysis is characterised by persistent, poorly recognised symptoms which 
affect quality of life outcomes. This also suggests that better recognition of symptoms is 
a probable first step in improving symptoms and thus improving quality of life. 
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4.1 Identifying and validating a symptom survey tool 
in dialysis patients
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Abstract
Context. The significant symptom burden in advanced renal disease is often poorly recognized by clinicians. Recently, the
Integrated Palliative Outcome Score (IPOS)erenal survey was developed from pre-existing tools to capture these symptoms
and other common concerns.
Objectives. We studied the validity and reliability of the IPOS-renal survey (patient and staff versions) in an Australian
population.
Methods. Adult patients with advanced renal disease and nurses caring for them were participated. We initially
administered the IPOS-renal survey simultaneously with other validated surveys and then retested the IPOS-renal after seven
to 14 days. We tested the construct validity of 1) IPOS-renal patient version in relation to the Edmonton Symptom Assessment
Surveyerevised and the Kidney Diseases quality of lifeeshort form version 1.3 questionnaire and 2) IPOS-renal staff version in
relation to the Support Team Assessment Schedule survey.
Results. Eighty-one patients (65 hemodialysis, 10 peritoneal dialysis, and six on supportive care; average age 64.9 years) and
53 nurses (average renal nursing experience 10.9 years) were participated. Intraclass coefficients for test-retest reliability were
>0.7 for most queries; Cronbach’s alphas for internal consistency were 0.84 (patient version) and 0.91 (staff version). In tests
of construct validity, Spearman’s coefficient of correlation between surveys and their comparators for similar questions was
significant, at 0.61 to 0.77 (patients) and 0.24 to 0.76 (staff). As expected, symptom scores and total symptom burden were
negatively correlated with summary scores of quality of life.
Conclusion. The IPOS-renal surveys, patient and staff versions, have good test-retest reliability, internal consistency, and
construct validity in patients with advanced kidney disease and their nurses. We recommend their use in symptom
assessment. J Pain Symptom Manage 2018;56:281e287. ! 2018 American Academy of Hospice and Palliative Medicine. Published by
Elsevier Inc. All rights reserved.
Key Words
Dialysis, symptoms, surveys, IPOS-renal, PROMs, validation
Introduction
Patients with end-stage kidney disease (ESKD) suf-
fer a multitude of pervasive symptoms.1e3 Persistent
physical symptoms contribute to a lower HRQOLd
both directly and indirectly through their effects on
functional status, health perceptions, and feelings of
subjective well-being.4 These negative effects of
symptoms on quality of life have been shown repeat-
edly in patients with kidney disease.5e9 The optimal
identification and appropriate management of symp-
toms in kidney failure have the potential to not only
facilitate symptom relief but also improve the overall
quality of life.
Symptom recognition by health professionals caring
for these patients is often inadequate.10,11 We have
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previously shown that when doctors and nurses rely on
standard consultations with patients in outpatient
clinics or dialysis facilities, they demonstrate poor
sensitivity to patients’ symptoms and only ‘‘weak’’
agreement with their ratings of severity.5 Similar find-
ings have also been shown in a North American health
care setting.12
Symptom surveys that are completed by patients
and then passed on to clinicians are potential solu-
tions to bridge this gap.13 Recommendations by the
Australia New Zealand Society of Nephrology support
these patient-completed surveys as enhancements to
comprehensive care.14
An optimal patient-reported outcome measure
(PROM) ought to be easy to administer, short, rele-
vant to kidney disease, and sensitive to change. Several
patient-reported measures are widely used, despite
limited validation data.15,16 A national survey of
nephrology units across Australia found that while
the majority collected patient-reported data, the
most popular instrument used was the IPOS-renal
symptom surveyda relatively new tool that has not
yet been adequately validated (ANZDATA Working
Group on PROMs 2017; unpublished data).
The IPOS-renal is part of a suite of PROMs devel-
oped in the U.K. The original Palliative Outcome
Score (POS) and subsequently, a symptom module,
the POS-symptoms (POS-S), and finally, the generic
IPOS tool (a synthesis of the POS and POS-S) were
developed for the comprehensive assessment of pa-
tients with advanced disease and receiving palliative
care.17e22 The kidney diseaseespecific surveys,
initially the POS-renal and later the IPOS-renal, were
developed based on the POS and IPOS palliative
care surveys, but with the additional inclusion of symp-
toms common in chronic kidney disease such as pruri-
tus and restless legs.23,24 These surveys offer staff- and
patient-completed versions assessing the same do-
mains. Although the generic questions in the survey
have been tested for content validity and face validity,
construct validity of the IPOS-renal in population with
advanced kidney disease has not been established. We
conducted this study to assess the reliability and
construct validity of the IPOS-renal (patient and staff
versions) in an Australian population of patients




Study Population. We included a convenience sample
of adult (>18 years) patients with advanced kidney
failure (estimated glomerular filtration rate
[eGFR] < 15 mL/minute/1.73 m2 on two occasions
3 months apart) who were treated with either hemodi-
alysis/peritoneal dialysis or with conservative, nondia-
lytic management in a renal supportive care clinic.
Participants were recruited from outpatient clinics or
dialysis services at two regional hospitals in Tasmania,
Australia. Exclusion criteria included those clinically
assessed by treating nurses to be cognitively impaired
or too unwell to participate. Patients completed these
surveys independently or with help from their carers.
Survey Instruments. Participating patients completed
the IPOS-renal, the Edmonton Symptom Assessment
Systemerevised (ESAS-r), and the Kidney Diseases
Quality of LifeeShort Form version 1.3 (KDQOL-SF
v1.3) (see Table 1).
Procedures. Demographic data collected for patient
participants from their medical record included age,
gender, and physician-assigned comorbid conditions.
The Charlson Comorbidity Index was assigned based
on the comorbidities.31
Survey data collection occurred at two time points,
concurrently for patient and staff participants.
Different survey instruments were used at each time
point, as shown in Table 2. At the second time point,
which was 7 to 14 days after the first surveys had
been completed, patient participants repeated the
IPOS-renal survey and also indicated if ‘‘their condi-
tion had changed’’ by answering ‘‘yes’’ or ‘‘no’’ to a
direct question. Patients on hemodialysis completed
these surveys during a dialysis session, whereas those
on peritoneal dialysis or conservative care completed
them during routine outpatient visits initially and
then mailed in completed surveys from home for the
follow-up IPOS-renal survey.
Data Analysis. Demographic data were reported us-
ing descriptive statistics. We tested for reliability and
validity as follows (all statistical analysis was done
with Stata" v 12, StataCorp LLC, Texas).
Tests of Reliability. Test-retest reliability using intra-
class correlation coefficients (ICCs) was calculated be-
tween the repeated IPOS-renal surveys in stable
patientsdthat is, those patients for whom, at Time
Point 2, patients answered ‘‘no’’ to the question:
‘‘Has your condition changed?’’. ICC estimates and
their 95% CIs were calculated based on a mean-
rating (k ¼ 2), absolute-agreement, two-way mixed-
effects model.32 Internal consistency was tested by
estimating Cronbach’s alpha.
Tests of Validity. In testing for convergent validity, we
hypothesized that there would be a positive correla-
tion between similarly worded items on the IPOS-
renal and the ESAS-r surveys and a negative
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correlation between the IPOS-renal and the compos-
ite scores of kidney disease burden, and physical and
mental QOL on the KDQOL-SF v1.3 survey. Conver-
gent validity was ascertained by testing the Spearman’s
correlation coefficient.33 Divergent validity was
explored by testing the correlation between symptom
scores and QOL subscales on separate surveysdwe hy-
pothesized that there would be only weak correlations
between items that were not directly related.
We checked for sensitivity to change by comparing
IPOS-renal scores at Time Point 1 and Time Point 2
using the Wilcoxon signed-rank test, among patients
who indicated that their clinical condition had
changed at Time Point 2.
IPOS-RenaldStaff Version
Study Population. For staff participants, we recruited
from registered nurses who were directly involved in
the care of the participating patients in hemodialysis,
peritoneal dialysis, or renal supportive care clinics. We
ensured at least two nurses per patient; one nurse
could report on multiple patients.
Survey Instruments. Participating staff completed two
surveys at initial participation on the same day as the pa-
tientdthe IPOS-renal (staff version) and the Support
Team Assessment Schedule (STAS). Seven to 14 days
later (on the same day as the patient), one nurse per pa-
tient completed a second IPOS-renal staff version survey.
In addition, staff scored patients on the Australia-
modified Karnofsky Performance Scale and the Phase
of Illness Scores on both occasions (see Table 1).
Procedures. Demographic data collected about partici-
pating staff nurses included age, gender, and years of
experience in renal nursing.
Procedures were similar to those in the patient
group of participants, other than differences in the in-
struments used (Table 2). Surveys were completed on
the same day as patients at both time points (7 to
14 days apart). At the second time point, staff also
noted ‘‘yes’’ or ‘‘no’’ to the questiond‘‘Has your pa-
tient’s condition changed?’’. Staff participants
completed the surveys in the dialysis or outpatient
clinics at both time points.
Table 2
Surveys/Scores Completed by Participants at Different
Time Points














2: 7 to 14
days later
" IPOS-renal " IPOS-renal
" AKPS
" Phase of illness
(one staff member
per patient)
IPOS ¼ Integrated Palliative Outcome Score; ESAS ¼ Edmonton Symptom
Assessment System; KDQOL-SF v1.3 ¼ Kidney Diseases Quality of
LifeeShort Form version 1.3; STAS ¼ Support Team Assessment Schedule;
AKPS ¼ Australia-modified Karnofsky Performance Scale.
Table 1
Survey Instruments and Scores Used in the Study




Patient and staff use; 10 questions including 23 subitems
covering physical and psychological symptoms, carer
anxiety, and practical issues; plus, optional items for any
other concerns; scored on a Likert scale from 0 to 4 for
increasing severity; total score reflects symptom burden.
Derived from the validated generic IPOS survey, itself a
synthesis of POS and POS-S surveys.24,25 Most widely
used PROM as per a 2017 survey of Australian renal
units (unpublished data).
ESAS-r Patient-completed; 10 items querying physical and
psychological symptoms; Visual Analogue Scale with
scores from 0 to 10; total score reflects symptom burden.
Cross-sectional and longitudinal validity established in a
renal disease population.7,26
KDQOL-SF v1.3 Patient-completed; assesses HRQOL; includes 36 generic
core questions and 48 specific renal-related questions,
encompassing symptoms, burden of renal disease, and
effects on daily life; allows calculation of summary
scoresdKDCS, PCS, and MCS.
Developed from the SF-36 specifically for patients with
renal disease; validated in dialysis and renal transplant
populations; too long for routine outpatient use.27,28
STAS Staff-completed; 16 items covering physical, psychosocial,
spiritual, communication, planning, family concerns,
and service aspects
Designed for treating staff to assess clinical and
intermediate outcomes in palliative care; widely used
and validated.22
AKPS Staff-assigned measure of the patient’s overall ability to
perform activities of daily living as observed by a
clinician. It is a single score between 10 and 100;
decreasing numbers indicate a reduced performance
status and vice versa.
Serial scores can be used by staff to monitor clinical
progress.29
Phase of illness Staff-assigned categories that characterize how unwell a
patient is; categories include stable, unstable,
deteriorating, and terminal.
Has been used as a predictor of cost in the Australian
health care setting.30
IPOS ¼ Integrated Palliative Outcome Score; ESAS-r ¼ Edmonton Symptom Assessment Systemerevised; KDQOL-SF v1.3 ¼ Kidney Diseases Quality of
LifeeShort Form version 1.3; KDCS ¼ Kidney Disease Component Score; PCS ¼ Physical Composite Score; MCS ¼ Mental Composite Score; STAS ¼ Support
Team Assessment Schedule; AKPS ¼ Australia-modified Karnofsky Performance Scale.
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Data Analysis. Analysis methods were similar to those
described for patients mentioned previously. We esti-
mated test-retest reliability between repeated surveys
of patients whose condition staff participants reported
as unchanged. To test convergent validity, we
compared similarly worded questions on the IPOS-
renal (staff version) and the STAS surveys.
Results
IPOS-RenaldPatient Version
Eighty-one patients participated in the studyd65
patients treated with hemodialysis, 10 patients with
peritoneal dialysis, and six patients with renal support-
ive (nondialysis) care. The average age of participants
was 64.9 years; 56% of patients were male. Other de-
mographic details are listed in Table 3.
Tests for Reliability. Of the 81 participants, 69 (85%)
completed the second IPOS-renal surveydamong
them, 56 reported no change in their status between
the two time points. Intraclass coefficients demon-
strating test-retest reliability showed ‘‘good’’ correla-
tion (0.75e0.9) for 13/23 of the survey questions
and ‘‘moderate’’ (0.5e0.75) for 8/10 of the remaining
ones (see Table 4).32e34 Cronbach’s alpha for deter-
mining internal consistency was 0.84 for the question-
naire, showing good consistency.32e34
Tests for Validity. In testing for convergent validity, we
compared the IPOS-renal with corresponding items
on the ESAS-r and with summary scores on the
KDQOL-SF v1.3 (see Table 5). ‘‘High-to-moderate’’
correlations (Spearman correlation coefficient values
of 0.61e0.77, P < 0.05) were seen for total symptom
burden scores and for all individual items that queried
the same domains in the IPOS-renal and ESAS-r
surveys.
As hypothesized, there was a statistically significant
negative correlation between the total symptom
burden and the composite QOL scores of Kidney
Disease Component Score, Physical Composite Score,
and Mental Composite Score, as measured by the
KDQOL-SF v1.3. Several individual symptom scores
were also negatively correlated with these summary
quality of life scores, with the strength of the correla-
tion ranging from ‘‘moderate’’ to ‘‘high.’’
In checking for divergent validity, we saw that items
on the IPOS-renal that were not questions about symp-
toms (such as ‘‘have practical problems been ad-
dressed’’ or ‘‘has time been lost on appointments’’)
showed no correlation with the physical or mental com-
posite scores of QOL (data not shown). The sample
size was not sufficient to estimate sensitivity to change.
IPOS-Renal Staff Version
Fifty-three staff nurses participated in the study, of
which 47 were female and six were male. Their
mean age was 47 (SD: 10.5) years. On average, staff
participants had spent 21 (SD 11.9) years as a nurse
and 10.9 (SD 8) years as a renal nurse.
Tests of Reliability. Test-retest reliability was checked in
those staff surveys where no change in the patient’s
condition was reported (n ¼ 42). Intraclass coeffi-
cients showed ‘‘moderate’’ (0.5e0.75) or ‘‘good’’
(0.75e0.9) reliability for 20 of 23 items on the survey32
(see Table 4). Cronbach’s alpha for the staff version
was 0.91, showing excellent internal consistency.
Table 3
Characteristics of the Patients in the Study Population
Characteristics N ¼ 81 %





Ischemic heart disease 30 37
Charlson Comorbidity Index (mean # SD) 4.5 # 2.6
Treatment modality
Hemodialysis 65 81
Peritoneal dialysis 10 12
Conservative care (mean eGFR 10 mL/minute) 6 7
eGFR ¼ estimated glomerular filtration rate.
Table 4
Test-Retest Reliability: Mean Intraclass Correlation
Coefficients (ICCs) Between First and Subsequent IPOS-







Shortness of breath 0.77 0.76
Weakness or lack of energy 0.84 0.69
Nausea 0.88 0.74
Vomiting 0.79 0.7
Poor appetite 0.76 0.4
Constipation 0.72 0.54
Sore or dry mouth 0.79 0.68
Drowsiness 0.78 0.72
Poor mobility 0.79 0.83
Itching 0.79 0.55
Difficulty sleeping 0.72 0.66
Restless legs 0.83 0.73
Changes to skin 0.64 0.73
Diarrhea 0.75 0.23
Anxiety 0.52 0.62
Family/friends anxious about you 0.72 0.63
Depressed 0.71 0.78
Felt at peace 0.73 0.74
Able to share with family/friends 0.48 0.67
As much information as you wanted 0.59 0.4
Practical problems addressed 0.78 0.58
Time wasted on appointments 0.35 0.68
Total symptom score 0.84 0.72
Interpretation of ICC values: <0.5 poor reliability, 0.5e0.75 moderate reli-
ability, 0.75e0.9 good reliability, >0.90 excellent reliability.32
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Tests of Validity. We determined the construct validity
by comparing IPOS-renal (staff version) with scores on
the validated STAS survey. Spearman’s correlation co-
efficients for answers to similarly worded questions
showed statistically significant correlation, with the
strength of correlation being ‘‘moderate,’’ as follows
(all P values < 0.05): pain (0.76), symptoms other
than pain compared to total scores for symptoms
other than pain (0.71), patient anxiety (0.65), family
anxiety (0.65), and time wasted (0.75).
Divergent validity was demonstrated by the lack of
correlation between unrelated items on the IPOS-
renal and STAS surveys (data not shown).
Discussion
Unlike traditional biophysical measures, PROMs
such as the IPOS-renal allow the clinician to capture
the patient’s subjective illnesserelated concerns.35
Validation of the psychometric properties of such an
outcome measure is valuable to clinicians, researchers,
and health administrators. The paucity of validation
studies specifically involving the IPOS-renal could be
considered a disadvantage, and our study sought to
rectify this.
Important aspects of psychometric validation
include tests of reliability (i.e., the extent to which
the scores are consistent, typically tested as test-retest
reliability and internal consistency), validity (i.e., the
accuracy of the assessment in measuring what it is sup-
posed todstudied as content, criterion, and construct
validity), and sensitivity to change.32e34 Our study of
the patient and staff versions of the IPOS-renal
demonstrated good test-retest reliability and internal
consistency, suggesting that the survey is reliable in
both versions. In stable patients, the ICC values for
test-retest reliability were in the range ‘‘poor’’ for
only two itemsd‘‘ability to share with family or
friends’’ and ‘‘time wasted on appointments.’’ Both
these items may well vary periodically, depending on
the opportunities to meet social contacts or the
requirement to go to medical appointments. Similarly,
‘‘poor’’ test-retest reliability was seen in the staff ver-
sions for the items addressing diarrhea and informa-
tion received by patients. Staff surveys in our study
were completed without asking the patients or their
carers direct questions, and reliability may improve if
tested in everyday situations where staff members
interact freely with patients and carers.
Face and content validity (i.e., the survey addresses
the concerns it is supposed to measure) in a patient
population has already been shown for the questions
in the survey.17e20 Criterion validity (i.e., the survey
correctly predicts symptoms) is difficult to test in the
absence of a ‘‘gold standard’’ for symptom elicitation.
We tested two aspects of construct validitydnamely,
convergent (i.e., presence of correlation between
item scores that measure the same construct) and
divergent validity (i.e., lack of correlation between
scores for unrelated items). The patient survey,
compared with other validated symptom and quality
of life surveys, showed satisfactory convergent validity.
We also showed, as expected, that higher symptom
burden reflected in the IPOS-renal survey correlated
with lower physical and mental composite scores,
further establishing construct validity. Similarly, we
were able to demonstrate construct validity for the
staff version when compared to the STAS survey. Feed-
back from staff participants who used the survey was
positive, with the staff version being described as
easy to understand and score. Both patient and staff
versions showed that when unrelated items were
compared in different surveys, the correlation was
poor, showing divergent validity. Our study was not suf-
ficiently powered to detect sensitivity to change or dif-
ferences between patient groups.
Patients’ reluctance to mention their problems and
clinician ignorance about symptoms remain
Table 5
Convergent Validity: Spearman Correlation Coefficients
Between the Patient-Completed Surveys and Summary




IPOS-Renal ESAS-r KDCS PCS MCS
Pain 0.77 L0.49 L0.59 L0.52
Shortness of breath 0.76 L0.29 L0.38 L0.28
Weakness or lack of energy 0.65 L0.51 L0.63 L0.4
Nausea 0.65 L0.33 L0.28 L0.28
Vomiting L0.13 L0.28 L0.2
Poor appetite 0.67 L0.49 L0.33 L0.35
Constipation L0.27 L0.21 L0.03
Sore or dry mouth L0.18 L0.21 L0.11
Drowsiness 0.67 L0.44 L0.4 L0.31
Poor mobility L0.44 L0.55 L0.37
Itching L0.29 L0.31 L0.16
Difficulty sleeping L0.45 L0.3 L0.36
Restless legs L0.39 L0.33 $0.2
Changes to skin L0.42 L0.28 L0.32
Diarrhea $0.2 $0.17 L0.24
Anxiety 0.61 L0.56 L0.28 L0.6
Family/friends anxious about you L0.45 L0.3 L0.36
Depressed 0.68 L0.44 L0.26 L0.54
Felt at peace L0.03 $0.19 $0.22
Able to share with family/friends $0.03 $0.2 $0.04
As much information as you
wanted
0.05 $0.06 $0.06
Practical problems addressed L0.27 $0.18 L0.28
Time wasted on appointments L0.29 $0.23 L0.26
Total symptom score 0.65 L0.65 L0.59 L0.6
KDQOL-SF v1.3 ¼ Kidney Diseases Quality of LifeeShort Form version 1.3;
IPOS ¼ Integrated Palliative Outcome Score; ESAS-r ¼ Edmonton Symptom
Assessment Systemerevised; KDCS ¼ Kidney Disease Component Score;
PCS ¼ Physical Composite Score; MCS ¼ Mental Composite Score.
Interpretation of Spearman correlation coefficient: 0.9e1, very high correla-
tion; 0.7e0.9, high; 0.5e0.7, moderate; 0.3e0.5: low; 0e0.3, negligible corre-
lation; negative values indicate inverse correlation.33
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important barriers to improving their management in
hemodialysis patients.1,10 Patient-reported symptom
surveys such as the IPOS-renal are a potential solution
to bridge this gap. The IPOS-renal survey has features
that recommend its use over other similar surveys. It is
short and easy to complete, and its domains also span
concerns relevant to chronic disease such as informa-
tion needs, carer anxiety, time wasted on appoint-
ments, and other practical issues. It invites patients
to use free text to list their most important problems
first, so that clinical attention can focus specifically
on issues that matter most to the patient. It also pro-
vides space to record other symptoms that may not
be included in the survey.21 Its popularity across units
in Australia, where it is used for both clinical manage-
ment and for research, suggests that clinicians are
already finding the survey useful in practice (ANZDA-
TA Working Group on PROMs 2017; unpublished
data). A further advantage is that the staff version of
the IPOS-Renal may be helpful in situations where pa-
tients become too ill to report their problems.
The study had limitations. We chose a convenience
sample of patients and their nurses; most of our partic-
ipants were on hemodialysis, with smaller numbers on
peritoneal dialysis or supportive care. We could not
achieve sufficient participant numbers to report sensi-
tivity to change. While some patients completed sur-
veys within the dialysis unit, others completed them
at home or in outpatient clinics. A study powered to
detect significant changes in symptom scores, and
with a more deliberate sampling of patients treated
with peritoneal dialysis and supportive care, will
address some of these limitations.
Conclusion
In our study population, the IPOS-renal symptom
survey, patient and staff versions, demonstrated good
internal consistency and test-retest reliability. Conver-
gent validity was also established by comparison to
other established surveys administered concurrently.
Our results recommend the use of this survey for the
documentation of symptoms in patients with advanced
kidney disease.
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5.1.1 Qualitative analysis  
Older patients appear to adapt to dialysis in different ways. While some patients adapt 
well and seem to thrive, others tend to deteriorate. If these outcomes could be predicted 
in advance, this would benefit patients and families that are considering treatment 
options for end-stage kidney failure. We do not have satisfactory methods of predicting 
these outcomes - in fact, as discussed, most prognostic scores focus on survival 
outcomes. This qualitative study was designed to explore outcomes on dialysis from the 
point of view of the older patients’ perceptions about life on dialysis - specifically, the 
concepts regarding a ‘good outcome’, and what they considered were the factors 
leading to such outcomes. 
Qualitative research, using the phenomenological approach, attempts to study the 
experiences of a phenomenon from the points of view of the participants themselves 
(214). The semi-structured interview format allows the interviewer to initiate and direct 
the flow of the interview, but because these questions are open-ended, they allow the 
participant to freely express themselves as they provide their recount of their 
experiences. Once interviews are recorded and transcribed, the transcripts then provide 
the researcher a rich source of material for analysis. 
With the aim of understanding the outcomes that are relevant to older patients, we 
chose a group of participants over the age of 70 who had already started dialysis 
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treatment.  Our area of interest was the description of experience. Moving beyond the 
assumption that survival is the only important outcome, we wanted to explore what 
patients on dialysis thought were the other important outcomes.  
In addition, we also wanted to explore the influence of patient-specific characteristics on 
how outcomes of dialysis were perceived. Specifically, we wanted to study the 
influences of illness perception and personality, as detailed below. 
 
5.2  Enabling good outcomes in older adults on 
dialysis: A qualitative study 
 
This qualitative study has been submitted to medical journals for publication and is 
under consideration, as:  
Raj R, Brown B, Frandsen M, Ahuja K and Jose M; “Enabling good outcomes in older 
adults on dialysis: A qualitative study”.  
The following is a Word document version of the final submission proof. 








Older individuals, the fastest growing subset of patients on dialysis, do not always have 
optimal outcomes on treatment, particularly with regards to quality of life. While 
previous research has focused on their survival, less is known about factors influencing 
other positive outcomes. Such information can guide decision-making around dialysis 
initiation and potentially improve outcomes for patients already on dialysis. This article 
describes the use of qualitative research methods to explore these factors from the 
perspective of elders already on dialysis. 
Methods: 
Semi-structured interviews with participants aged over 70, receiving dialysis at a 
regional Australian hospital, were recorded and transcribed. From participants’ 
responses, we identified descriptive themes using a phenomenological approach, with 
verification by two researchers. Factors affecting outcome were derived reflexively from 
these themes. 
Findings: 
17 interviews (11 male; mean age 76.2 years) were analysed prior to saturation of 
themes. Experiences of dialysis were described across four domains - the self, the body, 
effects on daily life and the influences of others; yielding themes of (i) responses to loss 
(of time, autonomy, previous life), (ii) responses to uncertainty (variable symptoms; 
unpredictable future; dependence on others), (iii) acceptance / adaptation (to life on 






Outcomes other than survival could be influenced by symptoms, physical status, 
psychological adaptation, social factors and availability of support. Appropriate pre-
dialysis education is needed, including information about lifestyle changes and 
restrictions. Once on dialysis, encouraging active adaptation to treatment and to ageing, 
with family and clinician support, could improve outcomes.  
 
5.2.2 Introduction 
By 2030, it is estimated that 4 to 7 million people will be receiving renal replacement 
therapy worldwide (215). Those over the age of 75 make up 22% of all patients on 
dialysis in Australia (31), and figures are similar elsewhere (USA – 20%, UK - 16% and 
Japan - 31% (216–218). The elderly, particularly if they have comorbidities, often do not 
derive benefit from dialysis - both in terms of mortality and quality of life (12,219). This 
suggests that comprehensive conservative or supportive care, without dialysis, may be 
a valuable treatment pathway for such patients.  
It is common for the older patient with advanced renal failure to frame the choice 
between dialysis therapy or conservative care as a choice between life (dialysis) or death 
(non-dialysis pathway) (220). Clinicians can access several recommended tools to 
predict prognosis in elderly patients with advanced renal failure (128). While these 
prognostic tools often consider survival, they may not predict quality of life or other 
outcomes, which may arguably be more important in these elders’ lives (221). The 
intrusive nature of dialysis treatment alters multiple aspects of daily life, including the 
effects on physical and cognitive states, and the worsening of the complexities of ageing 




dialysis and conservative care, or be used to suggest interventions to improve outcomes 
for patients already on dialysis (223). 
In adapting to a major illness, the older patient is likely to have different priorities and 
coping strategies compared to their younger counterparts (224). After starting dialysis 
some older patients appear to thrive, while others enter a progressive spiral of 
deterioration, dependency and repeated hospitalisation (58). These qualitative and 
individual consequences of dialysis are hard to predict. In order to understand factors 
influencing these outcomes, distinct from survival or mortality, we considered that an 
exploration of the patient’s perspective would yield useful insights (225). In this article, 
we report the results of a qualitative research study that used semi-structured 
interviews to document older patients’ experiences of dialysis and outcomes. 
 
5.2.3 Methods 
Study population, recruitment and sampling 
A convenience sample of eligible participants was recruited from among patients under 
the care of a regional Australian hospital. Participants were eligible to participate if they 
were aged over 70 years and were being treated with haemodialysis or peritoneal 
dialysis for more than three months. Exclusion criteria included patients judged by their 
treating physician to be too unwell or cognitively impaired to participate; and patients 
unable to converse in English. The research protocol was approved by the Tasmanian 
Human Research Ethics Committee (H0014515).  
Potential participants were invited to the study by the research nurse in person, 
provided information sheets and given the opportunity to read and ask questions of the 
study. Interested participants were then asked to sign a consent form. Face-to-face 




lasted approximately 45 minutes (range 30 to 75 minutes) and were audio recorded. 
Demographic data collected included age, gender and years spent on dialysis.  
Interviews 
Questions for the semi-structured interviews were derived from informal email surveys 
of experienced nurses and nephrologists prior to starting the research project (see Table 
5-1). The interviews were conducted face-to-face by a female registered nurse of 12 
years’ nursing experience, trained in conducting qualitative research interviews. Only 
the research nurse and participant were present at the interviews. Most interviews (14 
of 17) were conducted in participants’ homes; 3 interviews were conducted in a private 
room at the dialysis unit. 
(The questions, recording equipment and transcription services were pilot-tested on a 




Interview questions  Expected areas of interest for the 
study 
1.How are you doing on dialysis, and 
why? 
What do patients think influences 
their outcomes? 
2. How do the people around you 
influence you - at home, or in the renal 
unit (doctors, nurses or other patients)? 
Do the people around the older 
patient influence outcomes? 
3. How dependent / independent are 
you for: activities of daily living; other 
practical things (money, food, 
transport)? Who helps? 
Does being independent of others 
describe a good outcome? 
4. What are the best & worst things 
about life (on dialysis & overall)? 
Are there overwhelming positives and 
negatives to being on dialysis? 




Interview questions  Expected areas of interest for the 
study 
5. How do you see yourself if you were 
not on dialysis? 
How much has dialysis impacted on 
life course? 
6. What are your thoughts regarding 
the future or advance care planning? 




All interviews were audio-recorded and transcribed verbatim by external professional 
transcribing services (Outscribe Transcription Services, Australia). Transcripts were 
cross-checked for accuracy, and participants were offered the opportunity to read over 
their transcripts for accuracy (all declined). Transcribed interviews were then imported 
into data analysis software (NVivo qualitative data analysis Software; QSR 
International Pty Ltd., Australia. Version 10, 2014) to enable rigorous, low-error analysis 
of the transcribed text. The purpose of the analysis was to explore and describe the 
individual experiences and opinions of the participants with regards to dialysis 
treatment. A phenomenological approach was adopted, and iterative thematic analysis 
utilised to develop representative themes from the text.  
Primary analysis of transcripts was conducted by author RR, utilising line-by-line 
coding to identify key concepts and issues. Codes / concepts were then grouped into 
themes and categorized. A memo and project log were kept throughout this process. 
Supplementary analysis of the data by author MF was conducted to verify themes and 
domains identified by RR (18).  Throughout this process there was reflexive 
consideration of the analysis and discussion between the two investigators (19,20). Key 
domains and major themes were identified via consensus of the authors.  Interviews 
were conducted and analysed until there was saturation of themes, achieved after 17 








Transcripts from 17 interviews were analysed prior to saturation of themes. The mean 
age of participants was 76.2 years (range: 70 to 83); on average, they had spent 4.3 years 
on dialysis (range: 2 to 9 years). Eleven participants were males, and 6 females. None of 
the participants were employed. 
Participants' reports of their experience of dialysis and its effects could be classified 
under four main domains: (i) the concepts of self, (ii) the physical body, including 
symptoms, (iii) effects on everyday life and (iv) participants’ relationships with others. 
These descriptions are discussed in detail below. 
Dialysis and the Self 
“I don’t know, I’ve forgotten what it’s like not to be on dialysis”.  
[P7, Female, 75] 
Dialysis was described as a very intrusive treatment, which had a significant impact on 
the concept of self, caused major changes in lifestyle and altered the life-roles of most 
participants. There was acknowledgement that undergoing treatment was necessary to 
preserve life and the self. The decision to start dialysis and subsequently to continue it, 
despite discomfort, was framed as a choice between living and dying, since participants 
interpreted that without dialysis, death was certain. Even though dialysis was ‘chosen’ 
as a treatment option, there was ambiguity about whether there was choice after all, 




 “…no well I’ve got, well I’ve got a choice. I can have dialysis or go up the 
chimney!”        
[P5, Male, 75] 
Being on dialysis altered how some participants thought about good outcomes in their 
lives. When replying to questions about how they were doing on dialysis, some 
participants tended to frame themselves in terms of their illnesses and responses to 
treatment. For instance, they said that dialysis sessions without interruptions or medical 
problems indicated that they were having a good outcome. Similarly, ‘good’ 
biochemical test results, trouble-free machine behaviour, or positive reports from 
healthcare professionals implied positive outcomes for some, suggesting a shift from 
internal to external, ‘medicalized’ determinants of one's status.  
When asked about the reasons for their perceived good outcomes, participants cited 
their own personal factors. Prominent among these descriptions was the 
characterisation of themselves as independent entities that regained control over life’s 
events. Several participants described themselves as ’stubborn’, ‘obstinate’ or ‘a fighter’. 
These narratives about control over life’s events was the most frequently coded theme. 
A personality that remained independent yet adapted to adversity and carried on was 
cited as a reason for doing well on dialysis.  
“Yeah.  I'm just one of those people that feel you've got to, you know, get on with 
life and get on, you know, if you've got a problem, just deal with it yourself”. 
[P4, Male, 78]  
Participants highlighted the importance of a positive attitude which enabled them to 
bear the difficulties of dialysis and ageing. Such an attitude was demonstrated in their 




“the only one to help me is myself”. Participants spoke of never ‘thinking negative’. As 
one participant said, there’s “no point worrying it”. 
“I don’t let anything worry me, and I take everything in my stride, I don’t go 
sulking to somebody about this or about that, I just put up with it all. And [my 
nurse] says, you’ve got a good attitude”.  
[P6, Female, 75] 
In response to questions about the future, the older age of participants in this study was 
reflected in their attitudes towards mortality and death . Several participants 
demonstrated a pragmatic approach; they acknowledged that life was limited, and 
some declared that they did not fear death. 
“Just wait for the sun to rise the next day and we’ll live that one as it comes. That’s 
all you can say. Because we don’t know how long we’ve got…..I don’t think I’ve 
got that much left, really. Too bad to worry about it now”.  
[P4, Male, 78] 
Whereas all patients acknowledged the difficulties of living on dialysis treatment, only 
some patients were convinced that they were not doing well at all. Others described 
adapting successfully and valued the lives they led on dialysis, despite all the 
difficulties.  They accepted the necessity of dialysis treatment and adjusted their lives 
around the treatment, sometimes calling on family or healthcare personnel to help in 
their transition. For some such patients, stopping treatment and accepting eventual 
death was considered "giving up" of a valuable life. 
“Oh, life’s too valuable to turn around and do a silly thing like that. Throw the 
sponge in like that, just get sick of it like that…” 





Dialysis and the Body 
“Well, it’s hard to define because I have a problem – like, renal problem – right? 
And I also have an old age problem.”  
[P12, Male, 83] 
Our participants frequently mentioned the effects of persistent symptoms and 
progressive physical deterioration, compounded by the effects of growing older. This 
impacted on their ability to do things they had done earlier - a loss felt by several 
participants. Progressive loss of vision, worsening mobility and persistent fatigue were 
among the problems mentioned. Participants reported being now unable to read, drive 
or do things around the house unaided. 
“Just doing me housework and all that, you know. I used to do everything all at 
once, now I can't. Getting old.” 
 [P6, Female, 75] 
Not all participants had relief from bodily symptoms after starting dialysis, and this led 
to contrasting perspectives regarding symptoms and their impact on the experience of 
dialysis. On the one hand, a subset of interviewees remembered being severely 
symptomatic with renal failure prior to beginning regular dialysis treatments and were 
grateful that starting therapy made them feel much better. They continued dialysis, 
despite its difficulties, because they did not want to once more feel as bad as they had 
prior to the initiation of dialysis. 
“And I feel a lot better than what I did. But if you could have seen me before I got 
on dialysis, it was dreadful. Yeah.”  
[P8, Female, 71] 
On the other hand, there were others who developed a new set of symptoms as a result 




around inserting needles into the arteriovenous fistula (used for hemodialysis access) 
and the need to sometimes rest in bed for long periods after each dialysis session.  The 
symptoms were unexpected for some patients, who had expected that dialysis would 
actually make them feel better.  
“Well everybody tell me I’ll feel real good after it, but you don’t…No they told us 
that you know first off they said you’ll feel better and everything but you don’t.” 
 [P1, Male, 78] 
A third group of participants had pre-existing bodily symptoms from other illnesses - 
such as low back pain, or diabetic complications - which did not improve, and even 
worsened the experience of dialysis. Patients troubled by worsening physical status, 
and a severe symptom burden, often stated that they were not doing well on dialysis. 
Dialysis and its Effects on Daily Life  
Participants reported multiple effects on daily life as a result of being on dialysis. The 
amount of time spent on the treatment was repeatedly mentioned. Several participants 
were frustrated with having to remain immobile for the four hours or so of dialysis. 
Along with the hours needed for treatment, participants also reported the time lost in 
travelling to and from the dialysis centre. In all, this left no time for other activities on 
dialysis days, especially if they felt unwell after dialysis and had to rest for a while 
afterwards.  
The time commitment to dialysis forced some to give up activities that they enjoyed, 
including travel, hobbies such as fishing, or part-time work. Relatively inflexible 
dialysis schedules also meant that participants progressively withdrew from social 




“But I’d spend, and I used to work behind the bar on a voluntary basis one night a 
week.  There was always something to do and I’ve always got involved in things.  
And since I’ve been on dialysis … I had to give it away.”  
[P14, Male, 78] 
 
Several participants commented on the cyclical nature of symptoms related to dialysis 
treatments. Significant tiredness was common after dialysis, especially if there had been 
large fluid removals during the session. This tiredness slowly improved until the next 
day, when they felt much better, only to reappear the following day after the next 
dialysis treatment. These repeating cycles of severe fatigue and relative wellness 
contributed to the intrusive nature of dialysis. It prevented participants from 
committing to activities outside of dialysis. It also made them increasingly dependent 
on external help, especially during the days of post-dialysis fatigue. 
“...my kids used to say, ~You've got an extra day off.  We can go off here, we can 
go there... but you don't, those days is when you feel like you want to have a bit of 
a rest or something because, as I said, you feel, you don't feel like you're full of 
bean.” 
[P15, Male, 82] 
The food and fluid restrictions imposed impacted participants’ daily lives and their 
social interactions. Fluid restriction was difficult for some; participants had to be 
conscious about these restrictions  all the time, particularly when eating outside the 
home (including when eating with family or friends). Others felt that fluid restriction 





“But it’s hard, because I’ve been … with clubs and things like that, and to go and 
have a drink and a cup of tea and, so now I’m not allowed to have it.” 
 [P1, Male, 74] 
A few participants understood the necessity of restricting fluids, and made necessary 
adjustments, believing that their adherence to fluid restriction enabled them to do well 
on dialysis. Families and friends also contributed to helping patients maintain their 
restricted diets. 
Most of our participants were retired from work. One of them had his own business but 
reported that the time commitments of dialysis had forced him to hand over 
responsibility for everyday matters to others. Those who did not have financial stability 
reported difficulties with the increased expenses. This was particularly true for those 
that lived far from the dialysis unit if they had to pay transport charges. Some 
participants had to move homes to be nearer to the units, once again interfering with 
social connections. 
Dialysis and Others 
In this population of dialysis patients over the age of 70, relationships with others - 
partners, other family members, friends, neighbours and healthcare professionals - were 
important in how they experienced life on dialysis. 
The presence of a loving spouse or family members appeared to influence the decision 
to start and continue dialysis. As our cohort experienced increasing loss of physical 
abilities, people around them helped them cope. Many received help with activities in 
the house. Others were assisted with chores such as tending to the garden or shopping 
at supermarkets. This support structure of family and friends had positive influences on 




Friends and neighbours were also relevant to most participants, for both the practical 
benefits in and around the house as well as the psychological benefits of interacting and 
staying in touch.  Some participants considered it important to maintain relationships 
not connected to their life on dialysis. Other participants mentioned that over time the 
staff and other patients and families at the dialysis became part of an extended group 
that they could relate to. Dialysis provided an environment to meet more people. The 
shared experiences of dialysis, including the many restrictions, the long hours spent 
together at the unit and the similar interactions with healthcare personnel, strengthened 
these bonds. The camaraderie and humour lifted spirits. 
“Yeah, I think so, it helps you with your, you talk about, well some will moan and 
groan about things, and some will just talk like happy-go-lucky, and just forget 
their illness, talk about other things…” 
[P17, Female, 80] 
 Our participants all had close relationships with nurses, and acknowledged the central 
role played by nurses in their lives. For patients on haemodialysis, the nurse looking 
after them on the day had a significant impact - both on the conduct of dialysis 
(including needling of the AV fistula) as well as through how they made the 
participants feel. Both positive and negative interactions were recounted. Nurses that 
took an interest in their patients and spoke kindly were appreciated.  Overall, most 
participants appeared grateful for the care they received from their nurses and 
considered them part of a "new family"; there were several anecdotes of humorous 
interactions. 
At the same time, comments were made regarding the perceived lack of interest in their 
welfare exhibited by some nurses. Similar to the negative interactions with doctors 




patients of food and fluid restrictions - participants had varied reactions to this. While 
some appreciated the advice, others were not happy being told what to do. Thus, it 
appeared that despite their time on dialysis, there were some participants who still did 
not understand or accept the restrictions required for a life on dialysis. 
“Yeah, I mean you know they say oh he’s not supposed to do this, not supposed to 
– hang on a minute, I’ve got to have some, bloody quality of life. I’m not going to 
just starve myself.” 
 [P2, Male, 73] 
Most participants acknowledged the essential role played by doctors and trusted them 
implicitly to look out for the welfare of their patients. It was important to get along well 
with doctors. Participants emphasized how valuable it was to them that doctors 
considered them as individuals and showed respect and involvement. A sense of 
humour was appreciated. Tone of voice, manner of speaking and consistency of 
behaviour were important too.  
“…but just his approach to the patient and everything like that, always ready to 
listen and smile on his face.” 
[P5, Male, 75] 
Negative interactions with doctors had a significant impact on the participants.  Some 
participants felt let down by doctors who did not interact well, and preferred health 
professionals that they could better relate to. 
“…like every six weeks I’m supposed to come, and you talk to the nurse and don’t 
talk to me?…[made me feel] that I was inferior, that he thought he was too good to 
talk to me, do you know what I mean....but this other doctor has been different.” 




Our older participants relied on health care professionals for most of their medical 
information. Some participants were involved in their own care and were enthusiastic 
about asking questions to understand their treatment or the working of the dialysis 
machine. For others, there was no desire to gather more information and instead they 
relied on professionals "knowing what they are doing". 
Interestingly, some participants felt doctors could not help because doctors were too 
busy, or that they had not experienced first-hand what patients had gone through. This 
difference was highlighted by a participant who stated: 
“He [the doctor] hasn’t fallen on the floor, he hasn’t, and carted him off to hospital 
so he’s okay, you know.  So, as far as I’m concerned it is a waste (to speak to 
doctors).” 
 [P1, Male, 78] 
These beliefs eroded their trust in the doctor-patient interaction; they stated that there 
was no benefit in meeting their doctors regularly. Such comments were common when 
they felt that medical professionals had not been attentive enough or had not 
communicated well enough to satisfy their expectations.  
Several participants commented that the experience of dialysis was quite different to 
what they had expected, or that they had not been given enough information.   
“They just plonk you on the machine and that's it, you know, they do it, and they 
didn't explain things.” 
 [P16, Female, 75] 
Even participants who had received formal, structured pre-dialysis education regarding 
dialysis treatment did not retain all of the information received. (We could not explore, 




or other aspects of cognition, or whether the methods of patient education locally 
available were unsuitable for this older cohort.) 
5.2.5 Discussion and Synthesis 
 Our findings reflected the intrusive nature of dialysis, which impacted on almost every 
aspect of the life of the older adult on this treatment. There were four main overlapping 
meta-themes spread across domains: loss, uncertainty, acceptance and support (Table 5-
2). 
 
Domain Loss Uncertainty Acceptance Support/ Relationships 
Dialysis 
and the self 
- Of choice: it is 
now either dialysis 
or death 
 - Of control: 
nothing can be 
done about it  
- Of identity; 
personhood:  
dialysis must go 
well for me to be 
okay 
- Of pre-dialysis 
life: role, activities, 




- Dialysis sessions 
(determine how I 
feel) are 
unpredictable  
- The machine tells 
you how I am doing, 
not me. 
- Rely on HCPs to 
communicate clearly: 
otherwise, I know 
nothing. 
 - No future hopes, 
other than to 
continue dialysis 
until death. 
- Rationalizing the 
need to be on 
dialysis 
- Positive outlook 
- Taking control of 
life 
- Use of humour 
to cope 
- Life is worth 
living, purposeful 
- Relationships are 
crucial: as support 
and as reason for 
living 
- HCP interactions 
are crucial  
- HCPs cannot do 
much if they do not 








- Of wellbeing: the 
prominent 
- About needling of 
AV fistula - pain, 
bleeding  
- Unpredictable 
symptoms caused by 
dialysis 
- Acknowledge 
effects of ageing 





- Receiving help to 
look after oneself 
- Discussion of 
advance care plans 
with family, HCPs 
- Discussing health 
issues with HCPs 




Domain Loss Uncertainty Acceptance Support/ Relationships 
symptoms during 
and after dialysis 
- Of health: other 
medical issues 
continue 




- Fluid removal on 
dialysis and its 
effects: on energy, on 
BP  
- Discomfort in the 
dialysis unit- chairs, 
temperature 
- Other persistent 
symptoms 
 - Other unexpected 
illnesses 

















- Of time: for 
everyday things; 
social activities 
- Of dietary 
choices: fluid and 
food restrictions 
- Of travel 
possibilities: all 
trips linked to 
dialysis services 
- Of finances: 
transport costs, 
phone bills, lost 
earnings 
 
 - Repeating cycle of 
wellness and fatigue 
around the days of 
dialysis 
 - Episodic nature of 
haemodialysis: the 
need to arrange life 
around dialysis 
times 
 - What is done on a 
day depends on how 









health to engage 
in preferred 
activities 
- Seeking help 
where needed 




- Receiving support 
from HCPs/ allied 
health 
- Maintaining and 
strengthening 
helpful relationships 
among family and 
friends 
- Making time for 




Domain Loss Uncertainty Acceptance Support/ Relationships 
Dialysis 
and others 
- Of social ties 
- Of agency: the 
new need to 
comply with HCP 
instructions, rules 
for dialysis patients 
 
- Others did not 
communicate: 
dialysis is not how I 
expected 
- Social commitments 
now depend on 
dialysis schedules 
 
- Accepting help 
where available 
- Choosing to 
adhere to HCP 
recommendations 
 
- Engagement with 
HCPs to improve the 
experience of 
dialysis 
- Maintain activities / 
relationships outside 
dialysis 
- Family / friends / 
relationships that are 
nurturing 
- Dialysis unit as a 




Our population of older patients on dialysis felt a pervasive sense of loss across all the 
four domains of experience. Lindquist speaks of the dialysis patient's wishes for 
independence and normality - both these subjective feelings are lost when on dialysis 
(226).  Participants reported significant changes to their lives after starting dialysis, 
similar to the feeling of "life being lost" described by Monaro and colleagues (227). 
Changes in participants' concepts of themselves were seen when they described their 
health in terms of machine performance or biochemical targets. Various authors have 
described this as a transition into a life restricted (228); not finding space for "living" 
(229) or a life with physical shackles (230).  
 
McDonald described a continuum in responses to a life on dialysis, one aspect of which 
is a struggle between control and acquiescence (231). Similar to this, in our population, 




them and carry on. Such participants described positive adaptation and the 
transformation to a new self, capable of dealing with the new realities, and appeared to 
have good outcomes on dialysis (see discussion below).  
Uncertainty 
Uncertainty is another concept that spans several domains in our results. The repeated 
cycles of tiredness and improvement coinciding with haemodialysis sessions three 
times a week meant our participants were never sure of how they would feel, since 
dialysis sessions determined their status (variables such as large fluid removal targets, 
problematic needle insertion into the arteriovenous fistula or the behaviour of the 
dialysis nurses or doctors on the day). These feelings of vulnerability and uncertainty 
have been highlighted in several similar studies in the literature (229,232). 
 The future was unclear; several participants acknowledged that longevity was not 
certain and were happy to discuss advance health care directives. The inadequacies 
appearing with ageing and the experience of other dialysis patients (or other older 
acquaintances) dying impacted on their own outlook for the future.  This uncertainty 
introduced by dialysis could worsen the tendency of older adults to have lower 
"meaning in life" scores (233). 
Acceptance / adaptation 
Several researchers have studied the process of ageing, prominent in the narrative of 
our participants, as a process of adaptation to declining physical and cognitive 
capabilities (234,235). Previous studies have identified the theme of "attempting to 
maintain manageability" as part of life on dialysis (229). We identified adaptations in 
our older population as a series of changes - in lifestyle, activities, diet, fluid intake and 
mental attitude, undertaken with the aim of optimizing outcomes. In general, patients 




lives and in this way, to maximize the benefits of the restricted life on dialysis. Rittman 
describes this attempt by patients on dialysis to retain control over their lives by 
negotiating a new understanding of life and maintaining hope (236). This contrasted 
with those reports where patients did not show this acceptance, and instead focused on 
the difficulties. These patients did not engage in making adaptations to life in order to 
deal with adversity (237,238). 
Relationships and support 
Family members (and/or friends) had significant impacts on how life was perceived. 
Some participants felt that the involvement of their family was responsible for their 
positive experience of dialysis; on the other hand, others stated that they stayed on 
dialysis in order to take care of their family members. Interactions with family - 
including the new acquaintances at the dialysis unit - were related to "meaning in life" 
and to hope for the future. This is consistent with other studies which describe the 
ageing patient attempting to regain control of their life roles as their care situation or 
dependency needs change (239).  
Nurses played an important role in the lives of these patients. Their skills and their 
interactions with patients determined how dialysis was perceived. Similar observations 
have been reported by Madar, who commented that nurses have significant impacts on 
reducing the stress of dialysis (240). 
With regard to the relationship with doctors, the need to be seen as “normal” "as a 
human being", and "with respect” was manifest, similar to other qualitative studies 
(229,239). There was a spectrum of variable expectations from older patients on dialysis, 






reflexive interpretative analysis 
Physical factors: 
• prominent uraemic symptoms that may be relieved by dialysis (e.g., 
nausea, anorexia) 
• low levels of pre-existing frailty/physical dependence 
• absence of pre-existing significant symptoms that are unlikely to be 
relieved by dialysis (e.g., chronic pain, depression) 
• the ability to tolerate dialysis, particularly fluid removal 




• lack of conflict or ambiguity around the decision to start dialysis 
• expectations from dialysis that are reasonable and achievable 
• illness perception - an internal locus of control, willingness to take 
responsibility for own health 
• understanding of dialysis treatment and need for lifestyle changes, 
food/fluid restrictions 
• actively choosing a positive attitude; not "giving up", willingness and 
opportunity to adapt to changing circumstances 
• hopeful; engaged with the future; "meaning and purpose" in life 
Social factors: 
• family as motivation: providing physical/psychological support, 
family that requests continuance on dialysis or other treatment, 
participants who continue dialysis in order to be able to look after 
their family members 
• involvement of close family/friends/carers in daily life, in healthcare 
decisions 
• participants who derive social benefit from interactions of the dialysis 
unit (particularly if socially isolated) 
• ability to travel or engage in other activities (personal or social) 
separate from dialysis 
 
Healthcare provider/institutional/societal factors: 
• positive relationships with healthcare providers, where patients feel 
valued and listened to 




• appropriate skill sets among medical and nursing staff 
• opportunity to consider or participate in advance care planning 
• patient-friendly staff and dialysis facilities (e.g., flexible schedules, 
comfortable chairs, adequate heating) 
• easy access to dialysis facilities, including proximity, transport 
arrangements 
• financial stability or lack of financial penalties from being on dialysis 




5.2.6 Conclusions: Our results in the context of clinical practice 
The predictors of a good outcome on dialysis, listed in Table 5-3, were postulated by 
reflexive analysis, drawing interpretations from participants’ descriptions of positive 
and negative experiences on dialysis. Most of these factors can be assessed using 
targeted history-taking, or using several validated questionnaires and other tools, some 
of which are listed in Table 5- 4. When indicated, some psychological factors may be 
amenable to interventions such as cognitive behavioural therapy. Our research also 
highlights several social factors which have an influence on dialysis outcomes, thus 
highlighting the importance of a holistic approach to the elderly person considering 
dialysis.  
Table 5-4 offers some practical suggestions to mitigate poor outcomes on dialysis for the 
elderly and provides a list of objective assessment tools that may be useful. Nephrology 
teams may not possess all the skills required to ensure good dialysis outcomes for the 




including geriatricians, psychologists, nurse educators and social workers may be 
optimal.  
The importance of providing complete and detailed information cannot be overstated. 
More than mere altruistic intent, such an approach contributes to optimal conduct of 
shared decision-making and has legal relevance in the domain of informed consent for 
dialysis (241). Providing comprehensive information, and ensuring this information has 
been understood is one of the basic elements of a legally valid informed consent (241). 
 
Factors potentially 





(clinical / research purposes) 
The decision to 
have dialysis 
framed as a choice 




Specific discussions around 
choice; presentation of 
alternatives to dialysis such as 
maximal supportive care; 
involvement of family / carers 
in decision-making 
Decision support aids (e.g., 
web-based aids, (242)  
The Canadian CKM Care 
decision aid(93,243) 
The Yorkshire Dialysis Decision 
Aid (YODDA) (244)) 
The ‘SURE’ test (245) 
Undue expectations 
of symptom benefit 
from dialysis 
Discuss inconsistency of 
symptom relief; appearance of 
new symptoms with dialysis 
(e.g., needling pain, fatigue) 
 
Symptoms /quality of life 
surveys (210) 
Frailty indices (246) 
Comprehensive Geriatric 
Assessments (CGA ) (247) 
Assessment of health literacy  
(248) 
Becker-Maiman model for 
analysis of compliance (249) 
Beliefs and Behaviour 
Questionnaire (BBQ) (250) 
Dialysis Diet and Fluid non-
adherence Questionnaire (251); 
Being ill-prepared 
for the restrictions 
and the reality of 
life on dialysis 
Information tailored for the 
older patient (more time, 
more repetition); Specifically 
discuss restrictions to travel, 
diet, fluid intake 
Effects of ageing, 
physical or 
cognitive decline 
Screen for frailty and risk of 
falls; prevent deterioration if 
possible, address frailty, 
monitor functional status, 
provide support before the 
patient “fails” 










Explore personal values, 
discuss impacts of dialysis on 
the rest of the patient’s life  
The time 
commitment; 
losing time for 
‘living’ 
Specifically discuss time lost - 
including time needed for 
travel, and the time lost 
resting after dialysis. 
Impact and 
recurring nature of 
post-dialysis 
fatigue 
Warn patients of cyclic nature 
of symptoms like post-
dialysis tiredness and their 
impact on life 
Dedicated fatigue scales / 
inventory (253) 
Lack of a “positive 
attitude”, actively 
adapting to effects 
of dialysis on life 
Clinician focus and 
involvement in facilitating 
psychological adaptation, 
consider behavioural therapy 
if needed 
Illness perception  
questionnaire (252) 
Inventory of Coping Strategies 
Used by the Elderly ICSUE(254) 
Life Attitudes Profile (255) 
Personal Meaning Profile (256) 
Inability to 
maintain or enjoy  
goals /values / 
activities outside of 
dialysis 
Encourage and plan with 
patients regarding: Selecting 
the right activities according 
to current limitations, 
optimising self for their 
performance, and making 
compensations / accepting 
help where needed 
Loss of the feelings 
of being valued, 
loved, supported. 
Focus on meaningful clinician 
interactions; monitor support 
from family, friends; Consider 
needs of carers. 
Quality of life scales (210) 
Trust in Physician Scale (257) 
Zarit Burden Interview (258) 
 
The realities of ageing and its associated problems continue for patients on dialysis, as 




outcomes have often modified their activities according to capability, accepted support 
from those around them, and sustained beneficial social ties. An active choice to 
undertake dialysis treatment, with awareness of the difficulties of life on dialysis and in 
an environment of adequate support will increase the chances of being able to adapt 






5.3  The influence of illness perception and 
personality on outcome 
 
5.3.1 Background 
The study of illness perception in patients begins with the premise that there are 
rational appraisal processes that come into play when faced with illness and its 
symptoms. The  patient forms a perception of illness based on these symptoms and 
their cognitive and emotional effects. This perception then activates certain health-
related behaviours in order to restore well-being. These assumptions form the basis of 
Leventhal’s Self-Regulatory Model (SRM), which posits that patients form a “common-
sense understanding” of illness based on their perceptions, and these perceptions drive 
self-regulatory behaviour that attempts to restore normalcy (259). This model suggests 
five components of illness perception, namely -  identity, cause, time-line, consequences 
and cure or control. These components can be tested for using the Illness Perception 
Questionnaire - Revised (IPQ-R) survey, which has been validated in patients with 
ESKD (260,261). Illness perception attributes have been correlated with quality of life 
and mortality in patients with ESKD (262–266).  
Similar to illness perception, there is evidence that a patient’s personality can influence 
their outcomes on dialysis - in terms of survival, quality of life or coping methods (267–
270). In order to test if personality type or characteristics influenced outcomes, we 
administered the “Big-Five Personality Test” to our participants. This test scores 
participants on the characteristics of the major personality types, namely extroversion, 





The following analysis, which considered the influence of illness perception and 
personality type on the outcomes with dialysis, was performed concurrently with the 
study described in 5.2 above, but was not included in the research report sent for 
publication as this was outside the scope of the targeted journal. This ancillary 
information is presented here.  
5.3.2 Aims and objectives of additional analysis 
1. To test for a correlation between the components of illness perception 
(identity, cause, timeline, consequences and cure or control) and markers 
of quality of life outcomes on dialysis (physical and mental component 
scores, and answers to the “overall health rating” question on the Kidney 
Disease quality of life Short Form v 1.3 survey); and 
To look for correlations between personality type characteristics 
(extroversion, agreeableness, conscientiousness, openness and 
neuroticism) and markers of quality of life outcomes on dialysis (physical 
and mental component scores [PCS and MCS respectively], and answers 
to the “overall health rating” question on the Kidney Disease Quality of 
Life Short Form v 1.3 survey). 
 
5.3.3 Methods 
Selection of patients, inclusion and exclusion criteria have been detailed in the report for 
publication presented in 5.2.1. 
In order to study illness perception, we administered the IPQ-R survey, which 
generated numerical scores for each of the components of illness perception detailed 
above. In order to study personality characteristics, we used the ‘Big 5 Personality 




personality traits detailed earlier. Both surveys were administered prior to the patient 
interviews. 
In order to document quality of life outcomes, we performed a cross-sectional survey of 
the participants, using the KDQOL-SF v 1.3 quality of life survey (please see Chapter 3 
for details of this survey tool). For outcome variables, we used summary scores of 
physical and mental aspects of quality of life obtained from this survey (the Physical 
and Mental component scores), and the answer to a single survey question about 
overall heath (“How would you rate your overall health?”). We then  looked for 
correlations using  Spearman’s rho, with a p value of <.05 considered significant. 
5.3.4 Results of additional analysis 
The distribution of personality traits in dialysis elders was unremarkable, as shown 
below: 
 






















































































We compared scores on the components of illness perception in our cohort with their 
quality of life scores and their assessment of overall health, testing for correlation using 
Spearman’s rho. Among personality traits, significant (p<.05) correlation was seen 
between extraversion and the rating of overall health (r = .55), neuroticism and rating of 
overall health (r = -0.6), neuroticism and MCS (r= -0.6). Among illness perception 
characteristics, the concept of time (i.e., chronicity) was correlated with PCS (r = .61). 
No other correlation was found between personality traits, illness perception and these 
markers of outcome. 
The influence of personality traits on the responses to chronic illness is an intriguing 
area of research, especially in long-standing, potentially incurable diseases such as 
multiple sclerosis. It can be postulated that an extroverted personality is better able to 
cope with the rigours of dialysis treatment and may actually thrive in the open, 
communal nature of the dialysis unit. Similarly, it is conceivable that neuroticism, a 
measure of distress and anxiety, is correlated with a negative rating of overall health 
and a negative mental component score of health-related quality of life. Despite our 
very small numbers, these results are worthy of interest. The influence of personality on 
outcomes in chronic kidney disease has been previously reported in a Malaysian 
population (273). Similarly, illness perceptions have been known to affect survival and 
quality of life in patients with renal disease (274,275). It is conceivable that therapeutic 
targeting of these illness perceptions could improve psychosocial outcomes (276). These 
areas need further research. 
5.3.5 Conclusion 
Personality traits and illness perception concepts appeared evenly distributed in this 
small population. Within this group, we found small correlations between personality 




yielded more accurate results. However, our primary objective was the qualitative 
analysis of the interviews, and data collection was stopped after 17 participants, once 
saturation of themes was noticed. A separate future study, adequately powered, may 






Chapter 6:  




Pneumonia may well be called the friend of the aged. Taken off by it in 
an acute, short, not often painful illness, the old man escapes those ‘cold 
gradations of decay’ so distressing to himself and to his friends. 
– Sir William Osler, writing in 1912 (277) 
 
When older persons choose treatments that could extend their lives, a worthwhile 
consideration is that of the quality of the life so gained - it is still important to avoid the 
‘cold degradations of decay’ quoted by the prescient Sir William Osler more than a 
century ago (although pneumonia may no longer cause the mortality it once did in the 
pre-antibiotic era). Life expectancy is increasing, and medical progress has ensured that 
life-sustaining treatments for previously fatal illnesses like end-stage kidney disease are 
now widely available (278). Dialysis is a typical example for a life-sustaining treatment 
now widely available to the elderly. But while it extends life, it can completely alter 
lives for the worse in some older people and cause a significant decline in quality of life. 
Clinicians discussing dialysis treatment with older people are frequently asked for 
advice to address this dilemma that older patients and their families have to grapple 
with.  
Through the research projects in this thesis, I set out to explore aspects relevant to the 




chosen – an analysis of the available literature on the information that clinicians could 
use in discussions about treatment choice, the quality of life outcomes on dialysis as 
influenced by physical symptoms and an exploration of older patients’ perspectives of 
outcomes from dialysis. Finally, from an interpretative analysis of these research 
findings, I aimed to develop a comprehensive checklist that could be used by clinicians 
counselling older patients with ESKD, such that all important factors (identified from 
the literature review and from my own research) could be addressed. In the course of 
this work, I was additionally able to generate a list of initiatives that clinical teams could 
take to improve the lives of older people already on treatment. 
The following sections describe how I addressed each of these objectives through the 
studies carried out. Subsequently, I discuss in this chapter the contributions to the 
literature from my research. Finally, I reflect on the potential impact of my work on the 
field and consider the future. 
 
6.2 Research outputs mapped to objectives of 
research projects 
 
6.2.1 Scoping review: information for older patients considering 
dialysis 
As discussed earlier, in the scoping review of literature from 2000 to August 2018, I 
attempted to collate the information relevant to the discussion of dialysis options with 
older patients.  
Survival on treatment is an important concern for clinicians and patients. By referring to 
annual statistics published by data registries in a particular region, an overall estimate 




However, patients often ask for more individualised prognosis. Within the literature, 
prognosis was linked to  sociodemographic factors such as age, aspects of nephrology 
care and dialysis treatment, other co-existent illnesses, functional status, nutrition, body 
composition and individual biochemical tests. Some of these factors have also been 
combined into indices that could be used in the elderly population to predict survival 
with various treatment options. Additionally, I highlighted indices that predicted the 
risk of developing renal failure (and therefore the risk of eventually needing dialysis). 
To guide the appropriate use of the indices, I highlighted the populations in which the 
indices were derived, the cohorts used for validation and statistical information about 
the discriminatory abilities of the indices. From the available information, as 
summarised in Chapter 2 (p 71), the Kidney Failure Risk Equation derived by Tangri et 
al may be used for calculating the risk of end-stage renal failure developing in a given 
patient; and the Bansal index may be used to estimate the risk of mortality, to sub-select 
a group at high risk of mortality, who may be suited better to a non-dialysis, 
conservative pathway (84,118,184). 
I also provided a comparison between the survival with dialysis versus that with non-
dialysis, conservative care. This is relevant particularly to the older patient with 
multiple other co-existent illnesses, in whom the benefits of dialysis treatment are less 
certain. Table 6.1 is derived from the information previously presented in table 2 . 4 






Population Survival: CM versus 
RRT (months) 
Specific sub-groups Comments 
Age > 80 
Age> 80; recommendation for CM by clinical team 
Cr Cl < 10 (134); single 
French unit 
8.9 vs 28.9  Late referral, poor 
nutritional and 
functional status in 
CM group; peripheral 
vascular disease 
affects mortality at >1 
yr 
Age > 80; choice of CM by patient 
eGFR <20, (16); single 
UK unit 
Survival less with CM Those > 80 – no 




eGFR < 20 (140); single 
Dutch hospital 
17 vs 25 (n.s) 
 
Those > 80 - no 
survival advantage to 
RRT 
 
eGFR < 15 (141); single 
Spanish hospital 
No difference Those > 80 - no 
survival advantage to 
RRT 
 
Age > 75 
eGFR ≤ 15 (74); 4 UK 
units 




1- and 2-year survival 
better overall with 
RRT, except with 
comorbidities, IHD in 
particular 
eGFR 10 -15  (136); 
single UK clinic 
29.4 vs 36.8 with low 
comorbidity; 
20.4 Vs.25.8 (n.s.) with 
high comorbidity 





eGFR 16 (139); single 
Australian unit 






eGFR 10 -15  (142); 
single UK clinic 
23.1 vs 38.2 overall 
20.3 vs 28.4 with high 
comorbidity 
Those with high 
comorbidity, only 
marginal advantage of 
RRT 
Rapid rates of eGFR 
decline worsens 
survival in those > 75 
managed with CM 
Age > 70 
eGFR 10.8 (135); single 
UK clinic 
13.9 vs 37.8  Similar number of 
hospital-free days in 
both groups 




eGFR <20, (16); single 
UK unit 
Longer survival with 
RRT 
Worsening 




Across all 3 groups – 
eGFR<20, <15 and <10 
eGFR < 20 (140); single 
Dutch hospital 
At eGFR <15: 
18 vs 37 
At eGFR<10: 
6 vs 34 
High comorbidity: 





eGFR < 15 (141); single 
Spanish hospital 
Overall: 
39 vs 65 
After eGFR<15 
21 vs 46 
  
Age > 65 
eGFR≤ 15 (138); single 
Hong Kong center 
28 vs 45  CM compared to PD 
alone 
Hospitalisation risk 
lower with PD 
eGFR <10 (143); CM at 
single Austrian centre 
compared to registry 
RRT data 
1.1 vs 26.9 With comorbidities, 
survival benefit for 
RRT did not persist 
beyond 2.9 months 
(females) or 1.9 
months (males) 
compared to CM 
 
    
 
It is difficult to arrive at composite scores of survival because of significant differences 
in the patient groups studied and the methods of estimation of comorbidities. However, 
a few generalisations can be made. In those over 80, multiple single-centre studies have 
shown no benefits of dialysis over conservative management. In those over 75, the 
presence of comorbidities significantly reduces or even negates the survival advantage 
of dialysis over conservative management. In those over 70 years old, as well as those 
over 65, single-centre studies show a survival advantage of dialysis that appears to 
decrease as patients have increasing comorbidities. From these studies, the need for 




standardised descriptions of comorbidities is obvious. Additionally, it can be seen how 
survival alone is not a very good factor to consider - especially in those situations where 
the difference between the two treatment pathways is marginal. A focus on mere 
survival also takes the discussion away from the very real changes in lifestyle and 
overall quality of life that dialysis treatment brings about: a consideration that may be 
particularly important to certain patients. 
The next objective of the scoping review was to identify factors influencing quality of 
life on treatment. I identified potentially modifiable factors, such as functional or 
nutritional status, symptom burden or depression, as well as some non-modifiable 
factors like age or gender. Together, these factors allow clinicians to discuss potential 
effects on quality of life when talking to those considering dialysis. 
As anticipated, the study of descriptions within the literature of the lived  experiences 
of older people was relevant to the discussions with prospective patients – these reports 
mentioned the importance not only of physical symptoms but also that of psychological 
factors when on treatment. Patients wanted more information and involvement. 
Positive relationships with family members and  with clinicians were valuable. 
I also explored what patients want to hear from clinicians during these discussions by 
including research on information needs of patients and their families. I reported that 
while patients desired information about their disease, its treatment and prognosis, they 
also had other considerations that relate to individual factors, the needs of family and 





6.2.2 Outcomes on dialysis: Quality of life - studies of symptoms, their 
recognition and influence on quality of life  
Two studies addressed the topic of symptoms in ESKD patients. First, we studied 
symptom burden in dialysis patients and confirmed that patients with end-stage kidney 
disease, including those on dialysis or those undergoing conservative, non-dialysis care, 
suffered a significant burden of symptoms. This study was also able to show 
correlations between increased symptoms and lower quality of life. A high burden of 
symptoms is a factor that could lead to a lower quality of life – a finding that was 
reflected in our own patient sample.  
The second component of this study was investigating how well these symptoms were 
identified by healthcare professionals. We were able to show that there was poor 
recognition of symptoms by nurses and doctors looking after dialysis patients. This 
inattention to symptoms is a potentially modifiable factor affecting outcomes on 
dialysis.  
A possible solution to this poor recognition of symptoms in routine clinical practice 
could be the introduction of patient-completed symptom surveys. The IPOS-Renal 
Symptom Survey is a commonly used tool in Australia, even though it has not 
previously undergone validation among the dialysis population. As part of this PhD 
research, we performed, to our knowledge, the world first validation of this survey in a 
dialysis population. We demonstrated the reliability and validity of this instrument in a 
cross-sectional study of dialysis patients. We can now suggest that this symptom survey 
can be reliably used in clinical practice and research to document symptoms in the 
dialysis population. 
The outcomes of this research have been translated into clinical practice – patients 




of routine clinical practice. It remains to be seen whether the enhanced detection of 
symptoms leads to better treatments and reduction of symptom burden. This is a 
potential area for future research. I am now an investigator on an international clinical  
trial, the Symptom monitoring WIth Feedback Trial (SWIFT), which is a registry-based 
cluster randomised trial, funded by NHMRC and Kidney Health Australia, coordinated 
through the NHMRC clinical trials centre, University of Sydney and the South 
Australian Health and Medical Research Institute. The trial is designed to investigate 
whether symptom monitoring with the IPOS-Renal survey, followed by feedback to 
treating clinicians, and  the provision of evidence-based guidelines for symptom 
management, will eventually impact quality of life and mortality. The trial protocol has 
been registered with the Australia- New Zealand Clinical Trials Registry ( registration 
number ACTRN12618001976279; details available online at https://anzctr.org.au)  (280). 
 
6.2.3 Outcomes on dialysis: The perspective of the elderly patient 
Our qualitative interviews to explore the experiences of elderly patients provided us a 
unique perspective to describe dialysis outcomes from the point of view of the older 
dialysis patient. While there were frequent considerations of ageing and mortality, 
older patients’ experience of the outcomes of dialysis were characterised by a pervasive 
sense of loss of various aspects of their pre-dialysis existence, coupled with a recurring 
sense of uncertainty about their day-to-day lives and the future. Patients identified the 
successful acceptance of the difficulties caused by dialysis and the availability of 
support from their clinicians and family/friends as key to improving their outcomes. 
When clinicians are sensitive to these concerns, there is potential for improvement of 






6.3 Actionable outcomes from research 
 
In the following sections, the insights obtained from the literature review and the 
research studies have been used to suggest (i) checklists for the shared decision-making 
process around choosing treatment options, and (ii) potential initiatives for improving 
the experience of patients already on treatment. These lists are intended for clinicians 
caring for older patients with end-stage kidney disease. 
6.3.1 Checklist for discussions with patients considering dialysis  
Discussions with older people considering dialysis are conducted in different settings. 
For most patients, renal impairment is slowly progressive, and there are usually several 
opportunities to discuss the pros and cons of the various treatment pathways. However, 
the patient who presents in extremis, needing urgent, life-saving treatment for kidney 
failure often ends up starting dialysis without an opportunity to have detailed 
discussions.  
The following checklist is suggested to be used during discussions with older people 
considering dialysis and their families. It combines the information obtained from the 
literature review as well as from the research conducted for this PhD. It lists potential 
items for discussion, suggests how they can be considered and provides comment on 
the practical value of each item. Discussions about treatment options are usually held 
over many sessions with input from different members on the team, including doctors, 
CKD educators and nurses, and/or social workers. Elements of the checklist can 





        
 
Elements of the 
checklist 
Tools Comment 
1 Risk of renal failure Scores to predict 
progression  
[e.g., Tangri, 2011 (24), 
Schroeder 2017(37)] 
Risk of progression determines 
immediate priorities for counselling and 
planning 
2 Risk of mortality Scores to predict mortality  
[e.g., Bansal, 2005(32), Wick 
2017 (36),Couchoud 2009 
(38)] 
Mortality risk can influence choice of 
treatment. Such information is valuable to 
patients for future planning and advance 
care directives. Helps to set realistic 






Influences choice of treatment. Helps to 
set realistic expectations. 




Reduces decisional conflict and regret 







Helps to set realistic expectations; helps 
reduce regret and encourages adaptation 
by making patients better prepared 




Older patients have trouble 
understanding and remembering; they 
often also have cognitive impairment. 




Validated tools exist. 
[e.g., Legare 2010(230)] 
Older patients learn differently; make 
their decisions with input from various 
others; are likely to change their minds; 
are likely to have competing interests 
around all major decisions; there exists a 
sense of “dialysis or death”; or that not 
having dialysis is “giving up”. 
Addressing decisional conflict also 
strengthens the validity of informed 
consent to dialysis or otherwise. 




Carers are an important source of support 
for older patients. Patients can undergo 
physical and cognitive worsening, 
increasing dependence on carers. 









surveys such as the 
validated IPOS-Renal 
[Raj, 2018, Davison, 
2006(192,213)] 
Symptoms have a central role in the 
experience of treatment; influence 
expectations from treatment and affect 




baseline status  
Scores such as the Clinical 
Frailty scale, geriatric 
nutritional index, cognitive 
scores (e.g., MoCA), Beck 
depression index and, 
Comprehensive geriatric 
assessments (247,281–283) 
(233), [See review by 
Kallenberg 2016 (284)] 
Identifies a subgroup at risk for adverse 
outcomes; enables targeted preventative 
management and support. Nutritional 
index screening may require dietician 
support; other indices can be 
administered by renal personnel.  
 
 
While conducting these discussions, it is worthwhile remembering that several elders 
may have cognitive deficits (or hearing impediments) that interfere with 
understanding. For checklists such as these to be effective, frequent discussions, with 
adequate repetition and opportunity for clarification are essential. Future research will 
focus on measuring the effectiveness of this checklists in leading to outcomes that are 
optimal and appropriately matched to patients’ expectations. Paying attention to the 
items on the checklist ought to identify those areas of the patient journey most salient 
for that individual patient. Finally, one must consider that these vulnerable older 
patients often have other illnesses too, and therefore there are many other, holistic and 
age-related considerations to planning long-term treatment. Specialist geriatric 
intervention - whether through hospital-based geriatricians, nurses or community-





6.3.2 Potential initiatives by clinical teams to improve the experience 
of treatment for older people 
1. Provide appropriate information. 
Our qualitative research findings and reports from the literature collectively suggest 
that older patients on dialysis often report inadequate provision of information. There 
are potentially several reasons for this, but an easily modifiable factor would be to 
ensure that information routinely provided and is tailored to the older adult. Clinicians 
should receive training/upskilling in communication skills. Some educational initiatives 
to improve communication skills (e.g., “Nephrotalk”) exist, these are likely to make a 
difference (285,286). Older adults will require more time and repetition of information 
before they gain sufficient understanding. When providing such information, it will be 
useful to address the issues most relevant in this population such as the limited 
prognosis, the inconstancy of symptom relief, the appearance of new symptoms with 
dialysis and the lifestyle changes required to continue dialysis, especially in-centre 
haemodialysis. 
2. Introduce patient- reported symptom surveys, such as the validated IPOS-
Renal survey. 
This enables the enquiry and capture of common symptoms, the grading of their 
severity and monitoring their response to treatment measures. As discussed earlier, 
there are potential benefits to improving symptom recognition. 
3. Focus on individual patient needs, with sensitivity to patients’ perceived 
sense of loss. 
Healthcare professionals ought to consider, in partnership with their patients and 
carers, the things most important to patients and discuss how they are (or may be) 




relevant because older patients often face several ‘losses’ of their previous life-roles as 
they adapt to life on dialysis, with a significant impact on how patients perceive their 
outcome on dialysis. This could help prevent regret and enable a healthy adaptation to 
a life on dialysis.  
4. Be attentive. 
Patients also expect appropriate attention from their physicians and nurses.  Attributes 
of interactions considered valuable by patients include treatment with dignity, humour, 
encouragement of patient participation and the perception that the patient is being 
treated “as a person”. Clinicians play a crucial role in these patients’ lives, and the 
support provided by clinicians is vital to achieving good outcomes. 
5. Adopt a proactive approach to addressing causes of uncertainty for 
patients. 
Particularly for patients on haemodialysis units, there is significant uncertainty around 
the outcomes of each dialysis session (for instance, the pain from needling of 
arteriovenous fistulae or the ill- effects of fluid removal). Dialysis units can improve 
outcomes by ensuring appropriate technical skills of dialysis nurses and technicians and 
seeking patient feedback. Adverse effects of dialysis, particularly post-dialysis fatigue, 
should also be monitored closely. Clinicians should be agile in adjusting dialysis 
prescriptions, particularly fluid removal. 
6. Ensure a comfortable environment for dialysis. 
Patients spend several hours on dialysis. Within dialysis facilities, efforts must be made 
to ensure the physical comfort of patients. Uncomfortable chairs and poor heating were 
common complaints in our dialysis population. Such concerns with the dialysis 




requires attention since it has an immediate effect on how patients perceive their 
experience of dialysis. 
7. Be mindful of the relationships that long-term patients develop. 
Repeated visits to the dialysis units allow patients to develop relationships with nurses, 
other patients and their carers/families. These ties are important not only as a source of 
social enjoyment but also as a source of information and shared understanding. 
Similarly, older adults reported grief following the death of other patients well-known 
to them. Clinicians and unit administrators ought to acknowledge these close ties 
between patients, foster these relationships where possible and provide support and 
counselling to address grief when patients die.  
8. Pay attention to management of carers’ needs. 
Support from the people around the patient makes an important contribution to a good 
outcome on dialysis. Progressive physical and cognitive deterioration are common in 
older age groups, forcing patients to assume sick-roles and become progressively more 
dependent on their careers, family or friends. Management of the patients’ needs can 
only be complete if sufficient attention is paid to the carers who share their burden. 
Their support and information needs ought to be considered, and where appropriate, 
carers ought to be involved in the planning and discussions of treatment. 
 
6.4 Contributions to scientific knowledge 
 
The scoping review is the first such review of the information specifically applicable to 
the older patient with ESKD. This review is a useful summary of the literature between 
2000 - 2018. For healthcare professionals counselling older patients, I believe this will be 




review also contains up-to-date collections of validated prognostic indices and 
comparisons between conservative management and renal replacement therapy. 
We showed a significant symptom burden in Australian patients with ESKD - both for 
those on dialysis and those on conservative management. We demonstrated that 
symptom burden among dialysis patients correlated with quality of life scores. 
We demonstrated that during routine clinical care, doctors and nurses fail to identify 
the symptom burden in dialysis patients accurately when compared to patient-
completed symptom surveys. Studies such as this also set the stage for future research 
looking into whether patient-led reporting of symptoms followed by targeted 
interventions will eventually lead to reduced symptom burden.   
We demonstrated satisfactory reliability and validity of the IPOS-Renal symptom 
survey. The IPOS-Renal is commonly used but was not previously validated for use in 
this population. Our validation study paves the way for the greater use of this symptom 
survey in clinical practice and research. 
Our qualitative research project contributed a unique insight into older patients’ 
perceptions of outcomes on dialysis. We highlighted the experiences of loss (across 
multiple domains) and the pervasive uncertainty affecting patients’ thoughts about 
their lives. We also reported on how patients’ acceptance of their illness and adaptation 
to the demands of life on dialysis, coupled with support from carers, nurses and doctors 
were considered to have positive effects on outcome. 
We created a checklist to help the conversations in the shared decision-making process  
by combining information from the literature and from our own research projects. 
We also suggested a list of clinician initiatives to improve outcomes for older patients 





6.5 The future: Potential developments and research 
opportunities 
 
As medical technology advances, it is possible that dialysis therapies can improve as 
well. A method of replacing renal function that does not have the intrusive nature of 
present-day dialysis and does not worsen cardiovascular risk may significantly change 
the discussion around outcomes. Better methods of providing home-based dialysis, 
with minimal disruption of everyday life, could potentially reduce or abolish the 
burden of treatment. On the other hand, developments in transplantation could make it 
a widely available option for the older patient, relegating dialysis to the role of a 
temporary treatment or a “bridge” to transplantation. 
Newer fields of biomedical research – such as metabolomics or proteomics – have the 
potential to help us understand the causes of disabling symptoms, give us new methods 
of prognostication using novel biomarkers or even suggest targeted, individualised 
treatment for the new mechanisms of illness they could uncover. Advances in analytic 
technology, computing power and artificial intelligence have the potential to 
dramatically increase the amount of information we have about our patients – such 
innovations could have a significant influence and change the existing paradigms of 
care. 
As we wait for these developments however, we must continue efforts to improve 
outcomes for ESKD patients. Targeted management of patient reported symptoms 
might be an easily achievable method of improving quality of life; however, more 
research is needed. Specifically, interventions based on regular reviewing of patient-




related quality of life. As discussed above, the outcomes of the proposed SWIFT trial 
will be particularly relevant to this area of research. 
Similarly, it remains to be seen if detailed discussions, repeated often, providing 
information tailored to individual preferences and expectations will improve 
satisfaction with treatment and, by association, treatment outcomes. The influence of 
illness perception and personality type in the older patient also warrants further 
exploration. Interventions such as cognitive behavioural therapy for dialysis patients 
also are deserving of investigation, since they have the potential to alter several 
psychological factors that could influence outcomes. Finally, more research is needed 
into identifying the information needs of patients and families. Research into prognosis 
and outcomes will only be practically useful if information can be appropriately 
conveyed to patients. We continue to need research into the best ways of delivering 






6.7  Conclusion 
 
Good outcomes are not quantified merely by the number of days survived or 
hospitalisations avoided – rather, a good outcome is one that meets the expectations of 
the patient and allows patients to continue their lives with the least possible disruption. 
The results of my research show that clinicians can help their patients by providing 
realistic information about all the possible consequences of the different treatment 
options. Patients need to be well-informed; they want information about prognosis as 
well as about quality of life with treatment. They desire to be treated with respect, and 
as valuable individuals who have a say and sense of control in their health care. While 
several adverse consequences of renal disease and dialysis treatment are inevitable, 
outcomes could potentially be improved when well-informed patients undertake 
treatment with realistic expectations, when proactive efforts are made to improve their 
quality of life and preserve functional status, and when patients are supported by a 
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HD, n= 374; 
Age: 68 
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value less than 
0.001) - may 
have limited 
clinical utility in 
settings outside 
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Table A-15: Example of Search Terms used in databases: Pubmed 
Description Search terms used 
Renal failure / Dialysis / Supportive care (((("Renal Insufficiency, Chronic"[Mesh]) OR "Kidney 
Failure, Chronic"[Mesh]) OR "Renal Dialysis"[Majr]) OR 
"Kidneys, Artificial"[Mesh]) OR (((((((supportive[Text 
Word] OR conservative[Text Word])) AND chronic renal 
insufficiency[MeSH Terms])) OR ((((supportive[Text Word] 
OR conservative[Text Word])) AND renal dialysis[MeSH 
Terms]))) OR (((supportive[Text Word] OR 
conservative[Text Word])) AND chronic kidney 
failure[MeSH Terms]))))) 
Older subjects ((((((elderly[Title/Abstract] OR elder[Title/Abstract] OR 
old[Title/Abstract] OR older[Title/Abstract])) OR 
aged[MeSH Terms]) OR (aged, 80 and over[MeSH 
Terms]))) 
Prognosis (((Survival[Text Word] OR “survival rate”[Text Word] OR 
“survival analysis”[Text Word] OR Prognosis[Text Word] 
OR “proportional hazards model”[Text Word] OR “Kaplan-
Meier estimate”OR “time factors”[Text Word] OR 
“treatment outcome”[Text Word]))) 
Quality of life (((((((((Activities of Daily Living[MeSH Terms]) OR Health 
Status Indicators[MeSH Terms]) OR Adaptation, 
Psychological[MeSH Terms]) OR Health Status[MeSH 
Terms]) OR Patient Satisfaction / statistics & numerical 
data[MeSH Terms]) OR quality of life[MeSH Terms]) OR 
Severity of Illness Index[MeSH Terms]) OR (surveys and 
questionnaires[MeSH Terms])) OR Psychiatric Status 
Rating Scales[MeSH Terms]) OR principal component 
analysis[MeSH Terms] 
Lived experience ((((((((((((((((((((((Adaptation, psychological[MeSH Terms]) 
OR attitude to health[MeSH Terms]) OR advance care 
planning[MeSH Terms]) OR (Behavior and Behavior 
Mechanisms[MeSH Terms])) OR decision-making[MeSH 
Terms]) OR Life style[MeSH Terms]) OR health knowledge, 
attitudes, practice[MeSH Terms]) OR Delivery of Health 
Care[MeSH Terms]) OR role[MeSH Terms]) OR needs 
assessment[MeSH Terms]) OR Patient Education as 
Topic[MeSH Terms]) OR Attitude to Health[MeSH Terms]) 
OR Patient satisfaction[MeSH Terms]) OR patient 
preference 
[MeSH Terms]) OR Health Care Evaluation 
Mechanisms[MeSH Terms]) OR (religion and 
psychology[MeSH Terms])) OR (surveys and 
questionnaires[MeSH Terms])) OR Sociological 




uncertainty[MeSH Terms]) OR "lived 
experience"[Title/Abstract])) 
Information needs ((("information needs"[Title/Abstract]) OR 
information[Title/Abstract])) OR 
(((((((((((((((((((((Attitude[MeSH Terms]) OR 
"Caregivers/psychology"[Mesh]) OR "Algorithms"[Majr]) 
OR "decision making"[MeSH Terms]) OR ("Chronic 
Disease/psychology"[Mesh] OR "Chronic 
Disease/therapy"[Mesh])) OR Communication[MeSH 
Terms]) OR Comprehension[MeSH Terms]) OR Cost of 
Illness[MeSH Terms]) OR Computers, Handheld[MeSH 
Terms]) OR Decision Support Techniques[MeSH Terms]) 
OR "Decision Support Systems, 
Clinical/instrumentation"[Mesh]) OR Mobile 
Applications[MeSH Terms]) OR Needs Assessment[MeSH 
Terms]) OR Patient Education as Topic[MeSH Terms]) OR 
Patient Satisfaction[MeSH Terms]) OR (Surveys and 
Questionnaires[MeSH Terms])) OR "Withholding 
Treatment"[Majr]) OR Health Behavior[MeSH Terms]) OR 
Health Literacy[MeSH Terms]) OR life style[MeSH Terms]) 
OR transportation of patients[MeSH Terms]) 
Filters Publication date from 2000/01/01 to 2018/08/31; Humans; 
English; Adult: 19+ years 
Example of combinations of search terms for 
articles on prognosis 
(((((((("Renal Insufficiency, Chronic"[Mesh]) OR "Kidney 
Failure, Chronic"[Mesh]) OR "Renal Dialysis"[Majr]) OR 
"Kidneys, Artificial"[Mesh]) OR (((((((supportive[Text 
Word] OR conservative[Text Word])) AND chronic renal 
insufficiency[MeSH Terms])) OR ((((supportive[Text Word] 
OR conservative[Text Word])) AND renal dialysis[MeSH 
Terms]))) OR (((supportive[Text Word] OR 
conservative[Text Word])) AND chronic kidney 
failure[MeSH Terms]))))))) AND 
(((((((elderly[Title/Abstract] OR elder[Title/Abstract] OR 
old[Title/Abstract] OR older[Title/Abstract])) OR 
aged[MeSH Terms]) OR (aged, 80 and over[MeSH 
Terms])))))) AND ((((Survival[Text Word] OR “survival 
rate”[Text Word] OR “survival analysis”[Text Word] OR 
Prognosis[Text Word] OR “proportional hazards 
model”[Text Word] OR “Kaplan-Meier estimate”OR “time 
factors”[Text Word] OR “treatment outcome”[Text 
Word]))))  
Filters: Publication date from 2000/01/01 to 2018/08/31; 
Humans; English; Adult: 19+ years 
 
 
Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for 
Scoping Reviews (PRISMA-ScR) Checklist 
SECTION ITEM PRISMA-ScR CHECKLIST ITEM REPORTED ON PAGE # 
TITLE 




Provide a structured summary that includes (as 
applicable): background, objectives, eligibility criteria, 
sources of evidence, charting methods, results, and 




Describe the rationale for the review in the context of 
what is already known. Explain why the review 
questions/objectives lend themselves to a scoping 
review approach. 
Objectives 4 
Provide an explicit statement of the questions and 
objectives being addressed with reference to their key 
elements (e.g., population or participants, concepts, and 
context) or other relevant key elements used to 




Indicate whether a review protocol exists; state if and 
where it can be accessed (e.g., a Web address); and if 
available, provide registration information, including the 
registration number. 
Eligibility criteria 6 
Specify characteristics of the sources of evidence used 
as eligibility criteria (e.g., years considered, language, 
and publication status), and provide a rationale. 
Information 
sources* 7 
Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with 
authors to identify additional sources), as well as the 
date the most recent search was executed. 
Search 8 
Present the full electronic search strategy for at least 1 





9 State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. 
Data charting 
process‡ 10 
Describe the methods of charting data from the included 
sources of evidence (e.g., calibrated forms or forms that 
have been tested by the team before their use, and 
whether data charting was done independently or in 
duplicate) and any processes for obtaining and 
confirming data from investigators. 
Data items 11 List and define all variables for which data were sought and any assumptions and simplifications made. 




If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe the 
methods used and how this information was used in any 
data synthesis (if appropriate). 




















Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the review, with 





15 For each source of evidence, present characteristics for which data were charted and provide the citations. 
Critical appraisal 
within sources of 
evidence 





For each included source of evidence, present the 
relevant data that were charted that relate to the review 
questions and objectives. 




Summarize the main results (including an overview of 
concepts, themes, and types of evidence available), link 
to the review questions and objectives, and consider the 
relevance to key groups. 
Limitations 20 Discuss the limitations of the scoping review process. 
Conclusions 21 
Provide a general interpretation of the results with 
respect to the review questions and objectives, as well 
as potential implications and/or next steps. 
FUNDING 
Funding 22 
Describe sources of funding for the included sources of 
evidence, as well as sources of funding for the scoping 
review. Describe the role of the funders of the scoping 
review. 
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses 
extension for Scoping Reviews. 
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media
platforms, and Web sites.
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g.,
quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping
review as opposed to only studies. This is not to be confused with information sources (see first footnote).
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the
process of data extraction in a scoping review as data charting.
§ The process of systematically examining research evidence to assess its validity, results, and relevance before
using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable
to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used
in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).
From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-
ScR): Checklist and Explanation. Ann Intern Med. ;169:467–473. doi: 10.7326/M18-0850
















Table A-16: Summary of Studies Included in Scoping Review 




















study;  Patients 
> 65; Follow 
up:  66 months 






HD patients > 
65; n= 89; 
Age:73.5 ± 6.2; 
Depression in 41%;  
Those > 65: No 
statistically significant 
effect of depression on  
mortality; unlike 
























dialysis modality did 
not affect the 
association between 
frailty and mortality. 
In an adjusted Cox 
survival analysis, each 
1-point increase in the 
CFS score was 
associated with a 
relative mortality HR 
of 1.22 (95% CI, 1.04 to 
1.43;P =0.02) 












Mobility Single centre; 
patients 
hospitalised 
for RRT start; 
divided into 3 




n= 202; Age: 
80.4±4.3 
Those with preserved 
mobility in initial 

















HD patients  
n= 77; Age: > 
65 
Survival: No 
depression:  79.9%, 
63.5% and 52.9% at 1, 
2 and 3 years   with 
depression: 72.2%, 
47.1% and 38.5%  
Median survival with 
depression 23 months, 














































two  different 
studies;  
n=  8963 (5888 
from a 
cardiovascular 











associations with five 
your mortality: older 
age, men, white race, 
lower EGFR, higher 
UA CR, diabetes, 
tobacco use and 
history of heart failure 
and stroke. DC: C stat 
0.72, HL 0.5; VC: C 
stat 0.69; HL 0.9 














year groups of  
age up to more 

















patients  from 






increases the risks of 
mortality. 
-Overall survival: The 
mean survival was 
3.11 ± 0.01 years for 
70-75 years of age, 
2.51 ± 0.01  for 76 - 80; 
2.07 ± 0.01  for  81 - 85; 
and 1.59 ± 0.01  for > 
85 years at the time of 
initiation of dialysis. 
Mortality at one year 
was 39.4% (2.55 years 
mean survival on  
haemodialysis, 2.95 
years on PD.) 
For institutionalised 
patients, mean 
survival was 1.71, 
1.44, 1.25, and 1.04 
years in the various 
age groups, lower 
than the non-
institutionalised; 














Population Main Findings - 
Comment 
Forzley, 













HD, n= 374; 
Age: 68 
c Stat: 0.72; but poor 
calibration slope 0.57 
(0.3-0.83; thus 
crossing 0.5; P value 
less than 0.001) - may 
have limited clinical 
utility in settings 














up 16 months 
Survey based: 
SGA; MSAS-

















































clinic ( n= 72). 
 
Age, albumin, GFR - 
had the greatest 
impact on survival 
More Symptoms in  
CM; 57% had 
improved symptoms 
over 12 months 
No  significant QOL 
differences in the 2  
groups ( except for 
lower PCS in  CM at 
start) 
58% had stable QOL 










GFR of 10.8; 
Hospitalisati















clinic; n= 202 
(173 on RRT, 
29 on CM); 
Age: >70 
Survival: RRT vs CM: 
37.84  vs 13. 9 months 
RRT-more 
hospitalisation, more 
hospital days per by 
patient days survived 
CM-more likely to die 
at home or in a 
hospice  
Chandna, 


















stage V seen 
over a period 
of 18 years In 

















Population Main Findings - 
Comment 
n of CM 
and RRT 
a Canadian 
Centre. n= 844 
(CM 155, RRT 
689); Ages: 
CM 77.5± 7.6; 
RRT 58.5±15; 
less in CM (29.4 
Vs.36.8 months)  
Survival, severe 
comorbidity: 
less in CM (20.4 
Vs.25.8 months)  
(non-significant 
difference in survival 
with severe 
comorbidity). In those 
> 75 with severe 
comorbidity, no 
significant survival 


























10 and 15, 
cohort chosen 
between 1995 
and 2010; n= 
250; Age: 
80.9±4 
Rate of decline of 
GFR: -more rapid in 
those choosing 
dialysis (0.45 ML per 
month) vs CM (0.21 
ML); marker of 
mortality in CM 
Patients with high 
comorbidity on  RRT: 
nonsignificant 
survival advantage of 
five months;  
CM cohort: similar 
age, more 
comorbidities, but 
slower rate of decline 
in eGFR. 
Survival: less in CM 
(23.1 vs 38.2 months) 
Survival with high 
comorbidity: less in 
CM (20.3 vs 28.4 
months) 
CM choice was more 
likely in age> 75, 
females, high 
comorbidity or low 








































Overall survival rates 
were 80% and 65% 
after one and two 
years of follow-up; 
Univariate: age, 
albumin, pre-albumin, 



















































Age was the strongest 









diabetes ESRD; being 
employed; presence of 
AVF 
Best survival with the 
score less than -4 
c-statistic IC: 0.71 
(0.70-0.71) VC 1: 0.71; 
VC 2: 0.60 (0.57-0.63: 
poor discrimination) 
Cherukuri, 















HD; n= 94; 
Age: 63±15.6; 




























44,109; Age: > 
67 
23.3% died in six 
months. 
Older patients had 



































nursing home state, 
for mobility, low BMI 
or malnutrition. 
C statistics declined 
with older age; 
therefore, indexes are 
probably not useful. 
None of the indexes 
















less than 70 or 
more than 70; 
Follow up: 12 
months 
UREA5 




see chart in 
main text [ 
URate, EF, 
Age,   
Arteriopat
hy-PVD or 














6.7%; further 10.5% 
died between 90 days 
to one year 
first year mortality-
17.2%; older, more 
comorbidities, poor 
LVEF 
parameters:   
Score greater than five 
-  46% first-year 
mortality; C statistic 
0.74 for first-year 
mortality; C statistic 
















by using the 
stepwise 
selection based 





















n= 1028;  
Age: 61 ± 17 
Score: AUC: 0.87 for 
six months; 0.77 
across all time 
aHR: Surprise 
question 2.71; one-
unit albumin increase 
0.27; age: for a 10-year 
increase 1.36; 
therefore, adversely 













































1998 to 2002;  
n=  396 
Age: 71.6; 
more than one 
third older 
than 75 
Risk of surviving to 
require dialysis fell 
with increasing age 
(HR 0.44; 0.23-0.84) 
for those over 74 vs 
those less than 65 due 






































age: female  
64, male 59 
Age affected specific 
mortality rate: < 65 : 
16.8%, and > 65: 50.5%  
According to the age 
groups the mortality 
rate: 
65 – 74 years : 45.1%;  
75 – 84 years 55.0%,  














allowed us to 
select risk 





















(n= 2500) and 
validation ( n= 
1642) cohorts 
n= 3142 (in 
total) 
Age:>75 
Nine  risk  factors  
were  selected  and  
points  assigned for 
the score were as 
follows: body mass 
index < 18.5 kg/m  (2 
points), diabetes (1), 
congestive heart 
failure stage III to IV  
2  (2),  peripheral  
vascular  disease  
stage  III  to  IV  (2),  
dysrhythmia  (1),  
active  malignancy  
(1)severe  behavioural  
disorder  (2),  total  
dependency for 
transfers (3) and 
unplanned dialysis 
(2). 
C statistic: IC - n.a., 













Population Main Findings - 
Comment 
value: 0.93; good 
















age, sex and 
primary 
kidney disease  
Time 
between 
first visit to 
nephrolog












classified as : 
Those late (<3 
months), early 
(3 –12 months) 
or very early ( 
≥ 12 months) 







compared to  
<70 
Those ≥ 70 years had 
higher mortality rates 
compared to  <70 
years [HR 2.6 (2.0, 
3.5)].  
Delayed referral:  1-
year mortality – AHR 
3.2 - 5.4 compared to 
early referrals in  < 70  
de Jonge,  

















(QOL)   
Score 
consisting of: 



















Age: > 18; 40% 
at baseline 
and 32% at 1 
year(survivors
) were > 65.  






quality of life". 
Regression models 
explained 32% of the 
variance in PCS and 
40% in MCS. 
Risk factor for low 
MCS: INTERMED 
score 
Risk factor for low 
PCS: Diabetes, Age>65 
The risk score 
correlated with:  low 






























one year ago 
how would 

















Elders in the 
DOS 65+ 




35% reported worse 
health or had died at 
12 months.  
Reduced risk for 
worse health status : 
Pacific ethnicity(RR 
0.83) , greater bother 
on the Kidney 
Symptom Score and 
dialyzing at home 
with either home 
hemodialysis  (0.55) 
or peritoneal dialysis  
(0.86) 
Increased risk : social 
dissatisfaction  (1.66) 
lower sense of 
community (1.7) , 
comorbid conditions 
(1.7)  EQ-5D 
anxiety/depression 
(1.6); poor/fair overall 
general health rating 
(1.6) , and longer time 






















all patients on 
haemodialysis 
n=  715.(total: 
2153; >65: 715)  






Among targets, only 
PTH had an effect on 
mortality in the older. 
Older people less 
likely to achieve 
targets for Hb,  not for 
others. 
gender, dialysis 

































stage 4 and 
below seen in 
an Outpatient 
clinic;  
n=  2685 
(development-
1866, 
The final model 
included index eGFR, 
age, CHF, average of 
last five clinic systolic 
BP measurements, 
most recent potassium 
and albumin, and 
interactions between 
age and eGFR and 





















c-stat - 0.854, 










































ability for the 
predictive model of 
elderly people likely 
to have survival >70% 
at 3 years (and 
therefore are good 
transplant 
candidates); 
C - Statistic 
IC: 0.71 (0.69-0.71);  
VC: 0.71 (0.70-0.72); 

































four and five. 
n= 314 
Age:77 ( range 
74 – 81) 
Survival Advantage 
not significant in 
those over 80. 






study duration): less 
with CM (39 vs 65 
months) 
Survival from 
eGFR<15: less with 
CM (21 vs 46 months) 
Survival in those > 75: 
less with CM 
(p=0.003) 
Survival in those > 80: 
no difference between 
CM vs RRT 
 
Survival in those with 
IHD - no difference 
between CM vs RRT 
Survival with high 
comorbidity CCI 

















































patient survival from 
the time of first 
known CKD 5 was 21 
months. 
Patients known to a 
nephrologist survived 
longer (32 vs 15 
months) 
S. albumin > 35 – 












cohort study,  


























Age:76.2 ± 7.5 
Adjusted mean fall 
rate: 1.7 falls per 
patient-year;  
Patients with falls:  
more likely to be men, 
older , have higher 
comorbidity,  be  
recently initiated onto 
dialysis, more likely 
to have  fall in the 
previous 1 year, 
history of fractures  or 
visual impairment,  
more dependent at 
baseline. 
a HR 1.62 (1.29-2.02) 











































Sensitivity 70 to 80%; 
specificity 66 to 56% 
for one year and two-
year mortality 
respectively;  
Validated in the 
DOPPS cohort with 
similar results 




























obtained at < 3 
months of 
initiation in 






























2002 to 2005. 
n= 79 
Age:79 (range 
77 – 81) 
Overall mortality 
65%; one- and two-
year survival rate is 
76.9 and 59.3 percent. 
Adjusted HR: five-
year increments of age 
(1.24) comorbid 
conditions >3: 1.89, 
being underweight 
1.78, PD vs HD 1.26, 
later referral 1.19, 
unprepared access at 















1-year survival for 
elderly patients 
treated with:  
undifferentiated 
dialysis  — 73.0% 
(66.3–79.7%),  
haemodialysis: 78.4% 
(75.2– 81.6)  
peritoneal dialysis: 
77.9%  (73.8–81.9)   
Supportive care : 
















Population Main Findings - 
Comment 
Broadly similar 1-year 
survival in elderly 
ESKD patients, it does 
not allow a confident  
estimate of the 
relative survival 
benefits of dialysis or 


















n=  81 
Age: 67 (range 
60 — 73) 
Lower thigh muscle 





hemodialysis patients.  
Each 0 .1 cm² per KG 
increase in  muscle 
mass :  22% lower risk 
of all-cause mortality 














































n= 1040 (IC: 
593; VC: 447) 
Age:>65 
c-statistic 
IC: 0.79 (0.74-0.84)  

























Follow up:  Up 

















and 2006 July 
n= 112 
Age:81.3 ± 4.2 
More dependence in 
the older age groups 
(28 to 30%). 
mean survival: 19.6 
(13.9) months, median 
18 months. 
Survival at 1, 2, and 3 
years was 64.9%, 
40.6% and 14.9% 
respectively. 
aHR - AG GIR group 


































and 2010;  
n= 170 
Age:83 (range 
81 – 85) 
55% of patients died. 
Median survival 26 
months; 1, 2- and 3-
year survival rates: 74, 
52 and 41%  
aHR for mortality: age 
1.10, being seen by 
nephrologist 0.48 
Hatakeya










Follow up:  
"Until death or 





















Age: 84.2 ± 3.1 
Median survival time 
was 2.6 years (Lowest 
in those over 90: 0.9 
years) 
Mean life shortening: 
5.3 years ≥ 80; 9.4 
years 70 – 79; 14.6 
years 60 – 70 






points: ECOG greater 
than one; 





















over 3 to 4 








Follow up: 3.8 
years 





































Age: 66.6 (8.5) 
and those who 
died; 61.9 (8.1) 
in survivors 
Age was the strongest 
risk factor. 
Addition of other 
factors did not make 
major changes. 
C stat - 0.72 (0.7-0.75) ; 
HL good 
No comparing risks 
mentioned 
no external validation. 
Selected population is 













Risk of dialysis 






















 n= 492 (280 
were > 65) 
Age:65 ± 14 
U-shaped relationship 
between BMI and 
cumulative outcome 
aHR for combined 
endpoint in those > 65 
: low BMI - 1.73, high 








































































































aged >70 and 












eGFR was <20, 
<15 and <12. 
n= 441 (CM 
172, RRT 269). 
Age: CM 
82±5.6; RRT 
77±5   
 
(see table in main text) 
For survival, RRT 
better than CM except 
>80 or WHO 
performance score >3 
Comorbidity lowered 
the advantage of RRT 
but did not abolish 
this. 
In those >80, no 
survival advantage 
for RRT over CM. 
In those > 70, 
increasing 




advantage for RRT 
over CM. 
Those accessing a 
conservative 
management pathway 
had greater access to 
palliative care services 
and were less likely to 
be admitted to or die 




























three based on 
Barthell index; 
Physical functions 
scores at beginning of 
dialysis correlated 
with better survival, 













Population Main Findings - 
Comment 
into H, M and 


































Age: 83 (81 - 
86) 
Median survival 46 . 5 
months (0 – 107). 
1- and 5-year survival 
78.5 and 38.3% 
Reduced with low 
































DC; 2009 to 





Age: 60 ± 15 
Overall, six-month 
mortality was 6.1 %. 
C-statistic (HL test p 
value) 
IC: 0.751 (0.005-poor 
calibration) 
VC 1: 0.755 (0.58-
acceptable) 


















Age Single center; 
All patients 
who continue 
dialysis for > 1 
month; Period 
between 2006 





survival 60.9; elderly 
survival 25.6 months; 
younger survival 17.6 
months. 
Elderly patients: one-
year survival 68.5%; 















































1989 to 2000. 
n= 146 
Age: 83.2 ± 2.9 
37 patients 'not 
proposed for dialysis'; 
104 were; 6 of this 
refused 
Median survival was 
28.9 months in those 
on dialysis; 8.9 
months with CM 
12- and 24-month 
survival rates : 
dialysis: 73.6 and 60% 
and CM: 29 and 15% 
On dialysis:  
high female mortality 
during the first 2 
years but lower 
mortality thereafter; 
short-term  impact of 
later referral; 
persistent difference 
in survival among 
patients with lower 
Karnofsky. 
Negative impact of 
peripheral vascular 
disease was seen only 
after 18 months 
aHR up to 1 year and 
> 1 year: Late referral 
(2.28 and 0.68); 
functional 
dependence (2.34 and 
1); per BMI (0.83 and 
1); peripheral vascular 






































n= 148 were 
elderly 
Age: 71.3 ± 4.3 
The 1, 2, 3- and 5-year 
patient survival rates 
were 79%, 67%, 56%, 




for those over 65. 
Technique Survival 
did not differ. 
Age 1.09, diabetes 


















Follow up: 37.8 











within 90 days 
from start of 
dialysis;  








aHR 1.258 adjusted 















up 4.1 (ESRD) 
























Risk of ESRD 










and East Kent, 
UK; 
n= 382; Age: 
61.5 ± 14.3 
EGFR: 21.8 ± 
10.7 
Follow up: 4.1 
years and  
n= 213; Age: 
65.1 ± 13.5 
c-statistic: 
Prediction of ESRD: 
IC: 0.873 (0.836-0.909) 
VC: 0.91 (0.87-0.96) 
 
Prediction of death: 
IC: 0.82 (0.774-0.866) 













Population Main Findings - 
Comment 
EGFR: 21.6 ± 
13.6 (Kent) 
Kallenberg
,  2016 
(284) 



















In 34 of 35 (97%) 
associations reported 
in the 30 included 
studies, functional or 
cognitive impairment 
and frailty were 
significantly 
associated with a 















years;  median 
1.56 years 






















Age : all > 65; 
stratified into 
groups by age 
eGFR: n.a  
52% of 









c-stat:  0.908 (0.897-
0.919); good 



































































Age: 62 ± 16 
c-statistic: IC: 0.73; HL 
test p value 0.65 
VC: confirmed higher 
risk of death in 






























and 2013   
n= 122 
Age: 87 
aHR 90-day mortality: 
suboptimal start 3.98 ; 
hypertension 0.31; log 
CRP 1.12  
aHR 1-year mortality 
suboptimal start 3.19; 
hypertension 0.37; 



































Age:84.3 ± 3.4 
 
Increasing numbers of 
older patients 
receiving dialysis in 
2003 than 1996. 
1-year mortality rate 
is approximately 50%, 
this is not changed. 
Older age, non-
ambulatory stages 
and more comorbid 
conditions were 
strongly associated 
with an increased risk 
for death. 
aHR: Non-ambulatory 
1.54 ,albumin < 35 -
1.28;  being 
underweight  -1.2; 
congestive heart 
failure 1.21;  






















Age: 68.4 ± 5.7 
Relative risk for 
mortality: 0.4 for black 




































Median survival from 
initiation of dialysis 
was 29 months;  
Adjusted HR 4.66 
(1.79-12.16) 
Diabetes per se was 










































71% one-year Overall 
survival; 54% in those 
over 80; 71% in  75-80;  
88% in 70-74. 
Age, gender, 
modality, late referral, 
and comorbidities 
affected survival (0.56 
to 2.97). 
Despite being on HD, 
MCS similar to 
general population; 










Follow up: 37.8 




















Age: 71.9 ± 5.4 




disease and dementia 
carried higher aHR. 
Survival significantly 
higher in HD in this 
study (but no 
description of 
differences in the 
groups; no discussion 
of confounding 
factors; 81% of 
















Follow up: 17.7 
months 
CGA Single centre;  
elderly 




aHR (for composite 
outcome, not just 
mortality) 23.58 for 
frailty; other 
predictors include 
age, gender, diabetes, 

















































was 87%, three-year 
survival 52% and 10-
year survival 9%. 
Those with <3 months 
pre-HD care:  died 
within 7 years. 
With >3 months pre-
HD care: 5-year 
survival – 37% and 
10-year – 18%. 
Significant difference 
on survival ( if pre-
dialysis care was 







































and mortality is 
similar across all age 





only in elderly. 
aHR Low: 1.13 – 1.37; 
































75 years of 
age between 
96 and 2000; 
one group 
over 75 (67 
patients) and 
Older patients were: 
referred late, HD 
rather than PD, on 
catheters, no 
transplants, less likely 
to change modality. 
One-year survival: 
80% vs 93% 































OR for mortality : > 75 
years old: 2.66, more 
than 30 days in 
hospital: 34.85; weight 










Follow up: 32.7 








Patients with falls are 





aHR  1.63 (1.02-
2.28)(After falls due to 






























CCI (3 points) 
and mortality 
compared 
predictors of survival: 
Age,  higher CCI 
values 
Increased costs and 
mortality rates  in the 
oldest patients and in 
those with high CCI 
scores. 
Increasing age  aHR: 
1.37 to 2.27. Increasing 




































Increasing levels of 
uraemic toxins may 
have an effect on 
mortality 
aHR: free p-cresyl 
sulfate 1.66; total p-
cresyl sulfate 1.34; 



























Poor survival: lack of 
residual urine 
Higher ANP:  lowered 













































who started  
HD from 1997  
– 2003 and 
had a follow 
up of at least 
one year 
n= 5738 
Age:  64.6 ± 
14.4 
Overall mortality was 
16.5%. 
Main effect variables: 







chronic liver disease 
and malnutrition  













Follow up: 24 ± 














patients on  
HD 
n= 143 
Age: 60.6 ± 
13.4 
 aHR 3.46 (1.22-9.77) 
for disability; C 
statistic of 0.74 for the 
model 
Comorbidities, age 
and gender, disability 











Follow up:  





s vs non-) 
ANZDATA 
Registry data; 




were younger (69 vs 
74); mortality rate : 
23.9 per 100 pt. 
years(vs 21.2). 
Median survival time 
33.8 vs 41.1 
1, 3, 5, 7 and 9 
survival rates were 
lower for indigenous 
patients. 
On multivariate 
analysis, race, gender, 
age, obesity smoking, 
comorbidities and late 
referral were 
significant 


























cohort study;  
Follow up: Up 




















Age: 72 ± 11 
23% of the cohort had 
depression 
minor increase in 
mortality if 
depression is defined 




































Age: 77.5 ± 8.9 
Majority men; Low 
incidence of dementia 
overall 















Follow up:  1 
















No major differences 
blacks vs whites 
Blacks and other races 
: lower risk of acute 
coronary events, 
cardiovascular death, 
and all cause deaths 
Nutritional status 
significant predictor 
Adjusted survival of 
whites was worse 
than that of Blacks 


























Follow up: 5 
years 






divided into : 
≥ 75; 65 to 74, 
<65 
n= 58 
Age: > 75  
Survival: 1-year : 53.5, 
72.6, 90.6%  
               5-year: 2.4% 
18.8% and 61.4% at 
five years 
Those > 75:  spend 
20% of their time in 




on RRT.  
Withdrawal 38%, 
cardiovascular deaths 











Follow up:  540 
to 588 days 
Survival 
estimated from 
eGFR ≤15 to 

















made;   
 
CM patients were 
older (83) compared 
to RRT (79.6) 
Median time to death: 
588 for dialysis 
patients and 540 for 
CM. 
No survival 
advantage from RRT 
when comorbidity 
index was high 
(greater than two). 
Modality choice, age 








survival (IHD more 
than comorbidity). 
Choosing dialysis-2.9-
fold better survival; 
IHD reduced survival 
































into above and 
















included.   
n= 735 (314 
were aged 








lower platelet, higher 
β2-microglobulin, 




were independent risk 
factors. 
Strongest in 
multivariate model - 
diabetes 2.49 (1.7-3.6); 
high calcium 1.3 (1.04-
1.6) and neutrophil 
















(those ≥ 65) 
Registry data; 
Patients in the 
VA system 
with eGFR 
less than 60; 





GFR and age. 
n= 209,622 
Age:73±9 
Age affected the 
competing risks of 
end-stage renal 
disease and death. 
aHR once GFR was < 
30: 1.68 to 8.24 in 
elderly compared to 








chart analysis;  

















Patients,  who 
had been on 
dialysis for 





aged over 75 
n= 704 
Age:79.3 
 Mean survival: 46, 
41.6 and 35 months in 
less than 60, 60-75 and 
more than 75. 
BMI <20: 1.14 -3.53; 
CLP more than 10: 






















  Low levels of physical 




mortality and poor 
clinical outcomes in 
adult patients with 




activity limitations are 
more prevalent in 
patients with CKD, 
regardless of age, 





























Survival: No effect of 
initial GFR (therefore 
no benefit to early 
start) 
QOL: No effect at 12 
months; lower PCS at 
three months 
No effects from initial 






























The CCI and CFS 
scores at the time of 
referral were 
independent 






































Initiation with CVC 
and lack of conversion 

























































, after the 
eGFR declined 
<10;  
n= 8796 (8622 
on dialysis 
and 174 on 




95% of women in the 
conservative group! 
More comorbidities, 
older age and the 
conservative group 
median survival time 
26.9 months vs 1.1  
Most significance:  
Initial 2 months 
(benefited HD); once 
you survive the two 
months, there did not 
seem to be much 
difference.  
Time to event analysis 
: Benefit of dialysis 
decreases with age. 
aHR - HD treatment:  
0.23 (0.18-0.29)  
After two months, 
mode of treatment 
non-significant 
In those >65, with 
comorbidities, 
survival benefit for 
RRT did not persist 
beyond 2.9 months 
(females) or 1.9 
months (males) 






























than 75, CKD 
4 or 5; not 
seen by 
nephrologists 
in the three 
months prior 
to initiation 
Unplanned dialysis – 
greater mortality. 
Survival- unplanned 
vs. planned dialysis:  
3 months – 38.6% vs. 
90.9% ;  













































Age: 71.8 ±4.9 
Mean survival time : 
38.9±4.3 months;  
Survival rates at 1, 2, 
3, and 4 years : 78.8%, 
66.8%, 50.9% and 
19.5% 
aHR: Age: 0.75, 
comorbidities 8.33, 
peritonitis 0.24, low 
albumin 0.17, pre-
treatment urine 
volume 1.0; CAPD: 
2.86 













































GFR was the strongest 
predictor of 
progression to RRT 
RRT in 5 years: IC C-
statistic: 0.96, R ²: 79.7; 
VC 0.95,  R ²: 81.2 
Schwenger































in those <75) 
47% of all patients 
had later referral. 
More elderly had late 
referral (60% vs 43%); 
catheter start (69 % vs 
46%). 
No difference of 
survival  
History of MI, late 
referral and start of 




























Follow up: 24 
months 








of change in 
health-related 
quality of life 
between CM 
and RRT in 
elderly (>75) 
patients with 
ESRD (eGFR 8 





78; RRT: 71) 





compared to CM 
PCS, MCS stable in 
CM group; no 
significant difference 
from RRT group. 
RRT group: improved 
cognition function 
scale, but worse 
scores on effective 
kidney disease and 



























Adults ≥ 65; 
eGFR ≤15; 
followed for 






y chosen from 
the period 
2003- 2010; 
n=199 (CM 42 
; PD 157 ) 
Age: CM 75.3± 
5.7; PD: 73.4± 
5.3   
 
Hospitalisation rates: 
lower rates and days 




Mortality: CM: 92.9%; 
PD 61.1% 
Predictors of 
mortality in PD:  Age, 
comorbidities,  ADL 
impairment and 
emergency dialysis  
Survival advantage 
for PD persisted after 
adjustment for age 











Follow up:  3 























RRT: 186 started 
treatment; rest died or 
chose CM; CM: 11 
switched to RRT 
Survival: 
Recommended CM: 
6.3 vs 8.3 months if 
switched to RRT 
(not statistically 
significant) 
Cox PH: no survival 


























d: CM – 63; 
RRT – 258) 
Age: 61.5 ± 
15.4 
(recommende
d: CM – 71 ± 




for CM, regardless of 
eventual choice 
Likelihood of CM 
recommendation: 
Older, sicker, diabetic, 
more functionally 
impaired, less likely 
to survive one year 
In those older, more 
functionally impaired, 
more comorbidities 
and diabetes, who are 
recommended for 
CM, no survival 






























In both unadjusted 
and adjusted models, 
mortality for women 
was similar to men 
(HR 0.99 95% CI 0.96-
1.03) however it 
varied by age groups. 
Women less than 45 at 
a greater risk of death 
than men. 
This persisted even 
when adding the 




































change in body 
weight was -6%. 
Weight loss > 15% - 
aRR of mortality: 1.35;   












































strata by age 













Median 50% survival 
time after start of HD: 
56 months vs 120 
months(overall 
population) 
Survival rates were 
lower in bedridden 
patients only in those 
< 50, not other age 
groups. 
Bedridden: no 
influence on  survival 



















all > 75 on PD; 
Divided into 
two groups by 




Low EF: no effect at 1- 
year but reduces 
survival  at ≥ 24 
months; similar 







, 3-, and 5-








Follow up: Up 



















CKD in two 
Canadian 
populations 
n= 3449 in IC; 
4942 in VC 
Age 70± 14 in 
IC; 69± 14 in 
VC 
 
Among the various 
models, the 8 variable 
model performed 
best. 
ESRD risk: c stat: IC: : 
0.917 (0.901-0.933) 
VC: 0.841 (0.825-0.857) 
 Also tested for other 






























Follow up: Up 







over 75 who 
started PD in 









global quality of life 
and depression scores 
similar 
physical component 
scores lower than 
younger 
mental component 
scores better  
Older patients had 
reasonably good 
experiences on  
peritoneal dialysis 
with regards to 













Follow up: 6 
months 
A simple 

































AUROC = 0.69 in the 
validation sample.  
Comprehensive score 
AUROC = 0.72, high 
concordance between 
predicted vs observed 
risk. Mortality 
probabilities were 























Patients on  
HD 
n= 1443; 31% 
were > 65 
Age: 59.7±14.8 
Self-rated health is an 
independent predictor 
of mortality in all age 




Adjusted HR 10.58 for 
older patients with 
















































HD in the 
elderly  
Quality of evidence 
for benefit  (USRDS): 
Expected  remaining  
lifetime  for  patients: 
75-79 : 2.8 years 
80-84 : 2.3 years 
>85 years old: 1.9 
years; Modest 
survival benefit in 
elderly, low quality 
evidence. 
 
Quality of evidence 
for Harm: 
- Single cohort studies 
- poor functional 




On HD: Aggressive 
end-of-life care; 
deaths in hospital; 
lack of choice; regret. 
 
2 studies: QOL similar 
or equal in CM versus 
HD 
























n= 104Age: 72 
± 6 
aHR: GNRI > 92 - 0.41 
Risk of death for each 
one-unit increment:  







































2009 to 2014 
over the age 








Odds ratio: Age 5.5, 
Liu comorbidity score 
4.94,ECOG-PS 3.98 











Follow up:  n.s. 
Mode of 
treatment- 
CM or RRT 
Single centre; 
All patients ≥ 
70 receiving 









n= 311 (CM 
107, RRT 204). 
Age: CM 82.5± 
4.5; RRT 75.9± 
4.4 
 
Survival: less with 
CM (0.5 vs 2.8 years at 
eGFR<10; 1.5 vs 3.1 
years at eGFR<15) 
Survival in those over 
80: no statistically 
significant advantage 
(1.4 Vs 2.1 years, p 
0.08) 
Survival in those with 
high comorbidity: 
benefit of RRT 
significantly reduced 
(1 vs 1.8 years, CM vs 
RRT) 
In those > 80, no 
significant survival 












Follow up:  3.3 












Age:  78.6 ± 
2.6 
In the univariate 






heart failure and the 
Charlson index. In the 
multivariate model, 
only the Charlson 














Population Main Findings - 
Comment 











Follow up:  2.1 
(1.2, 3.4) years 
BMI variation 





to a baseline 
level and a 
slope 
coefficient for 











Age: 80.9 ± 4.2 
Mean BMI change 
was -1.1% per year. 
Each point lower 
baseline BMI : 4% 
increase in the risk of 
death (aHR 1 .04) 
Greater than 5% loss 
and gain were both 
associated with poor 
survival after 
adjustment when 
compared to normal 
BMI with no 
significant change. 
annual 5% decrease of 
BMI: aHR 1.5  
























Age:80.9 ± 4.3  
41% mortality rate 
overall. 
Main baseline serum 
albumin 3.63 (0.77). 
Mean annual rate of 
change  -0.04 (0.53) 
Both baseline value 
and rate of change 
associated with 
mortality; Compared 
to albumin > 3.8 and 
no significant rate of 
change, both low and 
high rates of change 
had poorer outcomes 
































Age over 75 
n= 292 
Age:  81.5 (75-
92) 
Worse survival with 





1-year survival- 80%, 















Follow up: At 



























thirds of the 
original 
cohort): 
n= 3631; Age: 
64 (49-73) 








 IC: 0. 0.74; VC 0.73 





with low (6%), 
intermediate (19%), 
high (33%), and very 










19- point risk 
score, 
narrowed to 7. 














































Patients in a 
multidisciplin





At one year, the 
survival for 
comorbidity grade 0, 1 
and 2 were 83%, 70% 
and 56 respectively. 
other prognostic 














Population Main Findings - 
Comment 










































64.5 initiated dialysis 
in the hospital; 36.6 
hospitalised for more 
than two weeks; 7.4% 
who underwent one 




those with high 





and less likely to have 
discontinued dialysis 
before death. 
Highest to lowest 
level of intensity of 
care at initiation: 


































Testosterone level was 
associated with 
skeletal muscle mass 
index 
Outcome worse for 
low testosterone level, 
except when adjusted 
for SMMI. 
Both had equally 
predictive value for 
mortality. 
Overall mortality C 
stat: testosterone 
0.812, skeletal muscle 





































n= 358 (145 
over 65 years 
old) 
Age: All ages 
Survival of elderly 
patients were shorter 
than that of younger 
patients. 
Technique survival 
was no different 
between older and 
younger groups.  
aHR mortality (initial 
values) : Albumin 
0.95, S Calcium 5.19; 


























forms of HD, 






rates were highest in 





Incident first month 
annualised mortality 



















Japan in 2007 





In overall data, 3-mo 
mortality is relatively 
common among 
elderly patients (over 

































"In Canada, use of an 
AV-access is 
associated with lower 
mortality across all 
age categories, even in 




















were > 65 
(All patients were on 
organ replacement 
register) 
aHR for AVF use , 
effect on mortality 
0.73 - 0.77 in all 





















Of these, 47%:  overall 
health-related and 
mental component 
summary QOL scores 
in elderly a similar to 
or higher than those 
of age-matched 
controls or younger , 
although the physical  
component summary 
QOL scores tended to 
be lower in older 
adults.  
Studies on health 
perception or 
satisfaction in older 

































units; part of a 




Age:  >60 
Multivariate analysis 
of factors affecting: 
PCS: older age, female 
gender, history of 
hospital admissions; 
three or more self-
reported chronic 
diseases 
MCS: three or more 
chronic diseases; long 
duration of  treatment 
Overall, lowest scores 
were for burden of 
kidney disease; work 
status and patient 
satisfaction; physical 
functioning, role-


























 Dialysis  has multiple 
impacts of lifestyle - 
therefore, choose 
carefully. 
Need to change the 
focus of care to 
quality of patient's 
life, rather than 
dialysis as default 
Several advantages 
and disadvantages of 


































QOL : Overall QOL 
Worse in dialysis 
compared to non-
dialysis in this brief 
study 
Each  5D index score 
significantly lower in 
dialysis population 
older adults more 

































QOL: Affected by 
age,somatization,  
dialysis vintage and 
education 
Number of symptoms 
increased with age 
Somatization (a global 
score) -  affected 
mental health vitality 
and pain 
More time on dialysis 
worsened positive 
symptom distress and 
obsessive behaviour;  
Higher the 
educational level, the 
more the negative 

























Low MCS score:  
depression 
Depression in 13%, 

































CKD 3 and 4. 
(%age of those 
































































Better HRQoL :  
patients <65 years old, 
males, patients with 
higher educational 
level and HD vintage 
< 1 year. 
PCS and MCS: Age 
(>65 vs <65) only 














































n= 170; Age: 
70.6 ± 7.2 
Reduced muscle mass 
was observed in 64% 
of the patients, 
reduced muscle 
strength in 52%, and 
Sarcopenia in 37%;   
Low muscle strength 
was associated with 
worse QoL domains.  
In multivariate 




























































n= 201 (>65 - 
74; <65 - 127)  
Age: >65 
versus <65 
Quality of life 
outcomes were lower 
than the general 
population 
Older patients : higher 
satisfaction with care, 
less effects of kidney 
disease better overall 
QOL   
No difference in QOL 


















 MCS: Cognitive 
impairment is a risk 
factor for mortality 
and morbidity;  
Depression is 




female gender, white 
race  


























Patients on  
both forms of 
dialysis. 
n=  140 (HD 
70; PD 70) 
PD : less illness and 
treatment intrusion 
than those on HD,  

































Age: 73 52% Involved in their 
modality decision;  
33%  desire greater 
involvement 
Decisions are 
influenced by :  
patients’ prior 
experiences, medical 
and social context; 
Quality of education 
(latter affects also  
integration of dialysis 






















n of the 
psychosoci







Elders on HD 
compared to 
elders in the 
community 
n= 83  
Age: >65 
 Older dialysis 
patients: lower scores 
in mood, sleep, 
happiness 
Parallel scores in 
family relationships 
and friendships 
Dialysis vintage had 
effects on: sleep, 
memory, family 
relationships. 
Sleep affected by: 
friendships, economic 








































into more and 




QOL influenced by: 
Beck depression item 
scores had a major 
effect; also 
haemoglobin, 




(Abstract only - full 

























QOL : Large study, no 
adverse effect on QOL 
from session length 
(although mortality is 
















































y all patients 
with CKD, 





treatment of anaemia, 
exercise, personalised 













































perception of QOL 
and symptoms 
Older Whites, 
compared to older 
Blacks, were at 
increased risk for 
reporting nausea, 
sexual dysfunction, 
recent bed disability 
days, fatigue, greater 











































Better QOL (all 
scales): better scores 
in physical function 
No effect on QOL:  
early vs late start, PD 






























































Age: mean 69 
QOL: No significant 
differences when 
using the Nottingham 
profile ( outputs are 
mainly psych than 
physical for this scale) 
despite differing 



































ESRD had lower 
scores in dimensions 
of physical function, 
role limitation and 
vitality. 
After adjustment, no 
difference in quality 





lowest quality of life; 
especially physical 














KDQOL - SF 




Single centre;  
patients on 
HD 
n= 74 (those 
>60) 
Age:  >60 
 
QOL: Age may affect 
the components of 
quality of life that are 
affected by dialysis. 
Older people have 












































gical,  iron  
status,    
inflammat
ory and  
nutritional  












> 57 years - worse in 
QOL domains of: 
Effects of kidney 
disease, work  status,  
physical  functioning, 
role–physical 




list, pain and quality 













 Comorbidity scores  
explained  < 20% of 
physical component 




Effect of comorbidity 
on quality of life is 
separate from effect 
on survival since 































with GFR less 









Lower QOL: lower 





alone (poorer morale 
and social interactions 


































































 QOL :  improved by 
spiritual, religious 
and existential well-
bring scores (in the 
physical, 
psychological, social 




























n= 216  
Age: mean 
67.9 
QOL affected by: Age; 
Duration of dialysis 
Health utilities  scores 
differed according to 
age groups; dropping 
in the groups above 
70 
Japanese elderly had  
better health utility 








Opinion Opinion paper Unique 
needs and 
characteris



































Vs death is an 
important 
consideration 
- Burdens / 
QOL risk 
exists with 
















SF 36; activities 






























n= 203 (190 on 
HD) 
Age: all ages; 
mean 72. 
QOL : Affected by 
components of frailty  
Improved by : living 
with family, economic 
condition, widespread 
social relationships;  





















Assessment of  
Chronic Illness 
Therapy  –  
Anaemia score 
(FACT-An,v 4) 
24 months of 





























status in older: lower; 
more decline 
Social well-being in 
older: less 
pronounced decline; 
finally equalised with 
younger population.  
Hospitalisation rate in 





















































n=  32,209 
Age: all ages 
(50% of 
patients were 
over the age 
of 60) 
QOL: Affected by 
socio-economic status; 
affected by birth 
cohort; affected by 
age. Older patients, 













 Psychosocial domains 
similar between older 




costs are higher. 








































Age: 70.5 ± 4.7 
Lower PCS: common 
in poor sleepers 
Sleep affected by: 
depression score, 
mental component 
score and age 
Overall: poor sleep in 
71%; depression in 
25% 



















- LF, MOS SF 
 Change in 
QOL, 
experience 








n= 1813 (391 
were >70) 
Older patients: better 
overall global quality 


















Population Main Findings - 
Comment 
36 completed 
every year  
Age: 57.6 





Only minor declines 
in physical or mental 
scores over a three-
year period in those 
over 70 in those who 
survived; no major 































n= 82 (those 
>60: 67) 




activities of daily 
living score and 
instrumental activities 
of daily living score 
No differences in 
mean quality-of-life 

































in  6 European 
countries 
n=  1079 
Age:  >65 
Symptom number 
and symptom severity 
affected both MCS 
and PCS 
Changing symptom 
number and severity 
relates to changes in 






PCS: contribution of 
symptoms is smaller. 
Women had more 
number and severity 
of symptoms and a 





















Age: 72 – 90 
Elderly patients can 
feel disempowered; 
they feel dominated 



















professionals seem to 
have all the power. 
1. The healthcare 
team's power and 
dominance (feeling 
like being in prison; 
healthcare teams’ 
knowledge; patients 
trust in fear; 
threatened identities) 
2. Struggle vision for 
shared decision-
making (blood access; 
dry weight; diet; the 





























Ages : all ages 
 
Falls are common in 
HD patients, with a 
higher incidence in 
females and elderly, 
and are associated 
with worse outcomes, 









  Inadequate 
information regarding 
falls in elderly dialysis 
patients. 
Reasons for falls - 
related to aging, to 
ESRD/HD; to CKD 
comorbidities. 
 Falls can have several 
complications. 
Important to assess 


































common in Egyptian 
older adults on HD  
More in those with 
older age, low 
education, lower level 
























vintage and higher 




























g end of 
life.  





Being aware that 
death may be near 
Adapting to 
approaching death 




































Age: 65 – 89 
20% of all deaths 
29% of all >80 
Those withdrawing: 














































Age:  >65 
Low eGFR <45 was 
associated with a 
trend toward a more 
rapid decline in life 
space mobility among 
community-dwelling 
older adults 
compared to those 























































2. Prioritisation is a 




























Age: mean 83 
Multiple symptoms. 




severity and not easily 
predicted on the basis 





























Age: Mean 62;  




Close and supportive 
relationships with 
HCPs; Busy cultures 
of unit, lack of 
opportunity to speak 
to a doctor; Conveyor 
belt nature of HD, 
Difficulty of getting 
information; culture 
of silence about other 
patients, esp. when 
they die, Impact on 
day-to day life, loss of 
independence, 
enjoyment; impact on 
family and friends 
Acknowledgement 
the various themes 
around dialysis 
initiation (Fear, 














Population Main Findings - 
Comment 
Struggle, Denial, 
Grief, Realisation)  
More detail around 
the lifestyle changes - 
mere booklets not 
enough;  
Greater involvement 
in  decisions  
Impact on lifestyle  
Facing mortality and 
constant thoughts of 
death  






Opinion Opinion paper PD for 
older 
people 
 - There are 
advantages to PD - no 
problems with access; 
no impact of cardiac 
disease; no transport. 
Older patients can be 
trained; may have 
others willing to help. 
 - No statistically 
significant difference 
between PD and HD 
regarding survival or 
hospitalisation rates 
or quality of life in 
either of the North 
Thames dialysis study 
or the French REI in 
registry. 
  - similar mental 
scores were obtained; 
lower physical scores 
than the general 
population 
 - assisted PD in 
several countries 
 - with community 
support, more 



























Population Main Findings - 
Comment 
changes  in body 
composition. 
Frailty as a measure of 
ageing.  
Biological and 
psychosocial age may 






























Elderly HD patients 
have a high frequency 
of visual impairment 
(95.6% decreased 
visual acuity; 39% 













then visited by 
research nurse 
every 2 weeks 
till the 
completion of 
the study to 
assess if they 
had fallen  
Minimum 
follow-up of  1 
year 







Age:  >65 
In the HD population, 
the fall risk is higher 
than in the general 
community 
47% of patients had 
falls (fall-incidence 1.6 
per person - year) 
Risk factors: age, 
comorbidity, mean 
predialysis systolic 
BP, and a Previous 
























with one or  
more  
disabilities  
in  the  













Age:  74.8±5.9   
Ex: Functional deficits 
very common;  




timing in "up and go" 




















from  bed  
to  chair,  
and  
walking 
within  the  
home)  and  
to  identify  
clinical  
variables  



















activity test, 30 

























CKD stages 3 
to 4 
Age: >60 





number double that of 
active patients 
reduce physical 
performance in both 
groups 
PD: association 
between STS and 
RAPA with 
malnutrition 




























Different strategies for 
how patients adopt to 
dialysis 
-coping as scaffolding; 
the power to hold on 
(clinging to something 
important) 
-coping as sailing: the 
power to let go; 
forgetting, 
overcoming 
-coping a sanguinity; 
the power to see the 
























analysis: – Two  
methods  of  
cross-Sectional 
data  collection  





















dialysing at  
home  or  
training  for  




Despite experiencing  
frustration  with  
dialysis  itself,  
expressed  satisfaction  
across  four 
categories:  staff,  
information 
provision,  






















recorded for 12 
months follow-
up 
Falls in HD 
patients  




Age:  median : 
70.9 overall, 
74.7 among 





3.9% experienced fall -
related fracture 
Risk factors: older age 
(odds ratio, 1.057/y; P 
= 0.01), diabetes (odds 
ratio, 2.747; P = 0.02), 
high number of 
prescribed oral drugs 
(odds ratio, 1.19/drug; 
P = 0.011), 
antidepressant use 
(odds ratio, 5.263; P < 
0.001), and failing to 
walk 10 m without 
help (odds ratio, 





Opinion Opinion paper Peritoneal 
dialysis in 
the elderly 
 Not very different 
with modality related 
complications. 
quality of life - often 
need assistance; 
peritoneal dialysis 


















life in elders 
Hospitalisation 
supposed to be more 
according to the study 
(however, this has 




























HD & their 
family 
members 





Duration on dialysis 
and physical losses 
change the perception 
of quality of life over 
time 
1. The reason they 
were alive has 
changed; how they 
spent their time each 
day has changed 
2. Patients described 
thriving; positive  
attitudes to help with 
this 
3. Surviving:  
diminishing abilities; 
family support and 




to poor quality of life: 
progressive decline 
5. End-stage - not 









































Presence of CKD 
increases the chances 
you will develop 
cognitive impairment 
over the next 2 years 
moderate-to-severe 
impaired renal 
function is associated 
with incident 
cognitive impairment 




































































Factors important to 
physical 
independence — prior 
cerebrovascular 
disease and increasing 
age — are associated 
with withdrawal.  
Increasing age, female 




dialysis withdrawal  
Analysis of free text : 
image of physical and 
psychological decline 


























with CKD 4 
and 5 not on 
dialysis 
n= 385  
Age:  mean 68 
Cognitive impairment 
in 68%.(most 




Risk factors: older 


























Age: >65: 34; 
45-64: 39 
Ex: Positive thinking 
and pain affected 
depression 
In older: positive 
thinking (p = 0.030) 
and pain score (p = 
0.038) were associated 













Population Main Findings - 
Comment 
































Age: mean 62 
(50 – 79) 
the haemodialysis 
machine as a lifeline 
alleviation of 
suffering 
loss of freedom 
dependence on the 
caregiver 
disrupted marital, 
family and social life 
gaining a sense of 
existential optimism 







































is common;  poor 
adherence may be 


























Analysis of self-care 
behaviours reveals 
varying types. 
Age, education level, 
and social support 
predicted value 
accounted for 36.8% 






















highest scores: Caring 
for an arteriovenous 
fistula, followed by 
taking medication 
Lowest scores: 
engaging in social 
activities and diet 
control 
negative correlation : 
between self-care 




















large print on 5 
× 8 laminated 
2-sided cards 
that were 





































given just before HD 
Varying levels of 
cognitive function; 
best usually just 
before dialysis. 
Poorer recall - Older 













of death on 
dialysis 
(comparin
g stop Vs 
discontinu








Age: mean 69 
- Risk factors for 




for < 3 mths.  
- Good practice to get 






































defined as a 
permanent 
transfer to an 
assisted-living 









In 6 months - 30% 
functional decline; 
stable after this. 
Most decline seems to 
occur in the first 6 
months after initiation 
poor  functional 
outcomes in relation 
to events occurring 
around the time of 















































Age:  >65 
Energy and protein 
intake in older people 
(regardless of 





Lower energy intake: - 
fewer social networks 
(P = .002) and lower 
PCS scores  
Lower protein intake:- 
Lower Index of 
deprivation score;  an 
interaction between 
SF-12 PCS and 
















Single centre; ; 
Patients on 
HD 
People differ in how 
they respond to the 
illness; individualised 













Population Main Findings - 
Comment 






















n= 100 for 
quantitative 





Age: 67.72 ± 
10.25 
High scores on OLS:  
adapted, internalised 
dialysis is part of 
daily life 
Low  scores on OLS: 
view dialysis an 
illness as a central 
feature; 
overwhelmed, 










 Frailty is common, 
multiple causes, 
associated often with 
PEW, leads to 
functional decline and 























life.   
 Physical Function: 
Elderly three times 
more likely to be frail 
Frailty - 2.5-fold risk 
of death & dialysis 
Cognitive function: 




- higher mortality  
Risk for 
development/worseni
ng of pre-existing 

















































decline or death after 
starting dialysis for 
87% of nursing home 
residents. 
Risk factors: older 
age, white race, 
cerebrovascular 
disease, dementia, 
hospitalization at the 
start of dialysis, & 
albumin < 3.5 
Initiation of HD itself 
































t,   
depression,   
and   life   
satisfaction   

















-  more functional 
impairment at 
baseline, and also at 
follow-up 
- higher depression 
scores at baseline, and 




significantly related.  
- dialysis patients 
reported lower life 
satisfaction at baseline 
than did controls, but 
the two cohorts were 
not significantly 
different on reported 












 Malnutrition is 
common: moderate in 
33%; severe  in 8% 






















High prevalence of 
cognitive impairment 
in elderly CAPD 
patients compared to  






























n= 147 (81 
elderly CAPD 
patients;  66 
healthy 
elderly) 
Age:  >65 
Worse: females, 
increasing age. 
Protective: years of 
education. 




and the number of 
































Elderly patients:  
higher peritonitis-
related and all-cause 





that PD is a viable 
renal replacement 


































Diagnosis of chronic 
illness in late life does 
not inevitably shatter 
lives or cause 
biographical 
disruption. Instead, 






and treatment choices.  
 3 interactive 
phenomena mitigated 




continuity: (a) the 
framing of illness as 
"old age”; (b) the prior 
experience of serious 
illness; and (c) the 













Population Main Findings - 
Comment 
treatment with the 





























‘Feeling tired’ and 
‘limitations of fluid’ 
were rated amongst 
the top five stressors 
The three coping 
strategies rated as 
being most used and 
helpful were ‘keeping 
a sense of humour’, 
‘look at the good side’ 
and ‘think positively’. 







































Decisions as a fluid 
process, rather than 
occurring at a fixed 
point of time and was 
heavily influenced by 
perceptions of oneself 
as becoming old, 
social circumstances, 






imperative: the need 
for length of life 
Delaying decision-
making was common 
- waiting for a clinical 















Population Main Findings - 
Comment 
 1. Maintaining one's 
independence - effect 
of dialysis 
2. Need for support. 
3. The choice as 
"dialysis or death". 
4. The ability to delay 
a decision on dialysis 
5. Significant impact 



















two trials with 
stance with 

















Age: Mean 63; 
51-83 
The period after 
hemodialysis 
treatment is 
particularly unsafe, as 
evidenced by 
significant disability 



























up to 4 times. 
Although 
interviewed 







Age:  mean 66 
Patients experience a 
variety of experiences 
that are difficult to 
talk about, including 
living with death,  
embodied experiences 
that were difficult to 
language. Speaking 
about death or dying 
is difficult for 
patients, even though 




















Opinion Opinion paper Review of 
dialysis in 
the elderly 
 - vascular access may 
be a burden to elderly 
- older patients often 
need assistance for 
home peritoneal 
dialysis 
- Functional decline, 
cognitive impairment 
common after dialysis 
initiation 
Moustakas



















3 themes regarding 
needs were revealed: 
-Shared decision 
making 
-perception of quality 
of life 
-the role of 
educational resources 
Experience: 
1. Decisions are often 
based on personal 
values beliefs and 
feelings towards life, 
not on effectiveness of 
treatment 
2. Greater educational 
both patients and 
families required. 
3. Patients' and 
nephrologists' 
opinions may differ. 
4. Poor 
communication may 


























Single centre;  
patients on 
HD;  
n= 338  
Age:  ≥ 55 




Moderate to severe 
cognitive impairment 
is common and 
undiagnosed in 
hemodialysis patients.  
Severe impairment 















































Findings indicated a 
transformed care 
dynamic, positive 
appraisal and active 
everyday engagement 
by participants.  
A positive outlook on 
life in the present - 








home (integrating into 
daily life 
for/reorganising) 
2. Partnership - 
spousal: professional 
3. The sense of self 
(ups and downs in the 
present; hope and 


























n= 49 - (30 





(Range: 68 - 
91) 
1. The decision not to 
have dialysis  is not 
always 
straightforward: Can 
be of different types - 
either taken in an 
informed manner, 
considering the 
difficulties of dialysis; 
or the less informed 
decision. 
2. Age considered a 
reason not to start 
dialysis. 
3. Multiple symptoms; 

















4. Uncertainties - 
approaching death, 
probable deterioration 
































a high symptom 
burden  
Preliminary studies 
suggest that QOL is 
similar. 
Findings are mixed as 
to whether dialysis 
prolongs survival; any 

























Older dialysis patients 
manage to achieve 
meaning in their lives 
Limitations and an 
uncertain future. 
1) Facing new 
demands, 2) 
Managing daily life, 
3) Partnership in care, 
























































Age: >67  
Falls risk higher after 
dialysis is started; 
incidence ratio 1.62.  




albumin>3; able to 
walk and transfer, no 




























































Low IADL score, 
Impaired vision, Poor 
mobility and frequent 
falls - more common 























Age: Mean 72, 


























rarely discussed these 
with their physicians. 
Poor communication 
about side effects and 
medication decisions-


































n=  47 















Elderly patients are at 

















to see if they 
reported falls, 
syncope, 






of falls and 
syncope 













patients have a high 
incidence of falls, 
syncope, presyncope   
or   dizziness. 
only falls was age-
related.  
38% of patients aged 
>65 reported 1 or 
more fall compared to 
4% of younger 




or standing BP 
between young and 
older or between 
fallers and nonfallers 
although the older 
patients did have a 













Population Main Findings - 
Comment 
change between pre-
dialysis BP and post-




































Severe falls in 28.6%; 
incidence 0.22 per 
patient-year;  
fractures in 54.8% of 
severe falls 
Falls are common; 4 
risk factors - age, a 
past history of falls, 
malnutrition, 
depression 
POMA  score  of > 21  
had  a  negative  























in dialysis -  
'temporal 
subjectivity
' for older 
patients 








Need to re-invent 
oneself. 
-difficulty in framing 
dialysis initiation as a 
choice 
-the amount of time 
required therapy 
-the lack of an end to 
treatment; the end of 
hope 
-being between life 
and death 
-contemplating death 
- life re-experienced 

























from the renal 
departments 
Personal and 
contextual factors are 
important as people 
choose treatment 
options: 
Impact of ESRD - 
Physical and financial 
burden, coping 
techniques. 
Making the decision - 
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the polls in reaching 
the final decision, age 
and life completion, 
financial and physical 
costs of dialysis, 
stories of suffering 
and burden inflicted 
by dialysis, 






for medical teams 
Sinclair 


















effects described as 
the following themes:  
magnitude of loss 
(loss experience from 
multiple social levels, 
individual levels, loss 
of freedom);  
the theme of constant 




of low levels, 
downsizing or 
decreasing activities) 
and finally  
the theme of 
accepting (a life worth 
living, the support 
one receives, the 


























with age and 
gender 
The HD patients in 
the study had a 
considerably lower 
functional capacity 
than the healthy 
subjects, this may 
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10 s) and a 
staircase test 



















at start and 6 
months after  
dialysis 
expectation





















throughout time on 
dialysis;  
several patients feel 
compelled by family 
to start dialysis 
1. At start, 75% felt it 
would be easy to 
tolerate; and six 
months only 45% 
2. 96% felt at the 
beginning the dialysis 
would make them feel 
better 
3. 88% expected to 
live longer by having 
dialysis 
4. Two themes 
regarding initiation: 
no choice; family 
compulsions (these 
patients were more 
likely to express 
regret at six months) 
5. More receptive to 
advance care 























Records of all 
patients on 
HD 
n= 382  




similar between older 
and younger patients; 
number of hospital 
days are similar. 
Greater number of 
hospitalisations for 
infections as a 










































Single centre;  
older patients 




No increased rate of  
technique failure, 
hospitalisation, 
peritonitis or exit site 
infection. 












































































Regret was more 






81% of participants - 
no decision regret 
(DRS score <50), 11% 
ambivalence (DRS 
=50), and 8% regret 
(DRS >50). 
19% felt dialysis had 
done them harm and 
16% would not make 










































s of older 
people ( > 
















had made a 
decision to 








The majority of 
patients were 
involved in the 
dialysis decision. 
Other aspects of 
experience: 
1. Delaying the 
decision to start 
dialysis 
2. The decision-
making continuum - 
sharing; role of hcp; 
role of family; too 
much information; 
information gained 
from other patients 
3. The reality of 
dialysis - not enough 
knowledge about the 
negative aspects 
Information needs: 
quality of the 
information provided 
could be improved, 
especially: 
- how daily living can 
be affected by 
dialysis. 
- difficulty with 
knowing what 
questions to ask 
because of lack of 
adequate information 
about the treatment 
-information was too 
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BEC 96), and a 





















and depressive mood 
are often overlooked 
and underestimated 
in this population.  
Depression 60%; 
Cognitive impairment 
up to 47% 
50% of those 


























Age: 76.2 ± 7.5 
Impaired physical and 
functional 
performance is 















for two years 
Influence 
of age and 











Age: Over 65 
compared to 
less than 65 
 Ex: very few 
hemodialysis patients 
maintain a good 
physical condition 
over a 2-year time 
span. Especially in 
older patients, 
physical performance 
is poor, and decline is 
faster than in the 
healthy population.  
15% (one in six) 
succeeded in 
maintaining a good 
physical condition 


















age (OR 1.96 to 2.38); 


























Impaired Ability to 
change lifestyle or 
adherence due to: 
1. Self in relation to 
others (burden to 






concealment of the 
illness; decision-
making) 
3. Adherence (dietary 
decisions are a 
burden; establishing a 
routine helps) 
4. Beliefs about illness 
and treatment 
(thoughts of side 












































with eGFR <30 
n= 157 out of 
825 
Age: >50 
13-18% of cognitive 
impairment with CKD 
1.5 to 2.6 unadjusted 
odds ratio of clinically 
significant cognitive 
impairment when 
GFR less than 30; not 
dependent on 































































1. Patients wanted 




manageable bites; and 
real-life examples to 
explain concepts. 
2. After multiple 









(feelings) and finance 





Opinion Opinion paper Conservati
ve 
manageme
nt for CKD 
 Symptoms, length of 
life, quality of life, 
frequency of visits, 
support available, 







































Age: All ages; 
mean: 55 for 
PD; 68 for HD; 
84 for CM 





lifestyle & distance / 
travel to the centre   
- Patients that were 
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Comment 
Several personal 
factors dictate choice 
of treatment modality 
- being married, being 
employed, having 
another person living 
at home.  
Including: ability to 
cope, fitting modality 
with lifestyle, distance 




Age affected choice 
(PD 55, HD 68, CM 
84). 
Degrees of 










 Information needs:   
Full exploration of 
patient's wishes;  
supporting the 
decisions;  










































Age:  64 ± 14 
97% wanted to know 
about life expectancy 
of dialysis limitations 
and quality of life, 
side effects, and how 
effective treatment 
has been on patients 
of similar age and 
comorbidity. 
95% of patients 
requesting life 
expectancy 
information did so 
because they could be 
better prepared. 
A majority consider 
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outcome might alter 




physicians to disclose 
life expectancy data 
without prompting 
and to be given as 
much information as 



































CKD 3 and 4 
attending a 
multidisciplin













92% wanted to know 
life expectancy on 
dialysis. 
98% wanted to know 
limitations on quality 
of life on dialysis. 
89% wanted 
disclosure of as much 
information as 
possible, whether 
good or bad. 
The most common 
reason 89% for 
wanting disclosure of 
life expectancy was to 
be better prepared to 
accept what happens 
on dialysis. 
82% wanted physician 
to disclose life 
expectancy without 















forms of treatment 
Discussion regarding 
intrusiveness and 
how to minimise this 
(daily routine, 
distance, travel, et 
cetera) 
Role of knowledge 
and information from 
other sources, 
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Comment 
the knowledge that 
decisions  are highly 
influenced by the 
personal 
characteristics, family 
values, context of 




timely, considering  
needs of family as 






























ary  CKD 









About dialysis; its 
effects on lifestyle; the 







personal factors (age, 
knowledge about 
dialysis; lifestyle and 




approach to learning 
(men did not seek the 
information; tends to 
delay decisions); the 






















12 studies, 206 
patients, 
mostly HD, 64 
HCPs 
Physician style and 
patient style (delivery 
and receipt of info) 
have impacts;  
-patient factors, health 
care professional 
factors, and their 
interaction 
determined decisions. 
- Whether the effect 
on QoL outweighed 
survival advantage, or 


















and not something 
health care 
professionals and 
family members could 
predict 
- Interaction: Power 
and communication ; 
effects of patient and 
physician styles 
- Communication of 
uncertainty led to 
fear; avoidance of 
decision-making 
- Patients preferred 
more rather than less 






















patients  at a 







Age: mean 86 




including old age, 
travel limitations, 
feeling well without 
dialysis and not 
wanting to be a 
burden.  












 1. Promote shared 
decision-making 
2. Support caregivers 
in decision-making 
and provision of care 
3. Provide culturally 
sensitive, tailored 
approaches to renal 
palliative care 













































Age:  >65 




quality of life, 
interventions); 
physicians reluctant 
to discuss prognosis 




(problems with health 








































Patient group  
n= 3 
Age: with 70 -
79  
Initial support needed 
with emotional issues; 
Lack of pressure from 
others in the initial 
phases;  
adequate follow-up;  
appropriate provision 












Opinion Opinion paper Serious 
illness 
conversatio
ns in  
ESRD 
 1. 90% of dialysis 
patients believe it is 
important to know 
prognosis or how the 
disease will progress 
2. Information about 
procedure and 
admission rates 
3. Absence of 





4. Patients expect 
serious illness 
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Comment 
early in the disease 
course. 
5. Conversations 
during the time 
patients are on 
dialysis can be 
difficult because of 
cognitive issues; 
privacy issues; time 
and space constraints. 
6. Preference on 
patient centred goals 
and preferences 
(symptoms, quality of 




preferred by doctors. 




units often not aware 
of discussion between 





Opinion Opinion paper End-stage 
Kidney 
disease at 
the end of 
life 
 Patients Considering 
stopping dialysis 
should receive more 
information about the 





















mortality; lack of 
choices; information 
about options; peer 
information is valued; 
























on a renal 
ward 
 
Family need to be 
informed, involved - 
dying patients often 






































often happens in a 
confusing/uncertain 
context. 
2. The advantages of 
shared decision-
making. 




rather than a current 
one; Patients that 
change their mind. 
4. Coping with 
uncertainty: shifting 
choice to patients or 
to guidelines; 
difficulties patients 
have with making 
choices; The benefits 
of making a firm 
decision that does not 
change. 
5. "Good" outcomes; 
and death; good not 
only from the 
patient's point of 
view, but also from 










 Information needs:  
Patients are anxious 
with uncertainty, but 




need to incorporate 













Population Main Findings - 
Comment 










 Patients tend to go 
along with current 
therapy rather than 
actively make choices; 
provision of 
information tailored 
to the patient's 
situation is relevant; 
prognostic 
information and 
information about life 
on dialysis/course 
after discontinuation 




























n= 28 patients 
over 65 on 
dialysis  or 
with 
advanced 







prompted by the 




negative impact on 






blood chemistry; less 
emphasis on 
prognosis; fear and 
worry about 
impending dialysis; 
little thought about 
the future 
(uncertainty; lack of 


















































clinics;  on 
dialysis; their 
nephrologists 








prognosis, effects on 
daily life 
Nephrologists: 
- struggled to explain 
disease complexity 
- manage a disease 
over which they have 
little control 
- tend to avoid 
discussions of the 
future 
- prognosis 
























benefits vs risks of 
dialysis; preparation 
for future setbacks; 
possibility of a time-
limited trial; features 
suggesting poor 
outcome; potential 
burdens of dialysis 
and their effects; 
explore 
understanding of and 
expectations from 





patient's worries and 
concerns; outlining 
milestones and pause 
points; documenting 



























































Age: mean 82 









gaps in information 
provision 
3. Information 
preferences - wanted: 
treatment options and 
disease; ambivalent: 
knowing details of 
text in the stage 
4. Treatment decision 
strongly influenced by 



































experience   
after   starting   
dialysis   in   






n= 32 (over 65; 
out of a total 
of 99) 
Age: >65 
1. What to expect with 
dialysis 
2. Informed decision-
making scores were 
significantly lower for 
the older. 
3. Older-doctor did 
not explain conditions 
that lead to kidney 
failure or impact on 
daily life or the 
lifelong need for 
dialysis 
4. Older - doctor did 

























 Patients want to know 
about prognosis - 
refers other included 
studies, which were 
inclusive of patients 

























from 3 groups: 
14 patients 

















information of all 
options, including 
conservative care,  
Advantages/disadvan
tages of dialysis vs 
conservative care,  
Understanding of 
symptoms and illness 
trajectories (to 
prevent changing of 
decisions);  
Discussions about 
















Surveys used:  





Survey,  the 
Summary of 
Diabetes Self-





























Older patients score 
lower on activation 
scores; Greater 
burden of kidney 
disease and lower 
MCS on QOL scores  
predict poor 
activation. These 
factors may need to be 
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(KDQoL-36) 









Appendix 2: Supplementary material for Chapter 4 
 
Participant interview guide 
1. Introduction 
a. Introduce yourself. 
b. Explain purpose of study; how interview is to be conducted and 
analysed. 
c. Offer option to review and edit interview after recording or 
transcription. 
2. Participants’ perception of outcome 
a. How are you doing on dialysis? (Are you doing well or poorly?) 
b. Why do you think you are doing that way?  (Explore what the 
participant’s thoughts on what affecting the outcomes on dialysis). 
3. The experience of being on dialysis 
a. What are the best and worst things about life, in general, for you 
now? 
b. What are the best and worst things for you about life on dialysis? 
c. If you were not on dialysis, what would you be doing? 
4. Relationships 
a. How do the people around you influence how you cope with 
dialysis? (Role of family, friends, social networks) 
b. Tell me about your relationships with nurses / doctors. (How do 
you get along? Can you discuss all your concerns with them? What 





6. Managing life on dialysis  
a. Regarding practical things (activities of daily living, money, 
transport, food) – how much  do you still do?  
b. How much do others help? Who helps? 
7. Thoughts of the future 
a. How do you see the future playing out? 
b. Have you thought about treatment options if you were to be 
seriously unwell? (explore thoughts regarding advance care 







Table A-17: Consolidated criteria for reporting qualitative studies 
(COREQ) 
No. Item Comments 
Domain 1: Research team and reflexivity* 
1 Interviewer/facilitator BB 
2 Credentials BB -Masters in Public Health; BN; Cert. in Neph. 
Nursing; RR - DM, MRCP(UK), FRACP, PhD candidate; 
MF – PhD (Psychology); KA – MSc Clinical Trials, PhD; 
MJ – FRACP, FASN, PhD 
 
3 Occupation BB-Nurse; RR,MJ- Nephrologist; MF-Qualitative 
researcher; KA- Research Scientist & Educator,UTAS 
4 Gender BB- Female 
5 Experience and training BB (interviewer) – Formally trained in qualitative 
research, interviewing; RR (primary author and 
analysis) – Trained in qualitative research  
6 Relationship established Some participants known to BB, RR 
7 Participant knowledge of 
the interviewer 
BB is a nurse with experience in dialysis 
RR is a Nephrologist undertaking research towards his 
PhD 
8 Interviewer characteristics BB is a nephrology nurse with interest in pre-dialysis 




interest in outcomes in the elderly with renal failure; and 
is a PhD candidate at the University of Tasmania 
Domain 2: study design 
9 Methodological orientation 
and Theory 
Phenomenology; iterative thematic analysis 
10 Sampling Convenience sampling 
11 Method of approach Face-to-face 
12 Sample size n=17 
13 Non-participation(reason) n=1; “not interested” 
14 Setting of data collection Participant’s homes (n=14) or dialysis unit (n=3) 
15 Presence of non-
participants 
No 
16 Description of sample Participants aged ≥70 years (range 70–83); undergoing 
dialysis in the period 2014-2016; all Caucasian, English-
speaking; 11 males, 6 females; none were employed 
17 Interview guide Attached. Yes, pilot tested. 
18 Repeat interviews No. 
19 Audio/visual recording Yes. Audio recordings. 
20 Field notes Yes. 




22 Data saturation Yes 
23 Transcripts returned Participant offered chance to review; none requested 
this. 
Domain 3: analysis and findings 
24 Number of data coders RR/BB/MF 
25 Description of coding tree No 
26 Derivation of themes Derived from data 
27 Software NVivo qualitative data analysis Software; QSR 
International Pty Ltd., Australia. Version 10, 2014 
28 Participant checking No. Participants offered chance to check; none requested 
this. 
29 Quotations presented Yes; identified by anonymised participant numbers 
30 Data and findings 
consistent 
Quotations provided to illustrate each theme 
31 Clarity of major themes Yes; identified as metathemes (Table 2) 
32 Clarity of minor themes Yes; see text under ‘Results’ and Table 2 
*BB – Mrs Bridget Brown; RR – Dr Rajesh Raj; MF – Dr Mai Frandsen; KA – Dr Kiran 
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